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ABSTRACT 
The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has 
been asked to evaluate the role of tobacco additives in the addictiveness and 
attractiveness of tobacco products.  
The criteria for dependence established in humans indicate that tobacco has a high 
addictive potential, but it remains difficult to assess the addictiveness of individual 
additives. In animal studies the addictive potency of the final tobacco product cannot be 
assessed. The reinforcing potency of drugs is measured after intravenous injections and 
suggests that the abuse liability of pure nicotine is weaker than the addictive potential of 
tobacco products in humans. The currently used methods to define addictiveness of 
nicotine and additives are thus not considered adequate. 
In humans, the positive correlation between tobacco consumption and dependence 
suggests that individuals with high nicotine levels in their blood are more dependent. In 
animal studies using self-administration, an inverted U-shaped dose-response curve has 
generally been revealed suggesting that the addictiveness of nicotine is not directly linear 
with the dose. There is however substantial variation in the response to nicotine in both 
animals and humans, and genetic factors probably play an important role.  
No tobacco additives which are addictive by themselves have so far been identified. 
However, sugars, polysaccharides and cellulose fibres which are naturally present in 
tobacco, or sugars added in high quantities to most tobacco products, give rise to 
numerous aldehydes, such as acetaldehyde, in tobacco smoke. Acetaldehyde given 
intravenously is self-administered and enhances the addictiveness of nicotine in 
experimental animals. Additives that facilitate deeper inhalation (e.g. menthol) or inhibit 
the metabolism of nicotine may enhance the addictiveness of nicotine indirectly. 
Substances such as ammonia that increase the pH of the tobacco and the smoke, result 
in higher amounts of uncharged nicotine. However, it is uncertain if more nicotine is 
absorbed with higher smoke pH. For smokeless tobacco it seems that an increased pH 
enhances nicotine absorption in the mouth.  
The methods used to quantify the addictive potency of additives have limitations because 
of technical challenges in experimentally manipulating the presence or absence of an 
additive in a tobacco product. Such experiments require large technical and financial 
resources. In addition, there are ethical issues if testing in humans is considered. Due to 
these limitations, the available methodologies are not considered adequate. 
A number of technical characteristics of cigarettes (paper, filter, packing, geometry) 
influence the content of different substances in the smoke and the size of smoke 
particles. Many smokers compensate for a lower dose of nicotine by increasing puff 
volume and frequency, and by deeper inhalation. The particle size of the smoke aerosol 
does not seem to substantially influence the exposure to nicotine. The technical 
characteristics of cigarettes may thus modulate smoking behaviour but it is uncertain if 
this leads to a higher risk of addiction. 
Attractiveness is defined as the stimulation to use a product. The attractiveness of 
tobacco products may be increased by a number of additives but is also influenced by 
external factors such as marketing, price etc. Animal models do not currently exist for 
the assessment of attractiveness. In humans, the attractiveness of individual tobacco 
products may be compared in panel studies, surveys, and by experimental measures. 
Another method is to experimentally adjust tobacco products to exclude or include 
individual additives and test responses to them. However, this type of research is difficult 
due to ethical considerations that will usually preclude human testing of tobacco 
products, particularly among non-users or children.  
The use of fruit and candy flavours seems to favour smoking initiation in young people. 
Menthol also attracts a number of smokers, in particular African Americans. Some 
additives decrease the harshness and increase the smoothness of the smoke. Certain 
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additives yield a full and white smoke and other additives reduce the lingering odour of 
the smoke in order to favour the acceptability of smoking to people around.  
Additives considered attractive may in principle lead to brand preference or a higher 
consumption of tobacco products. However, it remains difficult to distinguish the direct 
effects of these additives from indirect effects such as the marketing towards specific 
groups.  
 
Keywords: addictiveness, additives, attractiveness, cigarettes, cigars, nicotine, SCENIHR, 
smokeless tobacco, smoking, target groups, tobacco, waterpipe 
Opinion to be cited as: 
SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), 
Addictiveness and Attractiveness of Tobacco Additives, 12 November 2010. 
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EXECUTIVE SUMMARY 
The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has 
been asked to evaluate the role of tobacco additives in the addictiveness and 
attractiveness of tobacco products. A summary of the answers are presented below. 
1. Criteria which will define whether an additive or a combination of additives 
increases the addictive potency of the final tobacco product 
In human studies there are clinical criteria for dependence, laboratory measures of self-
administration, as well as preference studies. These criteria indicate that tobacco in 
humans has a high addictive potential, but they have limitations when assessing the 
addictiveness of individual additives in the final tobacco product. There is no widely-
agreed universal standard for human studies and as a result various possible endpoints 
exist. In addicted individuals a modified regulation of neural networks exists, and the 
potential to induce such modifications should be the criteria used to define the addictive 
potency of a product. 
In animal studies the reinforcing potency of a drug is used as a criterion for the addictive 
potential. Self-administration studies indicate that the abuse liability of pure nicotine is 
weaker than the addictive potential of tobacco products in humans.  
2. Methods currently used for assessing the addictive potency of a substance  
Many different methods are used in humans, but there is a lack of consistency between 
them. Human studies have limitations in design (e.g. the use of conditioned cues, and 
the need to work with smokers). Furthermore, ethical issues may arise when testing 
substances in humans.  
There is currently no animal model to assess the addictive potency of the final tobacco 
product; however, pure nicotine has been studied extensively. The experimental animal 
models are mainly based on self-administration in rodents, usually rats. The evaluation of 
addictiveness is based on the re-inforcing properties of the drug. However, there is no 
consensus on the predictive validity for the addictiveness of tobacco products in humans. 
In animal studies pure nicotine is injected intravenously and shows only a weak addictive 
potential whereas in humans, tobacco is used differently (e.g. inhalation, oral 
consumption) and is highly addictive. No method currently used to define the addictive 
potency of a compound can therefore be considered as adequate. 
3. Dose-dependency of development of nicotine addictiveness  
In humans, there are little data available on pure nicotine use. However, tobacco 
consumption (e.g. number of cigarettes smoked per day) is positively correlated with 
dependence. This suggests that individuals who maintain higher nicotine levels in their 
blood are more dependent than individuals who maintain low levels.  
In animal studies, an inverted U-shaped dose-response curve has generally been 
revealed suggesting that the addictiveness of nicotine is not directly linear with the dose. 
As mentioned before, pure nicotine is only weakly addictive in animal studies.  
There is substantial variation in the response to nicotine and its addictive potential in 
both animals and humans, and genetic factors probably play an important role.  
4. Additives in tobacco products that are addictive by themselves  
No tobacco additives which are addictive by themselves have so far been identified. 
However, sugars, polysaccharides and cellulose fibres, which are naturally present in 
tobacco, or sugars added in high quantities to most tobacco products, produce numerous 
aldehydes, such as acetaldehyde, when burned. Acetaldehyde is self-administered by 
animals and may thus be considered as potentially addictive.  
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However, experiments using denicotinised cigarettes show that besides nicotine, a 
mixture of factors in cigarette smoke probably plays an important role in craving and 
reinforcement. Although these factors do not have pharmacological effects similar to 
nicotine, they play a role in smoking behaviour.  
5. Additives that enhance the addictiveness of nicotine  
Sugars or their derivatives produce numerous substances upon burning. Among them are 
aldehydes which, as observed with acetaldehyde, enhance the addictiveness of nicotine 
when injected into experimental animals, probably by inhibiting monoamine oxidases 
(MAO) in the brain.  
Smokers have decreased levels of MAO in the brain. There is, however, no proof that 
acetaldehyde in the smoke contributes significantly to blood levels of acetaldehyde, and 
it is likely that aldehydes other than acetaldehyde intervene directly or through the 
generation of new compounds in the smoke, in the inhibition of MAO.  
Additives that facilitate deeper inhalation (e.g. menthol) may enhance the addictiveness 
of nicotine indirectly. Other substances may enhance the addictiveness of nicotine by 
inhibiting its metabolism. Substances such as ammonia that increase the pH of the 
tobacco (and the smoke) result in higher amounts of uncharged nicotine that is more 
easily absorbed by the cells. However, due to the high buffer capacity of the lining fluid in 
the lungs it is uncertain if more nicotine is absorbed with higher smoke pH. For 
smokeless tobacco it has been shown that more nicotine is absorbed in the mouth when 
the pH of the product is increased.  
6. Methods to quantify the potency of additives in enhancing the addictiveness 
of nicotine  
The methods used to quantify the potency of additives in enhancing the addictiveness of 
nicotine or tobacco products are described above. The limitations of these methods arise 
from technical challenges in experimentally manipulating the presence or absence of an 
additive in the tobacco products used in these experiments. Such experiments have 
probably been carried out by the tobacco industry for some additives, especially sugars 
and their derivatives, but they require large technical and financial resources. In addition, 
there are ethical issues if testing in humans is considered. Because of these limitations, 
the available methodologies are not considered adequate. 
7. Technical characteristics that enhance the addictive potential of tobacco 
products  
A number of technical characteristics of cigarettes influence the content of different 
substances in the smoke and the size of smoke particles. The so-called TNCO values (tar, 
nicotine and carbon monoxide (CO)) are determined by, amongst other things, 
ventilation (paper, filter), the packing of the tobacco and the geometry of the cigarettes. 
Many smokers compensate for a lower dose of nicotine by increasing puff volume and 
frequency, and by deeper inhalation. Based on the limited publicly available information, 
it seems that exposure to nicotine cannot be substantially increased by altering the 
particle size of the smoke aerosol. The technical characteristics may thus influence 
smoking behaviour but it is not certain whether this leads to a higher risk of addiction. 
8. Criteria for considering an additive or a combination of additives as 
attractive  
The criterion for attractiveness is the stimulation to use the product. Attractiveness of 
additives refers to factors such as taste, smell and other sensory attributes. In addition, 
a number of external factors (e.g. ease of use, flexibility of the dosing system, cost etc.) 
contribute to the attractiveness of the product.   
The attractiveness of tobacco products may be increased by a number of additives that 
create a specific taste/flavour in order to attract certain target groups. An attractive 
 Addictiveness and Attractiveness of Tobacco Additives  
 11
effect may be obtained by changing the appearance of the product and the smoke, 
decreasing the harshness of the smoke, and inducing a pleasant experience of smoking. 
In order to make smoking more acceptable to other people nearby, some additives 
reduce lingering odour or side-stream smoke visibility. 
9. Methods currently used for assessing attractiveness  
Animal models do not currently exist for the assessment of attractiveness.  
In humans, the attractiveness of individual tobacco products may be compared with 
other tobacco products by panel studies and surveys, and by experimental measures. 
When examining what is known about the additive content of these products, 
judgements can be made as to the role of individual additives in the overall 
attractiveness of the product.  
Another method is to experimentally adjust tobacco products to include or exclude 
individual additives and test responses to them. In addition, the quantity of the additive 
can be varied to assess dose response and whether there is a threshold below which any 
impact is not observed.  
However, this type of research is difficult due to ethical considerations that will usually 
preclude human testing of different tobacco products, particularly among non-users or 
children. The methods currently used are thus not adequate. 
10. Additives that increase attractiveness of tobacco products  
Numerous additives are used in order to increase the attractiveness of tobacco products 
but it is very difficult to identify the role of individual additives in enhancing 
attractiveness.  
Various sugars constitute a large proportion of additives, and the sweetness of the 
product is an important characteristic. The use of fruit and candy flavours in high 
amounts seems to favour smoking initiation by young people. Menthol also attracts a 
number of smokers (in particular African Americans), possibly due to its action on 
sensory nerve endings, resulting in a cooling effect.  
Some additives decrease the harshness and increase the smoothness of the smoke. The 
harshness depends partly on the tar/nicotine ratio, but may also be decreased by 
additives such as propylene glycol and glycyrrhizin, a substance in liquorice. 
Certain additives yield a full and white smoke (e.g. magnesium oxide, magnesium 
carbonate, sodium acetate, sodium citrate, calcium carbonate). Other additives reduce 
the lingering odour of the smoke in order to favour the acceptability of smoking to people 
around (e.g. acetylpyrazine, anethole, limonene, vanillin, and benzaldehyde).  
In several countries there is a growing trend of using “natural” tobacco products 
advertised as containing no additives. 
11. Association between additives and tobacco consumption – target groups  
Additives considered attractive may in principle lead to brand preference or a higher 
consumption of tobacco products although it is difficult to distinguish the direct effects of 
these additives from indirect effects such as marketing towards specific groups. In the 
USA, the consumption of menthol cigarettes is relatively high among African Americans. 
Cigarettes with certain flavours (e.g. fruit, candy) appear to be developed to target 
young people. 
Additives and design characteristics may modify consumption patterns. However, in spite 
of the many additives commonly used, tobacco products overtly marketed as containing 
additives (e.g. menthol cigarettes) command a relatively small market share in EU 
countries and there is presently a trend in several countries to use products labelled 
“without additives”. 
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It is notable that waterpipe smoking is becoming increasingly popular in some EU 
countries (and elsewhere), potentially due to the flavoured tobaccos used and the 
mild/cool smoke that may facilitate the inhalation of large volumes into the lungs. 
Smokeless tobacco products have gained increased interest from the industry because 
they may be used in places where smoking is prohibited. 
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1. BACKGROUND 
Some 72-92% of adult cigarette smokers meet the criteria for dependence1. While 
nicotine is recognised as an addictive substance in the tobacco leaf, the risk of addiction 
to pure nicotine products is very low compared to cigarettes1. Currently, it is being 
discussed in the public health community whether lowering the levels of nicotine in 
tobacco products would make people less addicted and accordingly reduce the 
consumption of tobacco products.  
Tobacco additives were hardly used before 1970, but today they represent up to 10% of 
the cigarette weight. By altering the taste and smell of cigarettes the products are made 
more attractive and the smoke more palatable which leads to an increase of smoking 
initiation. At present, the role of additives in enhancing the addictiveness of tobacco 
products is not clear. 
In order to make tobacco products more attractive, design features are introduced, e.g. 
package design and cigarette form. In addition, these features are used to undermine the 
effect of the maximum limits set by the Tobacco Products Directive 2001/37/EC on tar, 
nicotine, and carbon monoxide (CO) yields in cigarettes. 
 
Legal background 
Article 13 of the Tobacco Products Directive (2001/37/EC)2 stipulates that Member States 
can keep or introduce, in accordance with the Treaty, more stringent rules concerning 
the manufacture, import, sale, and consumption of tobacco products which they deem 
necessary in order to protect public health. Member States may prohibit the use of 
ingredients which have the effect of increasing the addictive properties of tobacco 
products.  
Article 12 of the Tobacco Products Directive invites the Commission to submit a proposal 
providing a common list of ingredients authorised for tobacco products, taking into 
account, inter alia, their addictiveness.  
In its comments to the Green Paper Towards a Europe free from tobacco smoke: policy 
options at EU level3, the European Parliament invited the Commission to propose, by 
2008 if possible, an amendment to the Directive including an evaluation and 
authorisation procedure for tobacco additives and an immediate ban on all additives that 
are addiction-enhancing4. In its 2nd Report on the implementation of the Tobacco 
Products Directive5 the Commission stresses the need for further work on the 
addictiveness of tobacco additives.  
DG SANCO wishes to have a better understanding of the criteria based on which an 
additive can be considered (classified) as an addictive and/or attractive substance, the 
role of additives in tobacco products and the role of design features in the attractiveness 
and addictiveness of a tobacco product.   
 
                                          
1 Henningfield JE, Zeller M. Could science-based regulation make tobacco products less addictive? Yale J Health 
Policy Law Ethics 2002; 3:127-38.  
2 http://eur-lex.europa.eu/pri/en/oj/dat/2001/l_194/l_19420010718en00260034.pdf  
3 http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/gp_smoke_en.pdf  
plus report on consultation: 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/smoke_free_frep_en.pdf  
4 http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+REPORT+A6-2007-
0336+0+DOC+PDF+V0//EN 
5 http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/tobacco_products_en.pdf 
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2. TERMS OF REFERENCE 
In the light of the most recent scientific information, the Scientific Committee is 
requested to answer the following questions: 
1. Which are the criteria which will define whether an additive or a combination of 
additives increases the addictive potency of the final tobacco product? 
2. What are the methods currently used for assessing the addictive potency of a 
substance and are they considered adequate? 
3. Is the development of nicotine addictiveness dose-dependent? 
4. Which additives are addictive themselves in tobacco products? 
5. Which additives enhance the addictiveness of nicotine and how? 
6. Which are the methods used to quantify the potency of additives in enhancing the 
addictiveness of nicotine and are they considered adequate?  
7. Which technical characteristics enhance the addictive potential of tobacco 
products? 
8. Which are the criteria based on which an additive or a combination of additives 
can be considered (classified) attractive? 
9. What are the methods currently used for assessing attractiveness and are they 
considered adequate? 
10. Which additives increase attractiveness of tobacco products? 
11. What is the association between additives and tobacco consumption (independent 
of any addictive potential they might have)? Which additives are used to target 
specific groups? 
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3. SCIENTIFIC RATIONALE 
3.1. Introduction 
According to a report from WHO (2008), about 100 million people died in the 20th century 
from tobacco use. The number of deaths in 2007 due to tobacco related diseases was 
about 5.4 million and if current smoking patterns continue, more than 8 million deaths 
are expected to occur each year due to tobacco smoking by the year 2030. In the EU, 
about a third of the adult population are smokers. The number of deaths from smoking 
per year is currently about 500,000 in the EU and more than 1.5 million in the whole 
European region (WHO 2007a).  
The vast majority of smokers use cigarettes, while other ways of smoking are less 
frequent (e.g. cigars, pipes, waterpipes). Apart from smoking tobacco, other tobacco 
forms (i.e. smokeless tobacco) may also have deleterious public health effects (SCENIHR 
2008). In addition, exposure to tobacco smoke in the environment, so-called “passive 
smoking” or “second-hand smoking” is an important cause of excess mortality and 
morbidity. Passive smokers have a significantly increased risk for several diseases such 
as lung cancer (IARC 2004), respiratory diseases (Jaakkola and Jaakkola 2002a, Jaakkola 
and Jaakkola 2002b) and cardiovascular diseases (Whincup et al. 2004). 
Table 1 shows that tobacco has a very high addictive potential in humans (Anthony et al. 
1994, O’Brien and Gardner 2005) whereas numerous studies indicate that the risk of 
addiction to pure nicotine is low. 
Table 1 Risk of addiction (adapted from Anthony et al. 1994, O’Brien and Gardner 
2005) 
 Ever used a (%) Dependence b (%) Risk of addiction c (%) 
Tobacco 75.6 24.1 31.9 
Heroin 1.5 0.4 23.1 
Cocaine 16.2 2.7 16.7 
Alcohol 91.5 14.1 15.4 
Cannabis 46.3 4.2 9.1 
a Column 1: Ever used – Prevalence of ever use in the total population 
b Column 2: Dependence – Prevalence of dependence in the total population 
c Column 3: Risk of addiction - Ratio of column 2 (dependence) and column 1 (ever used) 
 
The addictiveness of nicotine is enforced by substances in tobacco leaves that inhibit the 
action of monoamine oxidase (MAO) in the body (Berlin and Anthenelli 2001). Apart from 
naturally occurring substances in tobacco leaves, a number of ingredients in the final 
product may create or increase dependence. The tobacco industry has admitted the use 
of 599 different cigarette additives in the United States (US), which are claimed to 
improve taste and reduce harshness of the smoke (Rabinoff et al. 2007). Current US-
style cigarettes contain about 10% of additives by weight; mainly sugars, humectants, 
cocoa and liquorice. Most other additives are used in small amounts. As discussed later in 
this opinion, cigars, pipe tobacco and smokeless tobacco generally contain fewer 
additives than cigarettes. Tobacco used in waterpipes is characterised by a high content 
of water and various sugars.  
Certain flavours (e.g. candy and fruit) have been used largely to make tobacco products 
more appealing to children (called “young adults” by the tobacco industry). In order to 
decrease the appeal of cigarettes to children, the US Food and Drug Administration 
(FDA)6 banned the use of a number of flavours as additives in cigarettes in September 
                                          
6 http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/FlavoredTobacco/default.htm  
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2009. Menthol is not one of the banned additives, but is currently being evaluated by the 
Tobacco Products Scientific Advisory Committee of the FDA. In other parts of the world 
(e.g. Canada, Australia, New Zealand), legal measures on additives are established or 
are in preparation. In Europe, some countries, such as Germany, United Kingdom, 
Austria, Romania and France, use positive and/or negative lists which respectively allow 
or prohibit the use of specific compounds as tobacco additives, whereas other countries 
do not have such a regulation. 
It is the purpose of the present opinion to examine the criteria for classifying tobacco 
additives as addictive or attractive, and to evaluate their role for the creation or 
maintenance of dependence on tobacco products. This would serve as the scientific basis 
for regulation of the use of additives in order to reduce the toxicity and the addictiveness 
of the final tobacco product. An important question is whether some additives are 
addictive by themselves or if they act by increasing the addictiveness of nicotine. The 
different methods of assessing addictiveness of an additive, alone or in combination with 
other substances, will be reviewed. In addition to the interactions between additives and 
constituents of tobacco, the burning of tobacco creates other complex chemical 
substances that may be toxic or favour addiction. An example of this is aldehydes, such 
as acetaldehyde, formed by the pyrolysis of various sugars and polysaccharides in the 
tobacco (see section 3.8.1.4). The technical characteristics of tobacco products, in 
particular of cigarettes, may also influence their addictive potential. A number of 
additives favour attractiveness of tobacco products, and may thus promote smoking 
initiation. In this context special attention will be paid to how additives may be used to 
target specific groups.  
3.2. Methodology 
A public call for information7 was launched in November 2009, giving all stakeholders the 
opportunity to submit relevant scientific information concerning tobacco additives. The 
information asked for concerned: 1) details about the manufacturing process of tobacco 
products; and 2) methods applicable for assessment of attractiveness. A number of 
organisations and major tobacco companies responded. The information received has 
been evaluated carefully and was in many cases useful for writing the opinion. A 
particular problem in the area of tobacco products is that a number of studies relevant 
for this opinion have never been published but exist as internal documents of the tobacco 
industry. Some of the documents contain sensitive information showing health risks 
associated with smoking. In 1992, 60 documents were destroyed by Imperial Tobacco 
Canada in order to avoid exposure of the company to liability or embarrassment. 
Hammond et al. (2009a) have recently reviewed the contents of these documents that 
were recovered at the British American Tobacco headquarters in the United Kingdom and 
were released in 1998 through court disclosure in a trial in Minnesota. The author 
concludes that most of the studies that were carried out by researchers employed by the 
industry were scientifically valid. They gave evidence that cigarette smoke was 
carcinogenic and addictive. Since then, a great number of industry documents have 
become publicly available and can be found in two searchable databases, 
http://tobaccodocuments.org and http://legacy.library.ucsf.edu. The collections continue 
to be updated and currently contain more than 60 million pages in over 11 million 
documents.  
Furthermore, a tobacco documents bibliography is also available which includes papers 
and publications based on documented research, broadly classified into several groups. 
Some examples of publications based on research of industry documents appearing 
under the heading of  “Ingredients and Design”  illustrate the tobacco industry research 
and development strategy on issues including: smoker preferences (Chaiton et al. 2005); 
smoking behaviour and product design (Hammond et al. 2006); targeting consumer 
groups with specific psychological needs (Cook et al. 2003); research on nicotine (Hurt 
                                          
7 http://ec.europa.eu/health/ph_risk/committees/04_scenihr/scenihr_call_info_08_en.htm 
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and Robertson 1998); addictiveness (Scharfstein 1999, Slade et al. 1995, Stevenson and 
Proctor 2008, Vagg and Chapman 2005); manipulation/free base nicotine (Wayne et al. 
2006, Wayne and Carpenter 2009); flavoured cigarettes (Lewis and Wackowski 2006); 
menthol (Kreslake et al. 2008a, Wayne and Connolly 2004); youth targeting (Wayne and 
Connolly 2002); and particle size (Wayne et al. 2008a). Relevant publications are 
discussed in subsequent chapters of this opinion. 
For the purpose of the present opinion, the health risks of tobacco products and additives 
have been investigated within different lines of evidence such as epidemiological studies, 
experimental studies in humans, experimental studies in animals, cell culture studies and 
in silico studies. In order to answer the questions in the Terms of Reference to this 
opinion, a weighted approach has been used, where data from all the available lines of 
evidence were integrated as appropriate. A more detailed description of how such 
weighting is performed is given in an earlier opinion of the SCENIHR (SCENIHR 2009). 
The primary sources for this opinion were original scientific reports published in peer-
reviewed scientific journals. The secondary sources used were the stakeholder 
information mentioned above and reports and opinions of other Scientific Committees, as 
well as reports of various governmental bodies. In addition to the reports cited in the text 
and included in the list of references, various publications were noted but not considered 
appropriate for the purposes of developing the opinion.  
3.3. Definitions 
A number of terms related to tobacco products are explained below. For the list of 
abbreviations, see chapter 7. A full glossary can be found in chapter 9. 
3.3.1. Technical characteristics 
A wide variety of tobacco products are available worldwide such as cigarettes, cigars, 
pipe tobaccos, smokeless tobacco products (STP) etc. Each of these types is produced by 
using different tobaccos and additives and by using different manufacturing practices 
(Reviewed in IARC Monographs: 1985; 1986; 2004; and 2007).  
Cigarette: The most common form of tobacco is the manufactured cigarette. Cigarettes 
are made from fine-cut tobacco leaves and are wrapped in paper or other non-tobacco 
material, filter–tipped or untipped, approximately 8 mm in diameter and 70-120 mm in 
length. Cigarettes are highly engineered, exquisitely designed “nicotine delivery devices”. 
Design features encompass a wide range of design variables such as tobacco type and 
blend, chemical processing and additives, and in addition, physical features such as 
paper, filter and ventilation. It is also important to consider factors such as tobacco 
weight or density, and cigarette geometry (circumference and length). Cigarette 
additives have a range of purposes; e.g. to facilitate manufacture, increase shelf life, 
control burn rates, nicotine delivery, flavour and harshness/irritation etc. The physical 
design characteristics of the tobacco product interact with its chemical composition to 
influence its function and effect (WHO 2001). For example, the size of the cuttings of the 
tobacco in cigarettes and non-combusted and non-heated tobacco, and its level of acidity 
(measured as pH), interact to influence the release of nicotine from the product (Callicutt 
et al. 2006, Stevenson and Proctor 2008). Cigarette ventilation designs also modify free 
nicotine levels in the smoke. Similarly, the physical and chemical characteristics of 
cigarettes interact to alter the size distribution of the aerosol particles that convey 
nicotine and other chemicals, and thus influence absorption (WHO 2007b).  
Roll your own (RYO) tobacco denotes any tobacco product which, because of its 
appearance, type, packaging, or labelling, is suitable for use and likely to be offered to, 
or purchased by, consumers as tobacco for making cigarettes. RYO cigarettes are 
cheaper substitutes for commercially manufactured brands and have gained popularity 
worldwide. 
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A cigar8 is a roll of tobacco wrapped in leaf tobacco or any other substance containing 
tobacco. There are four main types of cigars: little cigars, small cigars (“cigarillos”), 
regular cigars and premium cigars. Little cigars contain air-cured and fermented tobacco 
and are wrapped either in reconstituted tobacco or in cigarette paper that contains 
tobacco and/or tobacco extract. Some little cigars have cellulose acetate filter tips and 
are shaped like cigarettes. Cigarillos are small, narrow cigars with no cigarette paper or 
acetate filter. Regular and premium cigars are available in various shapes and sizes and 
are rolled to a tip at one end. 
Pipe tobacco can be a blend of as many as 20-25 different tobaccos, or made of Burley 
varieties only. Some pipe tobaccos contain midrib tissues, and casings and sauces are 
frequently added. 
A waterpipe is one of the ancient forms of tobacco use. Cut or shredded tobacco is 
smouldered inside the head, which is covered by a perforated aluminium foil on which 
the glowing charcoal is placed. The smoke is drawn through a tube inside the waterpipe, 
filtered through water in a container and reaches the smoker's mouth via a long flexible 
tube. A great variety of tobaccos, or mixture of tobaccos with additives, is used in such 
pipes. 
Smokeless tobacco is consumed without burning the product, and can be used orally or 
nasally. It comes in two main forms: snuff (finely ground or cut tobacco leaves that can 
be dry or moist, loose or portion packed in sachets, and administered to the mouth, or 
the dry products to the nose or mouth); and chewing tobacco (loose leaf, in pouches of 
tobacco leaves, “plug” or “twist” form). According to the Tobacco Products Directive 
(2001/37/EC) chewing tobacco is not included in the definition of “tobacco for oral use”, 
the sale of which is banned in all EU countries except Sweden. Swedish-type moist snuff 
(snus) consists of finely ground dry tobacco (Kentucky and Virginia tobacco), mixed with 
aromatic substances, salts (sodium chloride), water, humidifying agents and chemical 
buffering agents (sodium carbonate). The large variety of smokeless tobacco products 
available worldwide has been described in detail elsewhere (SCENIHR 2008). 
Electronic cigarettes, or e-cigarettes, are battery-powered devices that vaporise nicotine, 
flavouring, and other chemicals into an inhalable vapour (Pauly et al. 2007). Chemical 
analyses have detected tobacco-associated chemicals that may be harmful to humans, 
including known human carcinogens (Kuehn 2009). E-cigarettes have been marketed 
recently for a range of uses, including, as a cessation aid and as an alternative to 
cigarettes in smoke-free zones. The different brands vary greatly in content of nicotine 
and other chemicals, but the health risks or efficacy as cessation aids have not yet been 
sufficiently documented (Bullen et al. 2010). 
3.3.2. Contents, ingredients, and additives 
According to the terminology used in the WHO Framework Convention and the 
recommendation by the Scientific Advisory Committee in 2003, the term “contents” is 
used synonymously with the term “ingredients”. Consequently, it means all product 
components, the materials used to manufacture those components, residual substances 
from agricultural practices, storage and processing, substances that can migrate from 
packaging into the product, as well as what may be termed “additives” and “processing 
aids” in some countries and regions (WHO 2007b).  
                                          
8 According to the Council Directive 2010/12/EU of 16 February 2010, the following shall be deemed to be 
cigars or cigarillos if they can be and, given their properties and normal consumer expectations, are exclusively 
intended to be smoked as they are: (a) rolls of tobacco with an outer wrapper of natural tobacco; (b) rolls of 
tobacco with a threshed blend filler and with an outer wrapper of the normal colour of a cigar, of reconstituted 
tobacco, covering the product in full, including, where appropriate, the filter but not, in the case of tipped 
cigars, the tip, where the unit weight, not including filter or mouthpiece, is not less than 2,3 g and not more 
than 10 g, and the circumference over at least one third of the length is not less than 34 mm. 
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Based on the 2nd Report on the Application of the Tobacco Products Directive (EC 2007b), 
the current definition of “ingredients” in Article 2 (5) covers any substance or constituent 
used in the manufacture or preparation of a tobacco product and still present in the 
finished product even if in an altered form, including paper, filter, inks and adhesives. It 
does not cover the tobacco leaf itself or other natural or unprocessed tobacco plant parts.  
For the purpose of this report, we consider that the WHO definition is the most useful, as 
some of the added ingredients (e.g. different forms of sugar) are already present in the 
tobacco leaves. Tobacco leaves may also in some cases contain various toxic substances 
such as cadmium or radioactive isotopes. The possible presence of residual substances 
from agricultural practices will not be addressed in this report.   
In order to avoid misunderstandings, the present report uses the term additives for 
added ingredients or substances. Additives are defined as any substance that is added, 
except water, during the course of manufacture of a tobacco product, including 
preservatives, humectants, flavours, and processing aids. 
Natural or clean cigarettes are being marketed as having no chemicals or additives and 
the filters are made from natural cellulose. However, smoke from these cigarettes still 
contains all the carcinogens and toxins that come from the tobacco itself (Malson et al. 
2002, McDaniel and Malone 2007).  
Herbal cigarettes, although they may not contain tobacco, yield tar and carbon monoxide 
when smoked, and are thus also dangerous to health (Chen et al. 2007a, Gan et al. 
2009). 
3.3.3. Addiction and addictiveness 
Addiction is the commonly used term referring to what is technically known as 
“dependence” and is widely employed to connote severe substance dependence, as has 
been demonstrated to occur in tobacco users. Dependence has been defined by the WHO 
Expert Committee on Drug Dependence (WHO 2003) and The ICD-10 Classification of 
Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines (WHO 
1992).  
Addictiveness refers to the pharmacological potential of a substance to cause addiction. 
Abuse liability of a drug is the likelihood that its use will result in addiction (dependence) 
and it can be assessed in laboratories by methods referred to as abuse liability testing 
(Schuster and Henningfield 2003, Wayne and Henningfeld 2008b, WHO 2003).  
The terms “dependence-causing” and “dependence potential” have been used as 
synonyms for “addictive” and “addictiveness”, respectively. In addition to the 
neurobiological characteristics of the substance itself, dependence potential is related to 
the dose, speed of absorption, metabolism, and to physical and chemical features of the 
formulation (WHO 2007b).  
3.3.4. Attractiveness  
According to the WHO, the terms “attractiveness” or “consumer appeal” refer to factors 
such as taste, smell and other sensory attributes, ease of use, flexibility of the dosing 
system, cost, reputation or image, assumed risks and benefits, and other characteristics 
of a product designed to stimulate use (WHO 2007b). Physical product characteristics are 
often integrated with marketing (WHO 2007b). For example, a flavour such as “menthol”, 
“mint”, or “cherry”, which is intended to appeal to a target population, may be 
incorporated into the product name or descriptors and marketed to reach out to that 
population (WHO 2007b). Attractiveness is also related to nicotine dosing characteristics, 
which is why smokeless tobacco product companies may include products ranging from 
lower dosing and slower onsetting “starter” products to higher dose maintenance 
products (FDA 1995, FDA 1996).   
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Although the risk of dependence on any substance is partially related to the 
attractiveness and/or ease of use of the delivery system, these features are not typically 
evaluated in dependence-potential testing but rather are generally described as factors 
affecting “consumer appeal” or “attractiveness”. Addictiveness and attractiveness go 
hand in hand as the real world liability for abuse of and addiction to a tobacco product is 
to a large extent also related to the attractiveness of the tobacco product.  
Attractiveness is powerfully determined by imagery and cultural associations that are 
cultivated by the tobacco industry and effects may therefore be indirect. Attractiveness is 
also influenced by product sensory characteristics using flavours, and product 
characteristics (as well as marketing) that are intended to reduce concerns or 
undesirable features (e.g. reduce concerns about cancer with “light” branding, and 
reduce noxious throat burn with various chemicals and “smoke smoothers”) (Wayne and 
Henningfield 2008b). 
3.4. Tobacco - manufacturing process 
The manufacturing process for cigarettes has been described in several publications 
(Davis and Nielsen 2006, Hoffmann and Hoffmann 1997, IARC 2004, Wigand 2006). 
However, while the exact composition of each brand remains a trade secret, according to 
the Tobacco Products Directive (2001/37/EC) tobacco industries have to report the full 
list of additives in tobacco products, including the exact amount, to the competent 
authorities in the Member States.   
Both the make-up of cigarettes and the composition of cigarette smoke have gradually 
changed in the last 50-60 years, including the use of a larger range of additives. The 
sales-weighted average “tar” and nicotine yields have declined. These changes have been 
primarily achieved by the introduction of filter tips, with and without perforation, 
selection of tobacco types and varieties, utilization of highly porous cigarette paper, and 
incorporation into the tobacco blend of reconstituted tobacco, opened and cut ribs, and 
“expanded tobacco” together with the use of a large number of additives/ingredients. At 
least four of the physical parameters of cigarettes have a decisive influence on smoke 
yields. These are the length of a cigarette, its circumference, the cut of the tobacco, and 
the packing density (Hoffmann and Hoffmann 1997). Agronomic factors such as 
production practices and soil characteristics, and environmental conditions such as 
rainfall, reportedly influence the accumulation of metals, including cadmium, beryllium, 
chromium, nickel and arsenic in the leaf. 
Commercial tobacco products are predominantly produced from Nicotiana tabacum, while 
Nicotiana rustica is used on a limited commercial scale. Within the species N. tabacum 
one distinguishes four types: bright (Virginia), Burley, Maryland, and Turkish tobaccos. 
Bright tobacco is flue-cured by drying with artificial heat; Burley and Maryland tobaccos 
are air-cured; Turkish tobaccos are sun-cured. The properties of tobacco are based 
primarily on curing methods, locality of growth, position on the stalk from which the 
leaves have originated and factors such as colour quality and ripeness at harvest. Curing 
is the process for drying freshly harvested tobacco with partially or fully controlled 
temperature and moisture schedules. Freshly cured leaf is then threshed to separate 
stem from lamina, sometimes blended with other tobacco lamina and then re-dried to a 
uniform moisture level then packed into bales or hogsheads.  
Virginia tobacco leaves contain a higher carbohydrate (e.g. sugars) level and lower 
nitrogen level than Burley leaves. The natural drying of the Burley leaves at relatively low 
temperatures allows plant respiration which continues to consume sugars during the 
process, leaving negligible sucrose and reducing sugars in the cured leaf. Burley leaves 
contain higher levels of nitrogen than Virginia leaves. The smoke of Virginia or flue-cured 
leaves is more aromatic and less alkaline than that of Burley tobacco, with a slight acidic 
taste resulting from the high levels of natural sugars. Burley tobacco produces a more 
alkaline smoke than flue-cured tobacco (Weeks 1999) and therefore imparts a bitter 
aroma and taste to cigarettes. Oriental leaves tend to have a low nitrogen content and 
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moderate levels of carbohydrates, but fewer proteins, than the other varieties (Philip 
Morris 2010, Wolfe 1962). 
A comprehensive integrated pest management programme is used to avoid insect 
infestation, e.g. chemical fumigation. The tobacco then undergoes aging and 
fermentation, usually for 1-3 years. 
For the manufacture of cigarettes, specific tobacco blends utilizing desired tobacco types 
are prepared. Blending is the selection and thorough mixing of the tobacco-based 
components plus any associated casings, humectants and flavouring required for a 
particular product or brand. The tobacco based components may include the leaf lamina, 
cut and rolled stem, reconstituted sheet and expanded tobacco.  
The tobaccos stored in bales are broken up, cut into specific dimensions, and combined 
with other blend components such as casing and top dressing, and adjustment of the 
moisture content. American blend cigarettes contain the four types of tobacco mentioned 
above plus reconstituted or homogenised sheet tobacco. This is made from tobacco dust, 
fines and particles, and leaf ribs and stems (IARC 2004). Reconstituted tobacco or 
homogenised sheet tobacco is a paper-like sheet approaching the thickness of tobacco 
laminae. It is made from tobacco dust, fines, and particles, and from ribs and stems; 
various additives may be incorporated. In the past, most of these “tobacco by-products” 
were wasted. The introduction of reconstituted tobacco or RECON is the primary means 
by which ammonia chemistry and other chemicals are introduced into a cigarette. 
Expansion is a process which increases the shred filling power, e.g. puffed tobacco. 
Puffed, expanded, and freeze-dried tobaccos are modified preparations of cigarette 
tobacco and have up to twice the filling power, thus requiring less tobacco per cigarette. 
The principle applied here is to expand the tobacco cell walls by quick evaporation of 
water and other agents that readily volatilize. 
Blending is carried out to achieve specific pH, taste, burning characteristics, and nicotine 
content. The pH strongly influences the concentration of free (i.e. non-protonated) 
nicotine in tobacco smoke, whereas the nitrate content influences the carcinogenic 
potential of smoke (IARC 2004). 
Table 2 presents the classification of tobacco types based on curing methods and 
function. 
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Table 2 Classification of tobacco types based mainly on curing methods (IARC 2004, 
US Department of Agriculture 2001)  
 
Tobacco type 
 
Characteristics/ 
alternate names 
 
Main use 
Flue-cured    Leaves are yellow, blond, 
bright therefore also called 
Bright or Virginia  
Cigarettes and also roll your 
own (RYO) cigarettes and pipe 
tobacco 
Fire-cured   Light to dark brown cured 
over open fires (Kentucky) 
RYO, chewing tobacco, cigars 
and smoking tobacco 
Light air-cured  Burley (cured without 
supplementary heat)  
Maryland  
Perique 
Mainly in cigarettes (also RYO, 
pipe tobacco and cigars)  
Cigarettes 
Pipe tobacco 
Dark air-cured Light to medium brown Chewing tobacco and snuff, 
snus, dark cigarettes 
Sun-cured  Oriental tobacco varieties  
Latakia  
Turkish cigarettes (also RYO 
and pipe tobacco) 
Some pipe tobaccos 
Cigar filler,  
Cigar binder,  
Cigar wrapper  
Tobacco types for use as 
cigar fillers, binders and 
wrappers 
Used for cigars 
 
Two principal types of commercial cigarettes have traditionally been sold throughout the 
world: (i) American Blend cigarettes, which are made from a blend of Virginia, Burley and 
Oriental tobaccos; and (ii) Virginia cigarettes, which contain exclusively Virginia tobacco. 
Casing refers to the sauce composed of a variety of ingredients such as humectants, 
sugars, cocoa, liquorice and fruit extracts (Hoffmann and Hoffmann 1997). The basic 
material of casing for reducing harshness is sugar. A commercial solution of tannin also 
sweetens and softens the smoke of tobacco. The best known example of an additive that 
changes markedly and even masks the taste of tobacco is the use of cloves. Addition of 
menthol is another example, but in this case the tobacco taste is still discernible. Burley 
leaf has the ability to absorb up to 25% of its weight of added material (Akehurst 1981). 
Casings are usually applied to tobacco strips or leaf early in the primary processing 
scheme to tone down or mute the strength or harshness of tobacco smoke, improve 
processibility of tobacco and add deep flavour notes to the smoke. Casings are 
traditionally added to US blended styles of product that contain significant proportions of 
Burley type tobacco blends. These casings are added to the Burley tobacco line through 
the means of the casing cylinder or Cased Leaf Dryer. 
Ammonia technology has been used with US blended styles of products containing cased 
Burley tobacco. Ammonium salts could be added at the Cased Leaf Dryer (CLD) stage or 
with the manufactured reconstituted tobaccos. 
There are no fixed rules as to where humectants, flavours and flavourings are added to 
the processed tobacco but generally the more volatile ingredients are added as late as 
possible during tobacco processing to prevent losses. Those tobacco blends that contain 
flavours and flavourings are usually held in a bin to allow for equilibration across the 
blend before it is passed to the making machine as the final blend. Top flavourings are 
generally applied to the total tobacco blend as one of the last steps in processing. They 
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are usually carried in an alcohol base. They are used to improve quality of smoke, impart 
a pleasant pack aroma and side-stream aroma. Menthol may be added at any of the 
following stages; spraying onto the final blend, through addition to the filter via a thread, 
or by application to the cigarette paper or the foil used to wrap the cigarettes. Due to the 
high level of volatility of menthol, different manufacturers have over the years developed 
a variety of methods for producing mentholated products that are as consistent as 
possible in terms of their finished product menthol levels (BAT 2010). 
In cigarettes, flavours may be added to tobacco, cigarette paper, or the filter, in a plastic 
pellet placed in the filter or the foil wrapper, in an attempt to enhance the tobacco 
flavour, mask unpleasant odour, and deliver a pleasant cigarette-pack aroma. Internal 
industry documents reveal additional flavour technologies such as flavour 
microencapsulation in the paper, carbon beads, and polymer-based flavour fibres 
inserted into the filter, flavoured tipping etc. (WHO 2007b). 
As described above, the physical elements of the cigarette such as packing density, 
particle size distribution, rag cut per inch, colour appearance, resistance to draw, the 
appropriate paper, filter, tobacco type and the final tobacco blend, are carefully 
controlled (Wigand 2006). The final product is manufactured using high speed automated 
machines.  
Over the years the tobacco industry has developed genetically modified (GM) tobacco 
plants with an aim, among others, to manipulate nicotine levels (Dunsby and Bero 2004). 
Reductions of nicotine levels have been in the range of 80-98%. 
Philip Morris sought to use anti-sense biotechnology to disrupt enzymes involved in 
nicotine biosynthesis (US Patent 5684241). In 2003, Vector Tobacco began marketing a 
new cigarette that is produced from GM tobacco containing trace amounts of nicotine. 
The GM plant was produced by disrupting expression of the gene for quinolinate 
phosphoribosyl transferase, which encodes one of the rate-limiting enzymes in the 
nicotine biosynthetic pathway (Bonetta 2001). Vector Tobacco market Quest Cigarettes, 
which exist in three forms, ranging in nicotine content from 0.6 mg per cigarette to 
0.05 mg per cigarette. They are marketed as a smoking cessation or reduction aid, with 
the manufacturer claiming that graded reduction of nicotine exposure through the 
gradual use of increasingly lower nicotine content cigarettes will lead to the eventual 
extinction of nicotine dependence and conditioned associations with related cues (Bonetta 
2001). 
Large scale field-trials have also been conducted despite consumer opposition and fear of 
tobacco growers that GM crops would be turned down by several countries.  
3.4.1. Conclusions on manufacturing 
Cigarettes, which are the predominant tobacco product, are highly engineered nicotine 
delivery devices that are mass produced by the major industries by integrated 
automation.   
The properties of tobacco products depend on locality of growth, position of leaves on the 
stalk, ripeness and curing method. The different curing methods (drying procedures) 
determine the sugar content and colour of the tobacco leaves. During the manufacturing 
process of cigarettes, a number of substances are added at different stages for various 
reasons, such as providing consistency of the product, creating a unique brand, and 
promoting attractiveness.  
3.5. Technical characteristics of cigarettes 
Parts of cigarettes, like the paper and filter have technical features which affect the 
constitution of main-stream and side-stream smoke. 
 Addictiveness and Attractiveness of Tobacco Additives  
 24
3.5.1. Introduction 
Considering the natural origin of tobacco leaves, their content will, both qualitatively and 
quantitatively, depend on the season, local weather conditions and geographical origin. 
Consumers do not like to smoke a product that changes over time, i.e. smoking a 
constant product is preferred. In order to produce a constant product, i.e. to mask the 
batch to batch variation in taste, tobacco companies use a large variety of additives in 
the manufacture of tobacco products. In addition, the tobacco companies strongly prefer 
to maintain the same TNCO values (tar, nicotine and carbon monoxide) of their products. 
To achieve consistency in TNCO values, tobacco producers change, amongst others, the 
ventilation of the products. The ventilation through the filter can be increased by 
punching more (or wider) ventilation holes. The ventilation of a cigarette can also be 
changed by using commercially available cigarette paper wraps with another grade of 
porosity. 
Relevant technical characteristics of cigarettes are the following: 
• Ventilation of the paper (paper porosity); 
• Ventilation holes in the filter; 
• Ventilation holes in the paper wrap; 
• Packing of tobacco (dense or loose); and 
• Geometry (length, diameter). 
Ventilation 
Large efforts have been made by the tobacco industry to investigate the effect of 
ventilation on the size distribution of the smoke aerosol. Depending on the size, the 
smoke particles enter and deposit at different levels of the airways (upper or lower 
airways). The purpose of this research was either to enhance the absorption of nicotine, 
to decrease the toxic potential of the product or to manipulate the taste of the smoke.  
The main effect of ventilation is the dilution of the tobacco smoke. As such, the 
concentration of smoke components is reduced which not only leads to a lower dose of 
nicotine, but also to a lower concentration of other (toxic) components. It appears, 
however, that smokers compensate for the lower dose of nicotine per puff (due to 
increased ventilation) by increasing their puff volume, puff frequency, and deeper 
inhalation of the smoke (Jarvis et al. 2001, Scherer 1999). Many other smokers 
consciously or unconsciously block a part of the ventilation holes with their fingers so 
that more concentrated smoke is inhaled. 
Another feature of ventilation is that it may affect the particle size and particle size 
distribution of the smoke aerosol, i.e. increasing the ventilation is supposed to decrease 
the mean particle size of the aerosol. It is difficult to assess whether an increase in 
ventilation indeed reduces the particle size as only few studies are reported in publicly 
available literature.  
3.5.2. Technical limitations 
It is difficult to determine the size of the particles and their distribution in cigarette 
smoke, mainly because the half-life of the particles is very short (0.1-1 sec). Rapid 
ageing of the aerosol results in larger particles as they have time to coalesce, i.e. a 
secondary aerosol containing larger particles at the expense of smaller particles is rapidly 
formed (Harris and Kay 1959). Therefore, only sophisticated on-line sampling and 
detection allows a proper measurement of the particle distribution of the smoke aerosol. 
Obviously, these techniques require large financial resources and highly qualified 
technical personnel. 
A number of variables other than ventilation may affect the particle size; moisture of the 
cigarette (relative humidity), puff volume, puff number (e.g. first or last puff), butt 
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length, length of the cigarette, electrostatic charges, etc. Different unities are used in the 
studies to express the size of the particles (mean diameter, count median aerodynamic 
diameter, mass median aerodynamic diameter) which hampers quantitative comparison 
of the data. The aerosol is produced during burning, i.e. directly behind the burning cone 
at the tip of the cigarette the superheated vapour condenses and forms an aerosol; the 
longer the aerosol stays in the cigarette, the larger the size of the particles. 
Due to the number of different particle sizing methods, instrumentation and sampling 
and detection techniques applied, as well as differences in the cigarettes and smoking 
conditions, variable results are found and the results of different investigations are 
difficult to compare. Important limiting factors for many techniques are low time of 
resolution and the ageing of the smoke. Over time various methods have been developed 
to improve the accuracy of the measurements. 
3.5.3. Smoke particles 
Particle size may be relevant for the absorption of nicotine into the bloodstream. 
Cigarette smoke particle size has generally been reported with mass median diameter 
(MMD) in the size range of 0.3-0.5 µm and count median diameter (CMD) in the range of 
0.2-0.4 µm (Bernstein 2004, Wayne et al. 2008a). Particles larger than 1 µm are mostly 
trapped within the cigarette, whereas ultra-fine particles (less than 0.1 µm - nano-
particle range) probably will adhere to the surface of the paper, tobacco and filter, or 
coagulate into larger particles (Stratton et al. 2001), see section 3.5.4. Differences in 
particle size found in many studies were quite small and some internal tobacco 
documents concluded that the measurable influence of conventional design changes was 
insignificant (Philip Morris 1991, Wayne et al. 2008a). Of the four variables applied by 
Philip Morris to change the size of the particles (filler, filter, paper and ventilation) only 
ventilation had any significant effect (Cox et al. 1992). In addition, butt length and puff 
volume affect the size of the particles. There is a clear trend of decreased size of the 
particles at shorter butt lengths; the average size at 20 mm was 0.29 µm and at 55 mm 
it was 0.34 µm. Cox et al. (1992), taking all the variables mentioned above into account, 
reported deviations of about 10 to 30%. Surface mean diameter increased from 0.32 to 
0.42 µm when the ventilation was increased from 0 to 60%. Based on their results, Cox 
et al. (1992) suggested that aerosol coagulation in the cigarette rod is the main 
mechanism for change in particle size.  
Bernstein (2004) reviewed the available data of the tobacco smoke particulates which go 
back to 1950s. The main findings include: 
• No difference in particle size between plain (non-filter) and filter cigarettes.  
• Particle size depends on puff number (e.g. first vs. last puff). 
• Relative humidity of the tobacco does not affect or only marginally affects particle 
size. 
• Aged tobacco smoke contains larger particles than fresh smoke. 
Considering all the studies reviewed by Bernstein, the size of the smoke particles range 
roughly from 0.17 to 0.60 µm, either expressed as CMD or MMD. 
A study by McCusker et al. (1983) compares mass median aerodynamic diameter of 
ultra-low-tar, low-tar and medium-tar rated cigarettes (with and without filter). Particle 
size was less than 0.6 µm and not affected by the cigarette filters. Among the 10 brands 
tested ventilation ranged from 22 to 94%. The mass median aerodynamic diameter 
ranged from 0.36 µm to 0.56 µm, but did not correlate with ventilation efficiency. The 
number of particles was, however, reduced by 20–90% by applying the commercial 
filters and the particles were present in the higher puff numbers. Interestingly, blocking 
of the ventilation holes on the filters of ultra-low-tar cigarettes increased the particle 
concentration. This is explained by the longer residence time (longer transit time from 
cone to filter) of the newly formed particles in the cigarette rod. 
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As mentioned in section 3.5.2, only sophisticated on-line sampling and detection allows a 
proper assessment of the particle size and distribution. Moreover, the relevance of ultra-
fine particles for nicotine absorption has only been taken seriously for the last two 
decades; therefore, most of the older studies did not focus on the presence of ultra-fine 
particles.  
Recently, using on-line measurement of the particle size (range measured 5–1000 nm), 
Adam et al. (2009) reported that non-ventilated cigarettes smoked under an intense 
regime, which includes blocking the ventilation holes resulted in a count median diameter 
of 0.18 µm, whereas 70% ventilated cigarettes smoked under a milder standard smoking 
regime led to a diameter of 0.28 µm. The particle size of mainstream smoke of Virginia 
cigarettes, smoked under a standard smoking regime, was 0.22 µm and 0.25 µm at 0 
and 70% ventilation, respectively. For the intense smoking regime the respective particle 
sizes were 0.18 and 0.22 µm. Interestingly, when the ventilation was increased from 0 to 
70% the total number of particles decreased dramatically from 2.3×1012 to 0.3×1012, 
and the total mass of particles dropped from 17.2 to 2.3 mg (standard smoking regime). 
In another recent paper by Gowadia et al. (2009) the particle size (mass median 
aerodynamic diameter) was found to be approximately constant (0.9–1.0 µm) for three 
different puffing regimes. The smoke was collected in a conditioning chamber and the 
particle size distribution was determined by UV spectrometry. 
The particle size of waterpipe smoke was shown to be somewhat smaller than that of 
cigarette smoke. Monn et al. (2007) reported waterpipe smoke particle median diameter 
of 40 nm in a full smoking set containing charcoal, tobacco and water; the smoke of the 
heated tobacco alone ranged from 10 nm to 200 nm while the burning of charcoal was 
mostly responsible for the particles smaller than 50 nm. Fromme and colleagues found 
two phases of particle emission during a waterpipe session; when the charcoal was lit, 
the particle diameter was around 100 nm and during the smoking session it decreased to 
17 nm (Fromme et al. 2009). Daher et al. (2010) found similar particle sizes to the Monn 
study in side-stream smoke from waterpipes, which were significantly smaller than 
particle sizes in side-stream smoke from cigarettes with a median diameter of 139 nm 
and a large number of particles smaller than 100 nm.  
3.5.4. Deposition of particles 
Although the size of the particle is an important factor for the deposition in the lung, the 
relationship between particle size and deposition in the lung is complex and factors other 
than size alone, such as respiration rate, depth of inhalation and flow rate, affect lung 
deposition (Sarangapani and Wexler 2000).  
In figure 1 the relative deposition of particles (dependent on the aerodynamic diameter) 
in humans is depicted. Particles larger than 1 µm will mainly deposit in the extra-thoracic 
region. Smaller particles will deposit in different regions, but the general statement that 
smaller particles deposit deeper in the lung is not entirely true. Very small particles (a 
few nm) will mainly deposit in the extra-thoracic region. Peak alveolar deposition is 
around 30-20 nm and becomes less important at sizes less than 8-9 nm (ICRP 1994, 
Oberdörster et al. 2005). The question whether the ultra-fine particle size is relevant for 
mainstream tobacco smoke is unanswered. From a theoretical point of view removal of 
ultra-fine particles is to be expected due to adherence to the surface of the paper or to 
the tobacco and filter, or due to coagulation into larger particles (Stratton et al. 2001) 
(see section 3.5.3), however this needs to be confirmed experimentally. 
Other points of concern in the inhalation of ultra-fine particles are the translocation of 
these particles: (1) from the lumen of the lung to the circulation; and (2) from the 
olfactory nerve endings in the nose to the brain. These two events have been described 
for several solid nanoparticles in the lungs of animals and humans (Kreyling et al. 2002, 
Nemmar et al. 2002), and in the noses of rodents (Oberdörster et al. 2002). These 
phenomena have not been shown for tobacco smoke derived particles which are not solid 
nanoparticles (although combustion derived particles have been studied in the lung); 
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therefore, only theoretical/hypothetical considerations can be made (which fall outside 
the scope of this opinion).  
 
 
Figure 1 Predicted deposition of inhaled particles during nose breathing. Fractional 
deposition in: extrathoracic (ET); trachea-bronchial (TB); and alveolar (A) 
regions (adapted from ICRP 1994).  
3.5.5. Light cigarettes as an example of cigarettes with high ventilation 
The best known application of changing ventilation is the development of light cigarettes. 
Light cigarettes have been marketed as products with a lower health risk as they should 
deliver less tar and other toxic compounds in the smoke inhaled. As will be described in 
detail in section 3.10.1 many smokers of light cigarettes inhale the smoke deeper and 
increase the number of puffs, so the health risks are probably not lower than for smokers 
of regular cigarettes (Frost et al. 1995). Animal studies have shown that self-
administration of a low dose of nicotine at a high frequency gives a more reinforcing 
effect as compared to self-administration of a higher dose at a low frequency (in this 
comparison total dose self-administered is the same) (Harris et al. 2008, Harris et al. 
2009, O’Dell et al. 2007).  
3.5.6. Conclusions on technical characteristics 
A number of technical characteristics of cigarettes influence the content of different 
substances in the smoke and the size of smoke particles. The so-called TNCO values (tar, 
nicotine and CO) are determined by, amongst other things, ventilation (paper, filter), the 
packing of the tobacco and the geometry of the cigarettes. Smokers usually compensate 
for a lower dose of nicotine by increasing puff volume and frequency, and by deeper 
inhalation. Data obtained in animal studies suggest that cigarettes with high ventilation 
(often described as “light” or “low tar”) may favour addiction to nicotine in the smokers 
of these products, because of an increased smoking frequency. 
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The particle size of smoke aerosol of commercial cigarettes is around 0.4 to 2 µm. A 
large fraction of ultrafine particles (<0.1 µm) probably adheres to the surface of the 
paper or the filter, or coagulates into larger particles, and will thus not be present in the 
smoke as such. The small smoke particles (submicron meter range) will enter the lower 
airways and alveoli, while larger particles (micron meter range) will be deposited 
increasingly in the upper airways.  
Considering the manufacturing of cigarettes, the change of the technical characteristics 
of cigarettes may affect the mean particle size and, therefore, the distribution of the 
smoke aerosol. However, based on the limited publicly available information, it seems 
that exposure to nicotine cannot be substantially increased by altering the particle size of 
the smoke aerosol.  
3.6. Nicotine 
3.6.1. Pharmacological effects (incl. metabolism of nicotine)  
3.6.1.1. Brief historical overview 
Nicotine is the principal component alkaloid of tobacco, occurring throughout the plant 
(Nicotiana tabacum), especially in the leaves. The plant and the compound are named 
after Jean Nicot, a French ambassador to Portugal, who sent tobacco seeds to Paris in 
1550. Crude nicotine was known by 1571, and the compound was obtained in purified 
form in 1828; the correct molecular formula was established in 1843, and the first 
laboratory synthesis was reported in 1904. It is one of the few liquid alkaloids; colourless 
and extremely toxic. Nicotine is commercially obtained from tobacco scraps; it has been 
used as an insecticide and as a veterinary vermifuge.  
 
Figure 2 Structure of nicotine (CAS number 54-11-5)  
3.6.1.2. General pharmacodynamic (physiological) effects  
Nicotine administration induces a series of multifaceted effects which show great 
interindividual variability, i.e. the effects vary greatly from person to person. This is 
reflected in a non-linear and complex dose-response relationship ensuing from a 
summation of stimulatory and inhibitory actions in the central and peripheral nervous 
systems. 
Low doses of nicotine, including those in the range of inhaled cigarette smoke (1-2 mg), 
produce stimulation of ganglionic neurotransmission (vegetative ganglia). This generates 
a complex response which results from a mix of sympathetic and parasympathetic 
actions. Thus, tachycardia and rise of blood pressure are to a large extent the 
consequence of sympathetic ganglia activation that induces an increased adrenaline 
release in the adrenal medulla (via splanchnic nerve stimulation). At the same time, the 
nicotine action on the carotid and aortic chemoreceptors and on the brain regulating 
centres modifies the cardiovascular effects determining the great variability observed in 
the final response. Therefore, the direct nicotine effects on heart rate and blood pressure 
are rapidly counterbalanced by the peripheral and central cardiovascular compensatory 
reflexes. Similarly, nicotine–induced activation of parasympathetic ganglia and 
cholinergic terminals causes an increase of the gastrointestinal peristalsis. In susceptible 
subjects, first doses may cause nausea, vomiting and related effects of hypercholinergic 
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activation. Nicotine also increases blood glucose levels and the activity of exocrine 
glands. In the brain, nicotine is clearly a stimulant at low doses. It produces a pattern of 
alertness in the electroencephalogram (EEG), mediates fast synaptic transmission, and 
positively modulates a range of cognitive functions. As a result, it improves attention, 
learning, arousal, motor skill, facilitates memory functions and decreases irritability and 
anxiety, among other central nervous system (CNS) functions (Balfour and Fagerström 
1996, Benowitz 2008, Fattinger et al. 1997, Grybko et al. 2010). 
An important pharmacological characteristic of nicotine is the rapid development of 
tolerance to its unwanted effects. Although there is a great individual variability, in many 
cases tolerance to the peripheral effects appears a few days after the first exposure 
(Benowitz 2008).  
3.6.1.3. Toxicity effects 
At high doses, after the initial stimulation, nicotine rapidly produces a ganglionic blockade 
due to the inhibition of transmission, which is a consequence of a persistent 
depolarisation of all autonomic ganglia. This depression of all autonomic ganglia results in 
bradycardia, hypotension, impairment of adrenaline release, etc. Similarly, a biphasic 
nicotine-induced action is also observed in the adrenal medulla (a discharge of 
catecholamines is evoked by small doses whilst their release is blocked by larger doses). 
It should be noted that most peripheral effects are influenced by compensatory reflexes. 
In the CNS large doses induce a generalised mental depression, tremors, nausea, and 
convulsions. The acute lethal dose of nicotine in an adult human is estimated to be about 
60 mg (Benowitz 2008, García-Estrada and Fischman 1977, Solarino et al. 2010). This 
dose (less than 1 mg/kg) is derived from old reported cases of intoxication when nicotine 
was widely used as an insecticide (Grusz-Harday 1967, Lockhart 1939). In rats the LD50 
is ~50 mg/kg and in mice ~3 mg/kg (Okamoto et al. 1994). Acute nicotine poisoning has 
occurred in children who accidentally ingest tobacco or are occupationally exposed to wet 
tobacco leaves. Children have played a role, and they continue to do so in many places, 
in agricultural production of tobacco, where absorption of nicotine from the plant is likely 
to happen. This nicotine-induced acute condition is known as green tobacco sickness. 
Clinical features are similar to those observed in adults (Gehlbach et al. 1974, McKnight 
and Spiller 2005). 
Ingestion of tobacco products is a major reason for infant and child toxic exposures 
reported to poison control centres. The large majority (90%) of such accidental 
poisonings in the population involve children up to 6 years of age (Connolly et al. 2010). 
However, ingestion of cigarettes and cigarette butts by children aged ≤ 6 years resulted 
in minor toxic effects (CDC 1997). 
Malizia et al. (1983) described four children who ingested two cigarettes each and 
developed salivation, vomiting, diarrhoea, tachypnoea, tachycardia, and hypotension 
within 30 minutes, and depressed respiration and cardiac arrhythmias within 40 minutes. 
Convulsions occurred within 60 minutes of ingestion. All recovered after gastric lavage 
with activated charcoal, intermittent positive pressure ventilation, and 5 mg diazepam 
intravenously for convulsions. 
A prospective review of 51 cases of tobacco ingestion and five cases of nicotine resin 
chewing gum exposure was conducted to evaluate the incidence and degree of toxicity 
caused by these products in children. A dose-response relationship was observed for 
cigarette exposures. Nine of 10 children ingesting more than one cigarette or three 
cigarette butts developed signs or symptoms (Smolinske et al. 1988). 
3.6.1.4. The nicotinic acetylcholine receptor 
Nicotine acts on a class of cholinergic receptors which are ligand-gated ion channels 
(nicotine acetylcholine receptors: nAChR). These kinds of receptors are structurally 
similar to the ones operated by GABA, glycine, glutamate, 5-HT3, etc. Nicotine binding to 
the nAChR opens the channel and increases its ionic permeability for monovalent cations 
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(Na+, K+) and divalent cations (Ca2+, Mg2+), although with difficulty for the latter and 
depending on the subtype of nAChR. Neuronal nAChR embrace a conjunct of at least 20 
homologous subtypes that mediate fast synaptic transmission throughout the central and 
peripheral nervous systems (Xiu et al. 2009).  
Neuronal nAChR are pentamers of homomeric or heteromeric combinations of α (α2 to 
α10) and β (β2 to β4) subunits, which possess different pharmacological and biophysical 
properties and locations in the brain (Gotti et al. 2006). 
The nAChRs in the CNS are localised both in postsynaptic and presynaptic neural 
membranes. Studies in recent years have shown that the primary site of nicotine action 
is presynaptic, and that nAChRs facilitate the release of neurotransmitters when localised 
in non-cholinergic terminals. In fact, nAChRs are present in the terminals of most of the 
neurotransmitter systems (GABAergic, glycinergic glutamatergic, dopaminergic, 
serotonergic, etc.). Likewise, nAChRs have been identified, in different densities, in most 
of the brain areas. 
Nine individual subunits of nAChRs in the human brain have been identified and cloned, 
and they combine in various conformations to form individual receptor subunits. The 
structure of individual receptors and the subtype composition are not completely 
understood. Only a finite number of naturally occurring functional nAChR constructs have 
been identified (Luetje 2004). 
The pentameric structure of the neuronal nAChR and the considerable molecular diversity 
of its subunits offer the possibility of a large number of nAChRs with different 
physiological properties. The stoichiometry of most nAChRs in the brain is still uncertain 
(Kuryatov et al. 2000).  
For example, the neuronal nAChR subunits on presynaptic terminals of dopamine 
neurons projecting to the striatum have been fully defined (Luetje 2004), as has the 
complete subunit composition of four major presynaptic nAChR subtypes in the striatum 
(Salminen et al. 2004). 
It should also be noted that chronic exposure to nicotine induces a marked increase in 
the density of nAChRs in most neurotransmitter systems and brain areas (Walsh et al. 
2008). 
3.6.1.5. Nicotine pharmacokinetics and metabolism 
Nicotine as a weak base (pKa = 8.0) is rapidly absorbed across biological membranes 
where the pH is at physiological (7.4) or slightly alkaline levels. This is the case for 
nicotine in cigarette smoke when it reaches the lung alveoli (Pankow et al. 2003). The 
average nicotine content of a cigarette (6-10 mg) delivers about 1 mg of nicotine (0.5-2 
mg) systemically through the smoker’s lungs (Henningfield et al. 1993). The pulmonary 
bioavailability (the amount absorbed from smoke) of inhaled nicotine is 80-90%. After 
inhalation it reaches high levels in the brain within 10-20 seconds, thus being equivalent 
to, or even faster than, an intravenous administration (Gourlay and Benowitz 1997, 
Hukkanen et al. 2005). In both cases the hepatic first-pass effect (metabolism) is 
avoided allowing higher levels of unmetabolised nicotine to be delivered to the brain. In 
addition, nicotine easily crosses the blood-brain barrier. 
In contrast, the buccal and gastric bioavailability of nicotine is low (20-40%) due to the 
acidic environment at which nicotine is protonated and therefore poorly absorbed through 
local membranes. Better absorption is obtained in the intestinal mucosa because of its 
alkaline pH. The liver first-pass metabolism contributes to the impairment of the 
bioavailability to a great extent. The time of nicotine blood maximal concentration for 
oral administrations is about 60-90 min. Nicotine bioavailability through the skin is high 
(75-100%). 
Nicotine is widely distributed in the body (liver, kidney, lungs, etc.; with adipose tissue 
showing the lowest affinity). Brain tissue exhibits a high affinity for nicotine. It has been 
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reported that nAChR binding capacity for nicotine is increased in smokers compared to 
non smokers (Breese et al. 1997, Perry et al. 1999). This reflects the higher density of 
nAChRs in the brain of smokers (nicotine-induced up-regulation of nAChRs). However, 
the quantity of nicotine delivered from the tobacco product which reaches the brain is 
higher in non dependent smokers than in heavy smokers (Rose et al. 2010a). 
The blood half-life (t½) of nicotine after cigarette smoking or intravenous administration 
is about 2 hours (t½ = 100-150 min). The disposition of nicotine shows a multiexponential 
elimination (Hukkanen et al. 2005). However cotinine, the main metabolite of nicotine, 
has a t½ ≈ 19 hours. It was found recently that every puff of a cigarette induces a peak 
of nicotine in the arterial blood (Berridge et al. 2010) with a t½ of 45 seconds, but that 
these peaks do not occur in the brain (Rose et al. 2010a). This finding rules out that the 
lack of efficacy of nicotine replacement therapy (NRT) (e.g. gums or patches) is due to a 
continuous delivery of nicotine. In the liver nicotine is mostly metabolised in the 
endoplasmic reticulum by the cytochrome P450 (CYP) system, mainly by CYP2A6 and 
CYP2B6. The major metabolite produced by CYP through nicotine oxidation is cotinine, 
which is further converted to cotinine glucuronide and other metabolites. It should be 
noted that CYP oxidative metabolism of nicotine to cotinine and its glucuronide 
conjugation are inhibited by menthol, a commonly used cigarette additive. The pathway 
of nicotine to cotinine represents around 70-80% of nicotine biotransformation in 
humans and, therefore, is commonly used as a quantitative biomarker of nicotine 
exposure as well as of CYP2A6 metabolic activity, which exhibits an important variation in 
function in humans (Benowitz 2008, Dempsey et al. 2004, Hukkanen et al. 2005, 
Hukkanen et al. 2010). Many other minor metabolites of nicotine are produced by CYP, 
glucuronidation, demethylation and other enzymatic pathways. These metabolites have 
no nicotinic activity, with the exception of nornicotine which is produced by N-
demethylation of nicotine in humans and other mammals (besides being a major tobacco 
leaf alkaloid). Although nornicotine is a minor metabolite, it has been shown that after 
repeated nicotine administration it accumulates in the brain at pharmacologically relevant 
concentrations acting as agonist on nAChRs but with about 10-fold lower potency 
(Dwoskin et al. 2001, Hukkanen et al. 2005).  
Renal excretion is the major route of elimination of nicotine and its metabolites (>90% of 
a dose). Unchanged nicotine accounts for about 10%, and nicotine glucuronide and 
nicotine N’-oxide for about 5% each, of the total nicotine-derived amount present in 
urine. Trans-3’-hydroxycotinine (35-40%) and its glucuronide (~10%) are the principal 
nicotine metabolites determined in urine, both after a single dose and in smokers; 
unchanged cotinine (10-15%), cotinine glucuronide (~15%) and cotinine N’-oxide (~4%) 
represent the rest of the cotinine metabolic pathway excreted. Small amounts of a large 
array of nicotine metabolites produced in the minor biotransformation pathways are also 
detected in urine. Nevertheless, the pattern of nicotine metabolites and their amounts 
are highly variable in humans due to the important polymorphism of CYPs and the other 
enzymatic pathways involved in the metabolic disposition of xenobiotics (Benowitz et al. 
2006, Benowitz 2008, Hukkanen et al. 2005). It has been suggested that this genetic 
variation in xenobiotic metabolism, especially that of CYP2A6, has a role in smoking 
behaviour and nicotine dependence (Malaiyandi et al. 2005). 
3.6.1.6. Conclusions on nicotine pharmacology 
The main effect of nicotine (besides its action on the cholinergic system) is the 
presynaptic release in the brain of neurotransmitters such as acetylcholine, 
noradrenaline, dopamine, serotonin, glutamate, GABA and opioid peptides. This allows 
the possibility that many compounds may modify the action of nicotine on the 
presynaptic nicotine receptors, and consequently modify the activity of nicotine in the 
brain. There is substantial interindividual variability in the action and metabolism of 
nicotine and many aspects of its pharmacology are still not fully understood.  
Nicotine metabolism may be modified by compounds inducing or inhibiting the activity of 
the cytochrome P450 system and other metabolic pathways, thus determining 
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pharmacokinetic changes. While the half-life of nicotine in the arterial blood is short, 
nicotine levels in the brain remain at high levels for much longer.  
3.6.2. Addictive properties of nicotine 
Nicotine exposure produces adaptive changes in the central nervous system (CNS) 
leading to an addictive process characterised by compulsive tobacco use, loss of control 
over tobacco consumption despite the harmful effects, the appearance of withdrawal 
symptoms upon the cessation of tobacco smoking, and relapse after periods of 
abstinence (McLellan et al. 2000). As in other addictive processes, the initiation of 
nicotine addiction has been related to its capacity to induce rewarding/reinforcing effects. 
However, the negative consequences of nicotine abstinence have a crucial motivational 
significance for maintenance and relapse of this addictive behaviour (Koob and Le Moal 
2008). The terms “reward” and “reinforcement” are often misused and confused. Reward 
describes stimuli that have appetitive (desirable) consequences and/or produce a 
hypothetical pleasurable internal state (hedonia). Reinforcement refers to the ability of a 
stimulus to promote behavioural responses in order to obtain (positive reinforcement) or 
to avoid (negative reinforcement) such a stimulus. A drug like nicotine that produces 
rewarding effects will also promote behavioural responses to obtain the drug, i.e. positive 
reinforcing effects. On the other hand, the effects induced by a drug can be associated 
with some particular neutral stimuli. After learning the association, this neutral stimulus 
becomes a conditioned stimulus associated with the drug that can also promote 
behavioural responses by itself. Several animal models of drug reward/reinforcement are 
based on these conditioning processes. 
The neurobiology of nicotine addiction is a complex phenomenon in which various 
transmitter systems are involved (Berrendero et al. 2010). The experimental animal 
models that have been used to investigate nicotine addiction are mainly models of 
nicotine reward/reinforcement and have been useful to define the neurobiological 
substrate involved in this behavioural response that is crucial for the nicotine addictive 
process. New complex behavioural models that resemble the main diagnosis for drug 
addiction in humans have been developed more recently (Belin et al. 2008, Deroche-
Gamonet et al. 2004, Vanderschuren and Everitt 2004). These models of addiction are 
extremely complex and have been validated only for cocaine addiction. Due to their 
complexity, these models have still not been used to investigate the neurobiology of drug 
addiction. Therefore, all the valuable information currently available about drug 
addiction, including nicotine addiction, is based on the results obtained in experimental 
models that evaluate drug rewarding/reinforcing effects (see section 3.9 for details about 
significance of the models). 
3.6.2.1. Nicotinic acetylcholine receptors subunits and nicotine 
rewarding/reinforcing effects 
The mesocorticolimbic system plays a crucial role in the rewarding/reinforcing properties 
of nicotine (Koob and Le Moal 2008). An important component of this system is the 
dopamine (DA) projection from the ventral tegmental area (VTA) to the frontal cortex 
and limbic structures, such as the nucleus accumbens (NAc). Nicotine administration 
increases DA activity in the NAc and other limbic structures (Di Chiara and Imperato 
1988) by direct stimulation of nicotinic acetylcholine receptors subunits (nAChRs) within 
the VTA (Nisell et al. 1994). α4β2 containing nAChRs located on DA cell bodies contribute 
decisively to the final activation of VTA DA neurons (Mansvelder and McGehee 2003). 
Indeed, the administration of selective α4β2 antagonists block nicotine-self-administration 
in rodents (Grottick et al. 2000). In agreement, mice with the β2 subunit knocked out do 
not self-administer nicotine (Picciotto et al. 1998). The specific location of nAChRs 
containing the β2 subunit in the VTA plays a crucial role in the mediation of nicotine 
reinforcement as demonstrated by genetic studies in mice (Maskos et al. 2005). In 
addition, α4 knockout mice fail to show nicotine-dependent enhancement of DA release in 
the NAc (Marubio et al. 2003), whereas a single nucleotide mutation rendering α4 
 Addictiveness and Attractiveness of Tobacco Additives  
 33
containing nAChRs hypersensitive to nicotine (Tapper et al. 2004) demonstrates that this 
subunit is sufficient to induce nicotine reward (Tapper et al. 2004). The precise role of 
the α7 homomeric nAChRs in nicotine reinforcing effects remains unclear since conflicting 
results have been obtained in mutant mice lacking this subunit and in rodents injected 
with selective α7 nAChR antagonists (Markou and Paterson 2001, Walters et al. 2006). 
On the other hand, repeated exposure to nicotine leads to up-regulation and 
desensitisation of nAChRs (Quick and Lester 2002), which are involved in the 
development of nicotine tolerance and the appearance of a withdrawal syndrome 
following smoking cessation. The brain regions underlying nicotine physical dependence 
have not yet been fully clarified, although an involvement of nAChRs located in the 
medial habenula and the interpeduncular nucleus has been recently reported (Salas et al. 
2009).  
Recent genome-wide association studies in humans have revealed a clear linkage 
between genetic variations in the nAChRs and the risk for nicotine dependence (Bierut 
2009). Thus, the region on chromosome 15 that includes the family of α5-α3-β4 nAChR 
genes has been associated with the development of nicotine dependence (Berrettini et al. 
2008, Thorgeirsson et al. 2008) and lung cancer (Amos et al. 2008, Hung et al. 2008, 
Thorgeirsson et al. 2008). These studies differ on whether the connection between the 
genetic variant at chromosome 15 and lung cancer is direct (Amos et al. 2008, Hung et 
al. 2008) or mediated through a modification of smoking behaviour (Thorgeirsson et al. 
2008). 
3.6.2.2. Involvement of glutamatergic receptors in nicotine 
rewarding/reinforcing effects 
Nicotine stimulates nAChRs on glutamatergic terminals that release glutamate in several 
brain regions including the VTA (Fu et al. 2000). Glutamate receptors located on 
postsynaptic DA neurons are critically involved in nicotine reinforcing effects (Liechti and 
Markou 2008). Thus, nicotine-induced DA release in the NAc is blocked by the 
administration of NMDA and AMPA ionotropic receptor antagonists (Kosowski et al. 
2004). In addition, the blockade of NMDA receptor decreases intravenous nicotine self-
administration in rats (Kenny et al. 2009). Several studies have also involved 
postsynaptic mGlu5 and presynaptic mGlu2/3 metabotropic receptors in nicotine 
reinforcing effects. Thus, mGlu5 receptor antagonists decrease nicotine self-
administration (Paterson et al. 2003) and the incentive motivation for nicotine in rodents 
(Paterson and Markou 2005). The administration of a mGlu2/3 agonist also decreases 
nicotine self-administration in rats (Liechti et al. 2007). This last result is in accordance 
with previous studies showing that presynaptic mGlu2/3 receptors modulate glutamate 
release in a negative manner (Schoepp et al. 2003). The administration of mGlu5 
receptor antagonists (Bespalov et al. 2005) or mGlu2/3 receptor agonists (Liechti et al. 
2007) also decreases cue-induced reinstatement of nicotine-seeking in rats. Cholinergic 
and glutamatergic inputs from the pedunculopontine tegmental nucleus (PPTg) to the 
VTA seem to play a crucial role in nicotine reinforcement since complete lesion of the 
PPTg reduces nicotine self-administration (Lança et al. 2000, Picciotto and Corrigall 
2002). On the other hand, the negative affective changes of nicotine withdrawal are 
related to a hyperactivity of corticotropin-releasing-factor neurons in the central nucleus 
of the amygdala (Bruijnzeel et al. 2007, Panagis et al. 2000) and a decrease of DA 
activity in the NAc (Hildebrand et al. 1999) that seems to be modulated by the 
glutamatergic system. Thus, mGlu2/3 receptor antagonists, which increase extracellular 
glutamate in the NAc, attenuate reward deficits associated with nicotine withdrawal in 
rodents and could also alleviate the depression-like symptoms related to nicotine 
abstinence in humans (Kenny et al. 2003, Liechti and Markou 2008). 
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3.6.2.3. Involvement of GABA receptors in nicotine 
rewarding/reinforcing effects 
DA neurons in the VTA are under the inhibitory control of GABAergic inputs that also 
participate in nicotine rewarding/reinforcing effects. Hence, the administration of the 
GABA-B receptor agonists such as baclofen, as well as several GABA-B receptor positive 
allosteric modulators, decrease nicotine self-administration in rats (Paterson et al. 2004, 
Paterson et al. 2008). Baclofen also inhibits nicotine-induced conditioned place 
preference in rats (Le Foll et al. 2008). Although GABA neurons are also activated by 
nicotine, α4β2 nAChRs located on GABA cells tend to desensitise rapidly during repeated 
nicotine exposure (Mansvelder et al. 2002). Desensitisation of these receptors following 
repeated nicotine exposure contributes to the final activation of mesolimbic DA neurons 
induced by the chronic administration of this drug of abuse. Recent studies have reported 
that the GABA system also participates in nicotine relapse. Thus, the administration of 
GABA-B receptor agonists decreases cue-induced reinstatement of nicotine-seeking 
behaviour in rodents (Fattore et al. 2009, Paterson and Markou 2005). In agreement, 
baclofen also prevents the reinstatement of nicotine conditioned place-preference 
triggered by nicotine priming in rats (Fattore et al. 2009).  
3.6.2.4. Endogenous opioid system in nicotine 
rewarding/reinforcing effects 
Nicotine administration has been reported to enhance the release of endogenous opioids 
in the CNS. Thus, an increased concentration of β-endorphin has been found in the 
hypothalamus after acute nicotine administration in rodents (Marty et al. 1985). In 
addition, chronic nicotine administration has been found to increase mRNA expression of 
prodynorphin and µ-opioid receptors (Wewers et al. 1999) in the striatum (Isola et al. 
2008). An enhancement of proenkephalin expression has also been observed in the 
striatum of mice following acute or chronic nicotine administration (Dhatt et al. 1995).  
Nicotine induces opposite responses on anxiety-like behaviour related to the 
development of nicotine addiction that are modulated by the endogenous opioid system. 
Thus, nicotine anxiolytic-like effects were blocked by a µ-opioid antagonist, and its 
anxiogenic-like effects were enhanced by a δ-opioid antagonist (Balerio et al. 2005). In 
addition, a reduction of nicotine anxiogenic-like effects was reported in knockout mice 
lacking β-endorphin (Trigo et al. 2009). The opioid system also plays an important role in 
nicotine rewarding effects. The efficacy of naltrexone on smoking cessation in humans 
supports the involvement of opioid receptors in nicotine reward (Rukstalis et al. 2005). In 
rodents, nicotine-induced elevations of extracellular DA levels in the NAc were modulated 
by the activation of µ-opioid receptors localised in the VTA (Tanda and Di Chiara 1998). 
In agreement, nicotine rewarding properties were blocked in knockout mice  lacking 
µ-opioid receptors (Berrendero et al. 2002) or the proenkephalin gene (Berrendero et al. 
2005), revealing an involvement of endogenous enkephalins through the activation of µ-
opioid receptors. In addition, proenkephalin knockout mice showed a reduction of 
nicotine-enhanced DA extracellular levels in the NAc (Berrendero et al. 2005). Mice 
lacking β-endorphin also showed a reduction of nicotine rewarding effects (Trigo et al. 
2009). κ-Opioid receptors and their endogenous ligands modulate nicotine reward in the 
opposite way to enkephalins and β-endorphins. Hence, knockout mice deficient in the 
prodynorphin gene showed an enhanced sensitivity to nicotine self-administration, 
probably due to the modulation of its aversive effects (Galeote et al. 2009).  
The opioid system is also involved in the development of nicotine tolerance. Thus, chronic 
nicotine exposure produces cross-tolerance with morphine (Biala and Weglinska 2006, 
Zarrindast et al. 1999), and increases the functional activity of µ-opioid receptors in the 
spinal cord (Galeote et al. 2006). In addition, µ-opioid receptor knockout mice developed 
faster nicotine tolerance than wild-type mice, suggesting that increased activation of 
µ-opioid receptors could be an adaptive mechanism to counteract the establishment of 
nicotine tolerance (Galeote et al. 2006). The involvement of the opioid system in nicotine 
withdrawal has also been demonstrated. In humans, the opioid antagonist, naloxone 
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induces somatic signs of withdrawal in heavy chronic smokers (Krishnan-Sarin et al. 
1999). In rodents, opioid antagonists precipitate somatic manifestations of withdrawal in 
nicotine-dependent animals (Balerio et al. 2004). In addition, somatic manifestations of 
nicotine withdrawal were reduced in mice lacking µ-opioid receptors (Berrendero et al. 
2002) or the proenkephalin gene (Berrendero et al. 2005). Different studies also indicate 
that the opioid system participates in the negative emotional states associated with 
nicotine withdrawal. Thus, naloxone induced aversive effects in nicotine-dependent 
rodents, which reflects the motivational manifestations of nicotine withdrawal (Balerio et 
al. 2004, Watkins et al. 2000).  
3.6.2.5. Involvement of cannabinoid receptors in nicotine 
rewarding/reinforcing effects 
Several studies demonstrate that the endocannabinoid system plays an important role in 
the rewarding/reinforcing effects of nicotine (Maldonado et al. 2006). Indeed, the 
selective CB1 receptor antagonist rimonabant reduces nicotine self-administration in rats 
(Cohen et al. 2002) and nicotine-induced conditioned place preference in rats and mice 
(Le Foll and Goldberg 2004, Merritt et al. 2008). In addition, rimonabant pre-treatment 
blocks nicotine-enhanced DA extracellular levels in the NAc (Cheer et al. 2007, Cohen et 
al. 2002) and in the bed nucleus of the stria terminalis (Cheer et al. 2007). Nicotine 
conditioned place preference was also absent in knockout mice lacking CB1 receptors 
(Castañé et al. 2002, Merrit et al. 2008). The endocannabinoid system has also been 
involved in the relapse to nicotine-seeking behaviour (De Vries and Schoffelmeer 2005b). 
Thus, rimonabant attenuates the reinstatement of nicotine seeking-behaviour induced by 
nicotine-associated cues (Cohen et al. 2005, De Vries et al. 2005a), and reinstatement of 
nicotine-induced conditioned place-preference provoked by nicotine priming (Biala et al. 
2009). The cannabinoid antagonist AM251 also reduced the reinstatement produced by 
the combination of nicotine-associated cues and a nicotine priming dose (Shoaib 2008). 
Based on the behavioural and biochemical results obtained in rodents, several clinical 
trials were developed to evaluate the efficacy of rimonabant for smoking cessation 
(STRATUS, studies with rimonabant and tobacco use) (Cahill and Ussher 2007). 
Rimonabant was effective in obtaining a significant smoking cessation in two clinical trials 
(STRATUS-NORTH AMERICA and STRATUS-WORLD WIDE), although this effect was not 
significant in the STRATUS-EUROPE trial. The different clinical trials performed with 
rimonabant have reported several gastrointestinal and psychiatric side effects including 
nausea, anxiety and depression. Due to these psychiatric side effects, the European 
Medicines Agency (EMA) recommended the suspension of the marketing authorisation for 
rimonabant on 23 October 2008.  
3.6.2.6. Other neurotransmitters involved in nicotine 
rewarding/reinforcing effects 
The serotonergic (5-HT) system, mainly through the activation of the 5-HT2c receptor 
subtype, seems to be involved in nicotine reward/reinforcing by exerting an inhibitory 
influence on DA activity in the VTA (Di Matteo et al. 1999). Thus, 5-HT2c agonists reduce 
nicotine-self-administration (Grottick et al. 2001), although responding for food was also 
attenuated by these antagonists. In contrast, no modification on nicotine-induced 
conditioned place preference was observed by a 5-HT2c agonist in a recent report (Hayes 
et al. 2009). On the other hand, tobacco smoke contains monoamine oxidase (MAO) 
inhibitors which are thought to enhance the reinforcing effects of nicotine. Behavioural 
studies have confirmed this statement since nicotine self-administration was facilitated in 
rats pre-treated with MAO inhibitors (Villégier et al. 2006a, Villégier et al. 2007). 
Recently, the hypothalamic neuropeptides hypocretins acting in the insula have also been 
involved in nicotine reward (Hollander et al. 2008).  
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3.6.2.7. Conclusions on addictive properties of nicotine 
Animal models of nicotine reward/reinforcement have enabled the neurobiological 
substrate involved in this behavioural response that is crucial for nicotine addictive 
processes. Similar animal models have been widely used to define the neurobiological 
substrate of the addictive properties of all drugs of abuse. Results obtained in these 
models suggest that the neurobiology of nicotine addiction is complex involving various 
transmitter systems in the CNS. Multiple neurotransmitter pathways are activated by 
nicotine, including dopaminergic, GABAergic and opioidergic pathways. The complexity of 
the mechanisms of addiction is further underlined by the involvement of the 
endocannabinoid system, and the serotonergic system also seems to be involved. Dose-
dependency appears to have been shown in animal studies. In general, an inverted U-
shaped dose-response has been revealed, which suggests that, such as for other drugs of 
abuse, the addictiveness of nicotine is not directly linear with the dose. The experimental 
animal models used for evaluating addiction are described in section 3.9. 
3.6.3. Conclusions on nicotine 
The action of nicotine on the CNS is multifaceted and the mechanisms of addiction are 
still poorly understood. There are substantial inter-individual differences in the action of 
nicotine and in its metabolism, which are in part genetically determined. A number of 
different compounds may in principle interfere with the binding of nicotine with its 
receptors, while others may interfere with the metabolism of nicotine via the cytochrome 
P450 system or other pathways. Addiction to nicotine is difficult to measure directly and 
is usually assessed experimentally with reference to reinforcement assessed in self-
administration paradigms. 
3.7. Possibilities to make tobacco more addictive or attractive 
3.7.1. Introduction 
Tobacco products are manipulated by tobacco companies by the addition of chemical 
compounds, most of which are flavours. Obviously, the flavours are added to the natural 
tobacco to give the product a better taste thereby increasing the attractiveness of these 
products. This includes the addition of humectants which keep the humidity of the 
tobacco product at a desired level; dry tobacco generates an unpleasant harsh smoke.  
“Light” cigarettes were introduced on the market in the 1970s. Typical for light cigarettes 
is their high grade of ventilation. Due to the delivery of less tar, the impact and taste of 
the “diluted” smoke is also decreased. It is therefore probable that the light cigarettes 
were “enriched” by adding more substances, and in higher amounts, to compensate for 
reduced taste and impact. For details see sections 3.5.5 and the different sections 
reviewing specific tobacco additives such as section 3.8. 
An important reason for using additives is to give the product a specific and standardised 
taste. A specific taste is important for the company to be competitive on the consumer 
market in view of the large variety of brands available. A unique product binds the 
customer/consumer to this specific product. The specific taste of a certain product must 
be preserved (standardised) to compensate for the yearly variation of the natural 
tobacco, because consumers do not like to smoke a product that changes from year to 
year. To circumvent this, some 40 or more substances per product are added to the 
majority of the brands in order to mask the variation.  
3.7.2. Additives with direct or indirect addictive potency  
In the following two sections, various approaches to increase the addictive and attractive 
potency of tobacco products have been briefly described. Details of these additives and 
further information about their effectiveness can be found in later sections (see section 
3.8.1). 
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The addictive potency of tobacco products may in theory be increased by:  
1. Direct enhancement of the nicotine content; 
2. Addition of substances which increase the bioavailability of nicotine; 
3. Addition of substances which facilitate the inhalation of tobacco smoke; 
4. Addition of substances which generate compounds in the mainstream smoke which 
increase the addictiveness of nicotine; 
5. Changing the physical properties of tobacco smoke, e.g. particle size.  
The five approaches are briefly described below.  
1. Direct enhancement of the nicotine content 
No examples of increasing the content of nicotine in tobacco are known. Moreover, in 
cigarettes sold (or produced) in the EU nicotine yield has to remain below a maximal 
level of 1 mg per cigarette. Some Member States also have upper limits for roll your own 
(RYO) tobacco. Genetic techniques or classical selection of variants are available to 
produce tobacco with relatively high nicotine content. From public sources it cannot be 
deduced or concluded that such approaches are indeed used by tobacco growers or 
tobacco companies. 
2. Addition of substances which increase the bioavailability of nicotine 
a) Increase the bioavailability of nicotine by adding alkalising ingredients which increase 
the pH of tobacco (such as ammonium compounds). At higher pH (pH >8.0) more 
nicotine is in its free uncharged form, which would therefore more easily pass the 
(lung) membrane i.e. higher absorption leading to higher blood and brain nicotine 
levels. For details see section 3.8.3.2 on ammonia and other compounds affecting 
smoke pH.  
b) Increase the bioavailability of nicotine by adding ingredients which serve as a carrier 
for nicotine. 
c) Increase the effect of nicotine by inhibiting its metabolism. 
3. Addition of substances which facilitate the inhalation of tobacco smoke 
a) Certain ingredients have local anaesthetic effects. As a result coughing due to 
inhalation of irritating smoke is dampened and the smoker can inhale the smoke 
deeper (and more frequently). Examples are etheric oils, such as menthol and thymol. 
For details see later sections e.g. section 3.8.1. 
b) Compounds which have bronchodilating properties (opening/broadening the airways) 
would enable the smoker to inhale deeper (a larger volume of) tobacco smoke 
implying an increase in the bioavailability of nicotine. It has been proposed that 
theobromine, generated from cocoa, caffeine and glycyrrhizine, serves such a 
function. 
4. Addition of substances which generate compounds in the mainstream smoke 
which increase the addictiveness of nicotine 
a) It has been suggested that certain natural components in tobacco promote the 
addictiveness of nicotine. Examples are components like sugars, which when pyrolysed 
generate aldehydes. The combination of acetaldehyde and nicotine appears to be 
more addictive than nicotine alone. The addition of sugars may thus increase the 
addictive nature of tobacco products. In tobacco smoke or in vivo, tryptophan may 
react with aldehydes to form beta-carbolines, like harman and norharman. Both beta-
carbolines are inhibitors of monoamine oxidases (MAO). Monoamine oxidases are 
enzymes that degrade neurotransmitters involved in addiction such as dopamine, 
serotonin and noradrenaline. As such, tryptophan as an ingredient may potentiate 
nicotine addiction.  
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b) Acetaldehyde and other aldehydes can react in vivo with biogenic amines to yield 
carbolines or isoquinolines, which have affinity for the opiate receptor. These ligands 
are, however, formed in very low amounts. 
5. Changing the physical properties of tobacco smoke, e.g. particle size 
It is possible to change the physical properties of tobacco smoke, for example the 
particle size of the tobacco smoke aerosol. Considering the entry of particles to deeper 
lung levels, there is probably an optimum in size. Cigarette paper and/or filters can be 
modified in a technological way to attain an optimal particle size (see section 3.5).  
The size and its distribution of smoke particles can be changed to obtain an optimum so 
that particles enter deeper levels of the lungs. As a result, a more efficient absorption of 
nicotine from the particles and higher blood nicotine levels can be attained. Examples of 
such applications are the use of cigarette paper with a higher porosity and filters with 
higher ventilation (see section 3.5).  
3.7.3. Additives with attractive properties  
A large number of tobacco additives are flavours, which are mostly aromatic compounds 
or generate aromatic compounds found in the smoke. Flavours are mainly applied for two 
reasons: firstly, to enhance the attractiveness of a product (appeal to consumers); and 
secondly, to produce a unique product, typical in “taste” and markedly different from 
competitor products. The aim here is to get and maintain a certain and stable market 
share. Note that each of the many flavours is added to tobacco in minute amounts (nano 
to microgram range per unit). As reported by the tobacco industry to several national 
competent authorities and as described on tobacco industry websites, cigarettes contain 
up to 40 (sometimes even more) different additives.  
Sugars are natural components of tobacco, but they are also added to tobacco products 
during manufacturing. The heating of sugars in the tobacco product initiates a 
caramalisation, generating secondary products which have an attractive smell and taste. 
Other additives which may increase the attractiveness of tobacco products, e.g. menthol, 
are mentioned later (see section 3.8). 
A number of additives have an effect on colour, smell, visibility, taste, and harshness of 
the smoke. 
Note that some additives may fall into several of the above mentioned groups. 
3.7.4. Conclusions on addictive and attractive additives 
Section 3.7 has provided a preview of the additives used in tobacco which may have 
addictive or attractive properties. Conclusions about their efficacy are found at the end of 
the individual sections, which describe their effects in full detail. The addictiveness of 
tobacco products can theoretically be increased by additives in a number of ways 
including generation of new compounds upon combustion, enhancing the bioavailability 
of nicotine, promoting smoke inhalation and influencing particle size. Attractiveness can 
similarly be improved in a number of ways, such as by adding flavours. Importantly, 
some additives may at the same time have addictive and attractive properties, or may 
influence addictiveness indirectly, for example by promoting smoke inhalation.   
3.8. Classification of additives  
According to the EU Tobacco Products Directive (2001/37/EC) tobacco companies are 
obliged to provide information about the ingredients added to tobacco products, and their 
function, to the local authorities. In Germany, this information is published on the 
website of the Federal Ministry of Nutrition, Agriculture, and Consumer Protection9. 
                                          
9 http://service.ble.de/tabakerzeugnisse/index2.php?site_key=153&site_key=153 
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Consumers can search for brands and ingredients. The reports from 2008 showed the 
amount of each ingredient listed. However, only the amounts of major ingredients such 
as sucrose, propylene glycol or cocoa are disclosed to the public. Furthermore, only 22 of 
the 50 most-used ingredients have been specified by name. In the reports for the 
general public the tobacco industry does not reveal the nature of all flavourings, colours, 
or adhesives used. Quantitatively, sugars and humectants (e.g. glycerol, propylene 
glycol) are the dominant additives in cigarettes. Furthermore, compounds which influence 
the taste of the cigarette are used in many brands; relevant substances are cocoa (incl. 
cocoa powder, cocoa extracts, shells of cocoa bean etc.) and liquorice (incl. liquorice 
extract). Other ingredients are part of the cigarette paper, the filter, or are used as glue. 
Even if the tobacco companies are secretive about the exact amount of flavours used in 
each brand, some information is available on the websites of the tobacco companies (e.g. 
BAT10). Most of the tobacco companies disclose only the highest amount of ingredients 
used in their brands (i.e. Quantity Not Exceeded (QNE)). Therefore, it is not possible to 
draw conclusions about the average amount added or about the percentage of brands 
that contain a particular ingredient. As an example the information on the Philip Morris 
website11 for German cigarettes has been evaluated. In the compilation the maximum 
use levels are given, i.e. Philip Morris only discloses the highest amount used in its 
brands. Most of the flavours are added in very small amounts. On the other hand, 
menthol and lactic acid are flavours used in milligram amounts per cigarette (see table 
3). For the calculation it was assumed that each cigarette contains about 700 mg of 
tobacco. 
                                          
10 http://www.bat-ingredients.com/  
11 http://www.pmintl-technical-product-information.com/aspx/IngredientsInformation.aspx  
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Table 3 Ingredients added to the tobacco based on a table presented by Philip Morris 
International (PMI) on cigarettes manufactured for sale in Germany11  
Ingredient Maximal use level(w/w%) 
Maximal use 
level(mg/cigarette (700 
mg)) 
sucrose 4.2 29.4 
propylene glycol 3.9 27.3 
glycerol 2.2 15.4 
invert sugar 2.1 14.7 
l-menthol 1.1 7.7 
d-sorbitol 1.1 7.7 
liquorice extract 0.9 6.3 
lactic acid 0.7 4.9 
guar gum 0.6 4.2 
benzoic acid  0.3 2.1 
benzoic acid sodium salt  0.3 2.1 
carob bean and/or extract 0.2 1.4 
cocoa and cocoa products 0.2 1.4 
acetic acid 0.01 0.07 
lovage extract 0.01 0.07 
peppermint oil 0.01 0.07 
vanillin 0.01 0.07 
benzoin, resinoid 0.005 0.035 
phenylcarbinol 0.005 0.035 
coffee extract 0.005 0.035 
ethyl acetate 0.005 0.035 
ethyl hexanoate 0.005 0.035 
ethyl vanillin 0.005 0.035 
fenugreek extract 0.005 0.035 
maltol 0.005 0.035 
methyl-cyclopentenolone 0.005 0.035 
3-methyl-butyraldehyde 0.005 0.035 
orange oil, sweet 0.005 0.035 
piperonal 0.005 0.035 
spearmint oil 0.005 0.035 
veratraldehyde 0.005 0.035 
bergamot oil 0.001 0.007 
ethyl heptanoate 0.001 0.007 
ethyl maltol 0.001 0.007 
isoamyl acetate 0.001 0.007 
isoamyl formate 0.001 0.007 
orris root extract 0.001 0.007 
2,3,5,6-tetramethylpyrazine 0.001 0.007 
valerian root extract 0.001 0.007 
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3.8.1. Addictiveness 
3.8.1.1. Introduction 
Only few scientific articles have addressed the possibility that individual additives may 
cause addiction. It is probable that many additives have not been examined/analysed or 
the results (either positive or negative) have simply not been described in publicly 
available literature. 
The available documentation on additives in respect to a direct addictive effect is 
reviewed in section 3.8.1.2. Examples of additives causing addictiveness indirectly are 
provided in section 3.8.1.3. Finally, an assessment of how different forms of sugar may 
have an indirect addictive effect due to combustion products such as aldehydes is 
presented in section 3.8.1.4. 
3.8.1.2. Additives with addictive properties (direct effect) 
In the peer-reviewed scientific articles assessed there is no documentation for certain 
individual additives to cause addiction directly.  
The following compounds, used as tobacco additives, may have an effect on the central 
nervous system: acetophenone, isoamyl alcohol, valerian oil, theobromine, and valerenic 
acid (Lington and Bevan 1994, Moreno 1978,, Oliva et al. 2004, Ortiz et al. 1999, 
Reynolds 1983a, Reynolds 1983b, Simons et al. 1985, Yuan et al. 2004). However, the 
fact that these additives may have an effect on the central nervous system (CNS) does 
not imply that they are addictive. Moreover, they are present in the products in very low 
amounts.  
Although several articles point out that some of the above mentioned additives may 
create dependence, it is probably more likely that they are acting by attractiveness, as 
they induce a more pleasant experience of smoking and therefore reduce the barrier in 
relation to smoking initiation.  
3.8.1.3. Additives enhancing addictiveness indirectly  
Additives which increase the absorption of nicotine or potentiate in whatever way the 
effect of nicotine on the nervous system implicitly increase the addictiveness of tobacco 
products. 
Examples of additives 
Ammonium salts 
It has been proposed that the free nicotine content of smoke increases with increasing 
pH, which would lead to a higher uptake of nicotine in the bloodstream. A higher pH also 
increases the nicotine/tar ratio (Wayne and Carpenter 2009) as well as the harshness of 
the smoke (Hurt and Robertson 1998). The increased harshness will be disguised by 
using different additives that remove the smoker’s sensation of harshness. Ammonium 
salts are used as additives to increase the pH of tobacco. See Section 3.8.3.2 for a full 
description of ammonia technology.  
Menthol 
Because of its local anaesthetic properties, menthol allows a deeper inhalation of the 
irritating tobacco smoke. As such, more smoke could be inhaled and deeper puffs could 
be attained, resulting in a higher nicotine dose. See section 3.8.3.1 for detailed 
description of the action of menthol. 
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Theobromine 
Theobromine is found in cocoa beans; therefore this substance is present in cocoa and 
chocolate, both of which are used as additives in tobacco. Theobromine is a 
bronchodilator and has been used in the treatment of asthma (Simons et al. 1985). It 
has been proposed that the bronchodilating effect of the substance may contribute to the 
absorption of nicotine in connection with smoking (Bates et al. 1999, Fowles 2001). In a 
document from the New Zealand Ministry of Health (Fowles 2001) it is reported that up 
to 3% of the weight of cigarettes is cocoa extract and another 0.2% is chocolate. There 
is typically 0.2% theobromine in cocoa (Rambali et al. 2002). In most of the types of 
cigarettes containing cocoa and chocolate, which were reported to the Danish competent 
authorities12 in 2006, the contents of cocoa and chocolate are 0.3-0.5% and 0.2%, 
respectively. Based on the information available on the PMI and BAT websites the 
percentage of cocoa used in cigarettes ranges from 0.2% to 0.66%. Taking this 
information into account, the content of theobromine per cigarette will be too low to have 
a bronchodilating effect on the lungs and thereby increase the absorption of nicotine.  
Eucalyptol 
Like theobromine, eucalyptol has an effect on the lungs as a bronchodilator (Hasani et al. 
2003, Juergens et al. 2003). For eucalyptol it is also clear that the contents per cigarette 
are not large enough to exert this effect. However, even though the doses of 
theobromine and eucalyptol are so low in cigarettes that they probably do not have a 
bronchodilating effect, it cannot be excluded that there are other additives with a similar 
effect. 
Lactones 
The addictive effect of nicotine may be increased if the metabolism rate of nicotine is 
reduced. Reduction of the metabolic rate of nicotine, e.g. by inhibition of the metabolic 
enzymes involved in nicotine degradation, implicates a higher bioavailability of nicotine 
(nicotine is present in the body for a longer time or at a higher blood level). The additives 
gamma-heptalactone, gamma-valerolactone, gamma-decalactone, delta-decalactone, 
gamma-dodecalactone, delta-undecalactone and gamma-hexalactone are mild to weak 
inhibitors of CYP2A6, an enzyme within the P450 enzyme system, involved in the 
metabolism of nicotine (Juvonen et al. 2000). However, with IC50-values in the range 
560-12,000 µM it seems unlikely that these compounds will inhibit nicotine metabolism 
at the amounts used in cigarettes. 
3.8.1.4. Additives enhancing addictiveness indirectly by 
combustion of sugar 
Sugar is already present naturally in considerable amounts in the tobacco leaf (up to 
20%) and the quantities remaining in the final product depend on the curing methods. 
Sugar in different forms is also one of the most common additives in tobacco (see table 3 
in section 3.8). When the sugars, including complex polysaccharides like cellulose 
(Seeman et al. 2002) in the tobacco product are combusted, various aldehydes are 
generated such as formaldehyde, acetaldehyde, propanal, 2-butenal, 2-methylpropenal, 
butanal, methylbutanal, furfural, benzaldehyde, methylfurfural, methoxybenzaldehyde 
(Adam et al. 2006, Baker et al. 2004b).  
Acetaldehyde is claimed to increase the addictiveness of nicotine in a synergistic way 
(Belluzzi et al. 2005, Charles et al. 1983, Philip Morris 1992). The mechanism of action 
may be that acetaldehyde forms secondary condensation products which inhibit 
monoamine oxidase (MAO). The inhibition of MAO by aldehydes has already been 
demonstrated many years ago (Townee 1964, Williams et al. 1992) and part of the 
inhibition is probably irreversible (Sowa et al. 2004, Wood et al. 2006). 
                                          
12 http://www.sst.dk/Sundhed%20og%20forebyggelse/Tobak/Indberetning/Indberetninger.aspx 
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However, even during heavy smoking, only minor amounts of the acetaldehyde in the 
smoke is absorbed into the blood stream (McLaughlin et al. 1990), suggesting no direct 
addictive effect of sugars through acetaldehyde when used as a tobacco additive. 
Moreover, alcohol consumption leads, in contrast to smoking, to a significant increase in 
the acetaldehyde blood level by its metabolism. Acetaldehyde is very reactive and forms 
adducts with proteins and DNA. Chen et al. (2007b) found only a small contribution of 
chronic smoking to the formation of acetaldehyde DNA adducts, whereas alcohol 
consumption had a much higher effect, suggesting again that in chronic smokers lower 
amounts of acetaldehyde enter the circulation than in alcohol consumers. Acetaldehyde is 
rapidly oxidised in the body by dehydrogenases which, however, are much less efficient 
for oxidation of more complex aldehydes that are formed in the smoke by combustion of 
sugars. The decrease in the level of monoamine oxidases which has been repeatedly 
found in brains of smokers may thus be due to inhibition by aldehydes other than 
acetaldehyde which are present in the smoke. 
Finally, the addition of sugars to tobacco increases the content of acids in the smoke, 
resulting in a lowering of the pH value of the tobacco smoke. This may be one of the 
reasons why ammonia compounds are added to neutralise these acids. 
Examples of sugar additives 
The sugars added to tobacco are mainly inverted sugar (fructose and glucose), and 
sucrose (Philip Morris 2002, Seeman et al. 2003), and are often added in the form of 
syrups (Covington & Burling 1992, Reynolds 1985). The main part of sugar substances in 
tobacco is non-volatile and only a small part is transferred unmodified into the 
mainstream smoke. The sugar substances are not hazardous to health by oral 
consumption, but are transformed to a number of toxic compounds under pyrolysis. 
These mainly include formaldehyde, acetaldehyde, acetone, acrolein, furans (Burton 
1976) and different complex aldehydes . The pyrolysis products have a hazardous effect 
on health; formaldehyde is classified as a carcinogen to humans (IARC 2006, IARC 
2009), whereas acetaldehyde and acrolein are highly irritating to the respiratory tract. 
Mono- and disaccharides (natural sugars like glucose, fructose, sucrose) 
Mono- and disaccharides are derived from a number of sources including brown sugar, 
honey, corn syrup, molasses, sugar cane, fig juice and prune juice. Sugars are 
flavourings that constitute the largest part of additives in cigarettes (Bates et al. 1999). 
According to table 3 in section 3.8 the levels of sugars applied to the cigarette tobacco 
blends constitute more than 10% of the total amount of additives. They are added to the 
tobacco in order to contribute to the taste and flavour (Philip Morris 2002, Reynolds 
1985, Reynolds 1994. This reduces irritation and makes the taste milder (Covington & 
Burling 1986, Covington & Burling 1987a, Seeman et al. 2002).  
Inverted sugars are responsible for a large part of the contents of formaldehyde in smoke 
and also contribute to the formation of furfural, furan, levoglucosan, and acetaldehyde 
(Baker et al. 2004b, Baker et al. 2004d, Philip Morris 2002).  
Polysaccharides (e.g. cellulose, pectin, starch) 
Apart from the sugar substances mentioned, cellulose fibres are a natural part of the 
tobacco, and are also added as a binding agent (Baker et al. 2004b, Baker 2006, Fox 
1993). Pyrolysis of cellulose fibres results in the formation of volatile aldehydes and 
levoglucosan (Seeman et al. 2002). The amount of pyrolysis products varies depending 
on the sugar contents and the temperature within the cigarette. It is difficult to estimate 
the relative contribution of pyrolysis products of simple sugars in relation to 
polysaccharides (Covington & Burling 1986). The pyrolysis products of polysaccharides 
and simple sugars are similar, but their yields differ (Fox 1993, Rodgman 2002, Sanders 
et al. 2003, Seeman et al. 2002). It is estimated that more formaldehyde and less 
acetaldehyde and acetone are generated from the pyrolysis of simple sugars compared to 
polysaccharides (Burton 1976). 
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Addictive potential of acetaldehyde  
Animal studies have shown that acetaldehyde can maintain self-administration behaviour 
equal to, or probably more effectively than, nicotine (Charles et al. 1983, Philip Morris 
1992). Belluzzi et al. (2005) found that acetaldehyde has reinforcing properties (Belluzzi 
et al. 2005). 
A number of studies have elaborated on the interaction between nicotine and 
acetaldehyde (Belluzzi et al. 2005, Cao et al. 2007, Charles et al. 1983, Philip Morris 
1992). The combination of nicotine and acetaldehyde increases the degree of self-
administration in young rats (Belluzzi et al. 2005). It is possible that norepinephrine 
contributes to the age-dependent difference in acetaldehyde uptake in rats (Sershen et 
al. 2009). A study by Cao et al. (2007) shows that acetaldehyde potentiates 
hyperlocomotive effects of nicotine in young as well as adult rats, but that these effects 
are more pronounced in adult rats. No effect of acetaldehyde on the nicotine level in the 
brain was observed (Cao et al. 2007). In the Philip Morris publications, the interaction 
between nicotine and acetaldehyde is examined with the purpose of increasing the 
reinforcing effect of tobacco (Charles et al. 1983, Philip Morris 1992). The synergistic 
interaction between nicotine and acetaldehyde is substantiated by experiments where the 
combination of nicotine and acetaldehyde results in a rewarding effect that exceeds the 
additive effects of each substance in rats (Philip Morris 1992). It is likely that the 
combination of nicotine plus acetaldehyde is more reinforcing than nicotine alone, as a 
long-lasting instrumental conditioned response in young rats was observed (maintains 
lever pressing at a higher rate than nicotine alone) (Charles et al. 1983, Philip Morris 
1992). However, the effect of acetaldehyde seems not to be mediated by opioid 
receptors in the CNS and the substance does not cause physiological addictiveness 
(Charles et al. 1983). Cao et al. (2007) discussed whether acetaldehyde may pass the 
blood-brain barrier and directly affect the CNS. It is proposed that acetaldehyde has to 
be present in high concentrations (>100 µM) in the blood to overcome aldehyde 
dehydrogenase in the blood-brain barrier (Tabakoff et al. 1976). It should be noted that 
the experiments in animals used intravenous infusion of acetaldehyde, and as mentioned 
before, it is uncertain whether the acetaldehyde in smoke contributes significantly to the 
blood level of this substance (Chen et al. 2007b, McLaughlin et al. 1990). However, 
acetaldehyde is definitely not the only aldehyde produced by burning of sugars. Because 
the chemical aldehyde group has a potent inhibiting effect on monoamine oxidase activity 
(Townee 1964, Williams et al. 1992, Wood et al. 2006), it is suggested that those 
aldehydes which are more complex than acetaldehyde are responsible for monoamine 
oxidase inhibition and increased addictiveness of tobacco.  
Proposed mechanisms of action 
The reinforcing effect of acetaldehyde may be due to the reaction between acetaldehyde 
and catecholamines, which results in the formation of tetraquinolines (beta-carboline and 
tetrahydroquinoline) (DeNoble 1994, Philip Morris 1992, Rahwan 1975). Tetraquinoline 
derivatives may act as false neurotransmitters and therefore promote addictiveness of 
the product (DeNoble 1994, Rahwan 1975).  
Others argue that acetaldehyde has an addictive effect because of the formation of the 
condensation products harman and norharman, which inhibit the enzyme monoamine 
oxidase (MAO). Inhibition of MAO results in a slower metabolism of the biogenic amines, 
like dopamine, noradrenaline and serotonin in the brain, so that the brain levels are 
increased by MAO-inhibition. However, it is only proven that harman could have 
significance for tobacco addiction by virtue of its inhibitory effect on MAO-A (Guillem et 
al. 2006). Indeed, harman is formed in the smoke (0.1 to 5.8 microgram per cigarette). 
At this level, harman, following its absorption, may be responsible for 3 to 11% of the 
inhibition of MAO-A (note that drinking a cup of coffee delivers 1 to 8 microgram orally). 
Nevertheless, whatever the active product, one smoked cigarette decreases MAO in the 
monkey heart by 25% (Valette et al. 2005). Smokers have decreased MAO-A and MAO-B 
activities in brain (Fowler et al. 1996), which recover following smoking cessation. 
However, harman and norharman are not irreversible inhibitors of monoamine oxidases 
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and it has been shown that only an irreversible blockade of MAO-A and MAO-B increases 
the reinforcing effects of nicotine (Guillem et al. 2005; Villégier et al. 2006a). This 
suggests that aldehydes, which are probably irreversible inhibitors of monoamine 
oxidases (Sowa et al. 2004, Wood et al. 2006), could be the inhibitors of monoamine 
oxidases responsible for the increased reinforcing effects of nicotine in tobacco and 
tobacco smoke. Acetaldehyde is rapidly inactivated in the body. Therefore, more complex 
aldehydes are possible candidates for the observed monoamine oxidase inhibition. In 
summary, the mechanistic explanation for the role of sugars in smoking addiction is still 
unclear.  
3.8.1.5. Denicotinised cigarettes 
Nicotine plasma levels are associated with cigarette smoking behaviour and nicotine is 
considered the main factor driving cigarette addiction. In apparent contradiction to this 
observation, nicotine replacement therapy, as a smoking cessation treatment, does not 
show the expected effectiveness. Therefore, it has been assumed that non-nicotine 
components are important in smoking reinforcement. The exact nature of these factors 
(chemical composition) is largely unknown, but constituents which provide reinforcing 
sensory stimulation and/or minimize excessive irritation from inhaled nicotine are 
considered to play an important role in non-nicotine effects in cigarette smoke (Rose 
2006).  
In this chapter several studies with denicotinised cigarettes are briefly described to 
highlight the importance of the non-nicotine components in tobacco. 
Denicotinised cigarettes have the appearance, draw and taste of standard cigarettes but 
contain (and deliver) virtually no nicotine (<0.06 mg). However, they deliver tar and 
carbon monoxide (CO) in a comparable way to traditional cigarettes (Pickworth et al. 
1999). 
In short term (for a few hours; maximum up to 24 hours) experiments, smoking 
volunteers were placed under tobacco (nicotine) abstinence and were allowed to smoke 
denicotinised or conventional cigarettes.  
• In 1999, Pickworth et al. reported that the denicotinised cigarettes did not increase 
heart rate or activate the EEG, but subjects reported that both conventional and 
denicotinised cigarettes reduced (subjective) measures of tobacco craving and 
withdrawal (Pickworth et al. 1999).  
• In a study by Eid et al. (2005) a stimulating effect on heart rate of denicotinised 
cigarettes was reported. Smoking of either denicotinised or conventional cigarettes 
caused a significant reduction in the craving score. The authors could not find a 
correlation between the nicotine yield and behavioural effects.  
• Perkins et al. (2010) simulated different stressful situations (negative affects) during 
smoking abstinence and studied how relief was perceived after smoking. The authors 
did not find an association between the relief of several negative affects and smoking 
(also not from denicotinised cigarettes) but the relief was not dependent on nicotine 
intake, therefore, challenging the assumption that nicotine in smoking alleviates 
negative affects. 
• Brody et al. (2009) found that, compared to conventional cigarettes, smoking 
denicotinised cigarettes (0.05 mg nicotine) resulted in a decrease in occupancy of the 
brain nicotine acetylcholine receptor (nAChR), as predicted on the basis of nicotine 
concentration. They did not observe occupancy of the nAChR with other factors, 
suggesting that only nicotine in cigarette smoke is capable of binding this receptor 
(Brody et al. 2009).  
These acute studies show that denicotinised cigarettes, compared to conventional 
cigarettes, do not exert the same pharmacological effects, but cravings and symptoms of 
withdrawal can be diminished and this phenomenon is, in many cases, independent of 
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the delivered nicotine. Some components of tobacco smoke, other than nicotine, may be 
biologically active; thus it has been suggested that non-nicotine components of tobacco 
smoke decrease brain levels of monoamine oxidase A and B which possibly change 
sensitivity to the actions of nicotine and/or exert independent behavioural effects (Eid et 
al. 2005). 
Recently, Rose et al. (2010b) found that denicotinised smoke was self-administered more 
than any other alternative (i.v. nicotine self-administration or sham puffs) in established 
smokers, even after a few days of nicotine abstinence. This preference for denicotinised 
smoke compared to i.v. nicotine was inversely correlated with subjective ratings of 
“comfort” (normally) associated with nicotine; therefore non-nicotine aspects of cigarette 
smoking have potent reinforcing effects in established smokers. These authors, therefore 
suggested that in contrast to current smoking cessation pharmaco-therapies, which 
address only the nicotine component of nicotine (tobacco) addiction, future cessation 
strategies should also be designed to target non-nicotine factors such as added flavour 
constituents (e.g. menthol). 
In conclusion, besides nicotine, a mixture of other factors in cigarette smoke probably 
plays an important role in craving and reinforcement. Although these unknown factors do 
not have pharmacological effects similar to nicotine and are probably not addictive, they 
definitely play a role in smoking behaviour.  
3.8.1.6. Conclusions on how additives can increase the 
addictiveness of tobacco products  
Certain tobacco additives may affect the central nervous system in smokers directly, but 
their concentration in tobacco products is probably too low to have a physiological effect. 
However, an indirect addictive effect of certain substances cannot be excluded.  
Some additives increase the pH of the smoke, thereby increasing the quantity of nicotine 
delivered to the smoker.  
Sugars generate aldehydes such as acetaldehyde during combustion. When given 
intravenously to animals, acetaldehyde potentiates the addictive effect of nicotine. The 
mechanism of action of the reinforcing effect of acetaldehyde in animals is not clear, 
although an inhibition of MAO is the most likely reason. Inhibition of MAO has also been 
observed in human smokers. However, acetaldehyde, generated from the sugars during 
combustion, is presumably not absorbed into the blood stream, and this suggests that 
other aldehydes, produced by sugar combustion are responsible for the inhibition of 
monoamine oxidases and the increased addictiveness of tobacco products. 
Natural tobacco already contains considerable amounts of sugars, especially Virginia 
tobacco. In addition, polysaccharides and cellulose fibres in the tobacco leaves generate 
acetaldehyde and other aldehydes upon combustion. In this respect addition of sugars to 
tobacco may lead to a significant increase in the addictiveness of the product.  
3.8.2. Attractiveness 
3.8.2.1. Introduction  
A number of additives increase the attractiveness of tobacco products. This may be 
attained by creating a better experience of the product (e.g. appearance of the product, 
white and full smoke) or by making it easier to start smoking (e.g. by means of a cool, 
sweet and mild smoke, as well as causing less irritation in the lungs). 
For many additives, attractiveness depends on multiple functions which may be difficult 
to distinguish clearly. One of the reasons to use additives is to attract the smoker to a 
specific product and to promote/encourage (young) people to start using the product. 
Other reasons for using additives are to produce a unique product, typical in taste and 
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markedly different from competitor products, and to maintain the stability of the taste of 
the product. 
3.8.2.2. Better experience of the product 
Preservation of humidity of the tobacco product 
Humectants are added to tobacco products to retain the water, i.e. to prevent them from 
drying out, and consequently increase the shelf life of the products. 
Examples of additives 
Examples of additives include: glycerol, propylene glycol and sorbitol.  
Appearance, smell and irritation of tobacco smoke 
In order to make the smoke more attractive to the smoker, but also to other people in 
the proximity of the smoker, it is important that the smoke is appealing and not 
annoying. This may be attained with additives which make the smoke whiter and more 
attractive to people seeing the smoke. The smell of the smoke may be also changed so 
that it is also more attractive and less irritating (Connolly et al. 2000, Ling and Glantz 
2005). 
Connolly et al. (2000) examined tobacco industry patents covering the function of 
environmental tobacco smoke masking. These strategies include reducing smoke odour, 
and reducing side-stream smoke visibility and emissions.  
Methods to neutralize or reduce lingering smoke odour include addition of acetylpyrazine, 
anethole and limonene to modify the side-stream odour. These compounds have rather 
low odour thresholds, and are subsequently easily picked up, while they elicit no 
trigeminal nerve response. Aroma precursors, e.g. polyanethole provided a noticeable 
fresher, cleaner and less irritating cigarette side-stream aroma, while others (e.g. 
cinnamic aldehyde, pinanediol acetal) produce slightly sweet, spicy, clean, fresh, and less 
cigarette-like aroma. Also, more “classic” additives (e.g. vanillin, benzaldehyde, 
bergamot oil, cinnamon/cinnamon extract, coffee extract and nutmeg oil) modify side-
stream odour. 
Reduced visibility of side-stream smoke is accomplished by the addition of magnesium 
oxide, magnesium carbonate, sodium acetate, sodium citrate and calcium carbonate to 
the wrapper (cigarette paper). This has an effect on particle size; particles become 
smaller and therefore do not easily scatter light and become less visible.  
Reducing side-stream emissions is based on encapsulating the smoke in an impermeable 
cone using different types of additives such as potassium succinate, potassium citrate 
and magnesium carbonate.  
By combining the use of additives and the look of the tobacco product, greater 
acceptance of the smoke may be created. Less resistance may be encountered from 
persons that do not smoke, and at the same time greater pleasure for the smoker may 
be created. The same agents may also be used to target the individual product at certain 
target groups (Carpenter et al. 2005a, Connolly 2004). 
Taste and experience of the smoke  
Cis-3-hexenol is added to increase the organoleptic characteristics of tobacco and it has a 
characteristic smell of newly mown grass (Alford and Johnson 1970). Cis-3-hexenol adds 
a green, foliaceous taste and a smell of chlorophyll to the tobacco smoke (Leffingwell et 
al. 1972). Apart from adding a taste and flavour of fresh tobacco to the tobacco smoke, 
the substance has another important characteristic: cis-3-hexenol reduces irritation 
(Alford and Johnson 1969).  
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The American tobacco company Brown & Williamson has tested the effect on the 
characteristics of the smoke when adding cis-3-hexenol to cigarettes (Alford and Johnson 
1969, Alford and Johnson 1970). Cigarettes with added cis-3-hexenol in concentrations 
of 0.05, 0.10 and 0.15 mg per cigarette were tested against control cigarettes without 
added cis-3-hexenol by having an expert panel smoke the various cigarettes. All 
cigarettes with cis-3-hexenol were preferred to the control cigarettes (Alford and Johnson 
1969, Alford and Johnson 1970). The effect of cis-3-hexenol was ”A dramatic increase in 
smoke freshness and acceptability. Irritation is also markedly reduced.” 
Harshness  
According to the tobacco industry definition, harshness is a chemically induced physical 
effect associated with a roughness, rawness experience generally localised in the mouth 
and to a lesser degree in the upper reaches of the throat and the trachea due to 
inhalation of tobacco smoke. Harshness can also cause a drying, rasping, coarse, 
astringent sensation usually associated with the smoke flavour of Virginia or air-cured 
type tobaccos.  
Harshness is classically measured in four degrees: (i) Free – an absence of harshness; 
(ii) Touching – a slight awareness of a sensation; (iii) Scratchy – some discomfort, a 
stinging effect; and (iv) Harsh – rough, raw, raspy, coarse, astringent, painful inhalation. 
Reducing the harshness of the smoke makes it possible to inhale deeper and increase the 
number of puffs, as more physical barriers will be reduced (Wayne and Henningfield 
2008b). 
The ratio between nicotine and tar is an important parameter in relation to the smoker’s 
experience of the cigarette. If the concentration of nicotine in relation to tar is too high, 
the harshness of the smoke will be much higher (Hurt and Robertson 1998). Nicotine is 
irritating in high doses compared to other substances in the smoke (Baker 1990). 
The irritating effect of nicotine on the lungs and the bad experience at too large amounts 
of nicotine in relation to the amount of tar may be remedied by additives that may drown 
or reduce the harshness of the smoke. This may also be achieved by adding nicotine salts 
that do not cause the same irritation, but are still delivering nicotine or keeping the 
nicotine effect by means of a quicker absorption by ensuring larger amounts of free 
nicotine (Bates et al. 1999, Keithly et al. 2005). 
Smoothness  
Tar provides a strong flavour and mouth sensation, masking the harsher, bitter taste of 
nicotine which may be unpalatable to new smokers and uncomfortable to established 
smokers. Certain highly flavoured additives may also have the same properties to 
“smoothen” or reduce the harsh irritation of nicotine in tobacco smoke.  
A central feature of tobacco marketing strategy has been to promote the perception that 
some cigarettes are less hazardous than others, so that smokers worried about their 
health are encouraged to switch brands rather than quit. Products bearing the word 
“smooth” or using lighter coloured branding mislead people into thinking that these 
products are less harmful to their health. Adults and children are significantly more likely 
to rate packs with the terms “light”, “smooth”, “silver” and “gold” as lower tar, lower 
health risk and either easier to quit (adults) or their choice of pack if trying smoking 
(children). For example, more than 50% of adults and youth reported that brands 
labelled as “smooth” were less harmful than the “regular” variety. The colour of packs 
was also associated with perceptions or risk and brand appeal. For example, compared to 
Marlboro packs with a red logo, cigarettes in packs with a gold logo were rated as lower 
health risk by 53% and easier to quit by 31% of adult smokers.     
Plain packs significantly reduced false beliefs about health risk and ease of quitting and 
were rated by the children as less attractive and appealing (Hammond et al. 2009a). 
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Examples: 
Propylene glycol 
The addition of propylene glycol (1,2-dihydroxypropane) to tobacco results in a milder 
smoke (Danker 1958). It was found that propylene glycol reduces the delivery of 
nicotine, while the formation of tar is increased (Shepperd and Bevan 1994b). In another 
study, also by the Brown & Williamson Tobacco Company, a reduction of nose irritation 
was observed and a reduced delivery of nicotine was confirmed (Shepperd 1994a). It 
was suggested that the sensation of reduced effect and irritation in cigarettes with added 
propylene glycol is caused by reduced liberation of nicotine, since the tar/nicotine ratio is 
of importance to the sharpness of the smoke (Danker 1958, Shepperd and Bevan 
1994b).  
Levulinic acid and levulinates  
Based on the information submitted by the tobacco industry to the competent authorities 
of the EU Member States, these two substances have in many cases not been included in 
the reports, but have been used and mentioned several times in the internal documents 
of the tobacco industry.  
These organic salts would also be able to reduce the harshness of nicotine, as the salts 
do not cause the harshness that otherwise characterises high levels of nicotine (Bates et 
al. 1999). In a study of the published literature up until 2004, Keithly has also shown 
that the primary purpose of levulinic acid as an additive in tobacco is to make the smoke 
sweeter and softer and at the same time increase the nicotine absorption and the effect 
of nicotine in the brain. Keithly also describes the use of nicotine levulinate and levulinic 
acid to cause less harshness (Keithly et al. 2005). 
3.8.2.3. Easier to start smoking  
Tobacco products may also be designed in such a way that they are easier to start 
smoking with. This may be attained by making it easier to inhale the smoke in the lungs 
and by creating a sweeter, milder or “colder” smoke. By reducing and changing the 
harshness of the smoke, special target groups may be reached (Carpenter et al. 2005a, 
Carpenter et al. 2005b, Cummings et al. 2002, Klein et al. 2008, Wayne and Connolly 
2002). 
In a number of countries, sweet and tasteful tobacco products are the most preferred 
tobacco products among children and adolescents as well as experimenting smokers 
(Ashare et al. 2007, Giovino et al. 2005, Klein et al. 2008).  
How to make inhalation of smoke less aversive 
Liquorice 
Glycyrrhizin is the active substance of liquorice i.e. the root extract of Glycyrrhiza glabra 
and has a sweet taste (Hodge and Shelar 1979). Apart from glycyrrhizin, liquorice also 
contains sugar substances, cellulose fibres and essential oils (Covington & Burling 
1987b). 
The taste and flavour of tobacco with liquorice/liquorice root added are described as 
sweet, woody and round (Leffingwell et al. 1972), but adding liquorice/liquorice root also 
has the objective of camouflaging the unpleasant taste of tobacco (Covington & Burling 
1987b). 
The use of adding liquorice/liquorice root to tobacco has the following advantages (Vora 
1983); it reduces the harshness of tobacco smoke, the dryness in the mouth and throat, 
and it provides a pleasant sweet undertone to the smoke. 
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Menthol 
The additive menthol is relevant for how a smoker experiences the smoke in the lungs 
and the concentration of menthol may be an important issue for the group that the 
cigarette brand is targeted at. This is described further in section 3.8.3.1, which broadly 
outlines the potency of menthol to inhale smoke more easily and deeply. 
Cooler and milder smoke 
Certain substances make the smoke milder and cooler, e.g. menthol (see section 
3.8.3.1), liquorice and propylene glycol. However, many more additives probably have 
these effects on the smoker’s lungs, but they have not yet been evaluated, or have not 
been described in the literature. 
Sweeter taste 
The presence of sugars in cigarettes is associated with a more favourable taste. The 
experience of the smoke is less negative and the irritability is somewhat masked.  
The tobacco producers have used additives that create sweetness and taste in the smoke 
to make it easier for new smokers to start smoking, since these tobacco products do not 
have the same harshness and bad experience at the first inhalations (Cummings et al. 
2002, Wayne and Connolly 2002). 
3.8.2.4. Conclusions on how certain additives can increase the 
attractiveness of tobacco products  
The attractiveness of tobacco products may be increased by a number of additives. An 
attractive effect may be obtained in a number of ways, such as changing the appearance 
of the product and the smoke, decreasing the harshness of the smoke, and inducing a 
pleasant experience of smoking. The harshness depends partly on the tar/nicotine ratio, 
but may also be decreased by certain additives such as propylene glycol or levulinates. 
Various sugars constitute a large proportion of additives, and the sweetness of the smoke 
is an important characteristic.  
Many different additives are used to create a specific taste/flavour in order to attract 
certain target groups. In order to make the smoke less aversive and permit deeper 
inhalation, additives such as liquorice and menthol are used. Finally, in order to make 
smoking more acceptable to people around, some additives have the function of reducing 
lingering odour or side-stream smoke visibility. 
3.8.3. Most prominent additives in tobacco products  
3.8.3.1. Menthol 
Menthol is an important tobacco additive and it is the only additive explicitly declared to 
the consumer. For more than 40 years, scientific discussions have covered the health 
effects of the addition of menthol to tobacco. Menthol is a monocyclic terpene alcohol. It 
is a naturally occurring compound of plant origin which gives plants of the Mentha 
species the typical minty smell and flavour (Eccles 1994). Mentholated cigarettes have a 
major share of the market in the USA. However, in most European countries, the market 
shares for mentholated cigarettes range between 1 and 5% (Giovino et al. 2004). The 
menthol content has been investigated in the USA in 48 commercially available 
mentholated cigarette sub brands. Menthol content per g tobacco was reported to range 
between 2.88 and 5.75 mg menthol (Celebucki et al. 2005). In Germany, the menthol 
content was analyzed in non-mentholated cigarettes as well as in raw tobacco. Menthol 
content in raw tobacco and home grown tobacco was in the range 0.02-0.18 µg 
menthol/g tobacco. Menthol content per g tobacco in non-mentholated cigarettes ranged 
between 0.019 and 13.3 µg menthol (Merckel et al. 2006). These data clearly prove 
three points: firstly, menthol occurs naturally in very small amounts in tobacco; 
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secondly, some brands contain no added menthol at all and in some brands, microgram 
amounts of menthol have been added; and finally, mentholated brands contain milligram 
amounts of menthol per g tobacco. 
The tobacco industry advertises menthol as a substance which alleviates harshness and 
enhances taste and smoothness, but menthol may also facilitate nicotine delivery and 
increase the sensory impact of cigarettes.  
Menthol can be applied to cigarettes in a number of ways; it can be applied directly to 
the tobacco or introduced into the cigarette filter, or it can be applied to the cigarette 
packaging (see section 3.4.).  
The fate of menthol in the cigarette has only been investigated by the tobacco industry. 
Philip Morris showed with 14C-labelled menthol that 29% of the activity went into the 
mainstream smoke, and 98.9% was as unchanged menthol (Jenkins et al. 1970). The 
transfer of menthol from tobacco into smoke was investigated by another company in 11 
cigarette brands; the values ranged from 19 to 31% (Brozinski et al. 1972).  
A report by Schmeltz and Schlotzhauer raised concerns about the pyrolysis of menthol. 
The authors pyrolysed menthol under nitrogen at 860°C and analysed the pyrolysate by 
paper-chromatography and thin-layer chromatography. They found approximately 400 
µg benzo[a]pyrene per g menthol (Schmeltz and Schlotzhauer 1968). However, under 
normal smoking conditions, the menthol evaporates before being burned. The question 
was investigated again later on by Baker and Bishop who heated menthol at 30°C per 
second from 300 to 900°C under a flow of 9% oxygen in nitrogen. The products were 
analysed by gas chromatography and mass spectrometry. The authors found that 99% of 
the menthol was unchanged in the gas phase; additional products were menthon (0.9%) 
and menthen (0.1%) (Baker and Bishop 2004a).  
Some companies have investigated the influence of tobacco additives on the composition 
of smoke constituents. For example, Philip Morris studied experimental cigarettes with 
many additives. They prepared two sets of cigarettes containing, among other additives, 
18,000 ppm menthol, yielding 13 mg menthol per cigarette (Carmines 2002). The 
cigarettes were machine-smoked and compared to control cigarettes without ingredients 
added. The benzo[a]pyrene content in the smoke of menthol cigarettes was significantly 
higher compared to the smoke of the control cigarettes. The smoke of the control 
cigarettes contained 5.1 ng benzo[a]pyrene per cigarette in comparison to 5.63 and 
5.51 ng benzo[a]pyrene per cigarette in menthol cigarettes (Rustemaier et al. 2002).  
Recent reviews on health effects of menthol in cigarettes published by the tobacco 
industry have maintained its claim that menthol does not pose any adverse health effects 
when used as an additive in cigarettes (Heck 2010 Werley et al. 2007).  
The hypothesis that smoking mentholated cigarettes increases lung cancer risk compared 
with smoking non-mentholated cigarettes was tested in several epidemiological studies. 
Sidney and colleagues found a 1.45-fold increase of the relative risk for men smoking 
mentholated cigarettes for 20 years and more (Sidney et al. 1995), whereas three other 
studies (Brooks et al. 2003, Carpenter et al. 1999, Stellman et al. 2003) did not find a 
difference between menthol smokers and non-menthol smokers. 
Menthol has a cooling effect on the skin or mucosal surfaces. The perceived temperature 
effect is not caused by evaporation of menthol. Furthermore it is not due to 
vasodilatation, but is due to a specific action on sensory nerve endings (Eccles 1994). 
Menthol activates a transient receptor potential channel (TRPM8). This channel is 
expressed in small-diameter primary sensory neurons (Clapham et al. 2005). The use of 
menthol causes a subjective sensation of improved airflow without any change in nasal 
airway resistance, breathing pattern or ventilation (Eccles 1994, Nishino et al. 1997). 
Furthermore, menthol has a local anaesthetic activity (Galeotti et al. 2001).  
It is important to take into account that this cooling and anaesthetic effect may mask 
early symptoms of tobacco induced respiratory disease (Garten and Falkner 2003). In a 
follow-up paper, it was postulated, that there is a greater opportunity for exposure and 
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transfer of the contents of the lungs to the pulmonary circulation. For the smoker of 
mentholated cigarettes this could result in a greater exposure to nicotine and the 
particulate matter of the smoked cigarette (Garten and Falkner 2004). Additionally, it 
was postulated that menthol increases the absorption with other chemicals through 
permeability and increased salivation. This would mean that menthol facilitates the 
absorption of other substances from the smoke (Ahijevych and Garrett 2004, Eccles 
1994). Two recent biomarker studies addressed the question if the use of mentholated 
cigarettes would lead to higher exposure to toxic compounds from smoke (Heck 2009, 
Muscat et al. 2009). Muscat and colleagues investigated a group of 525 smokers and 
stratified them for sex and race. In the United States, African American smokers 
preferred mentholated cigarettes (90% of men and and 82% of women); whereas 
European Americans smoked predominantly non-mentholated cigarettes (percentage of 
menthol cigarettes smoked was 25% and 31%, respectively). European Americans 
smoked significantly more cigarettes per day than African Americans. There were no 
significant differences in the mean concentrations of all cigarette smoke metabolites 
(plasma cotinine, urinary cotinine, plasma thiocyanate and urinary 4-N-
nitrosomethylamino)-1-(3-pyridyl)-1-butanol (NNAL)) between menthol and non-menthol 
cigarette smokers in African Americans and European Americans, after adjustment for 
sex and other factors (Muscat et al. 2009). However, the ratio of NNAL-glucuronide to 
NNAL, a possible indicator of lung cancer risk, was significantly lower in menthol versus 
non-menthol cigarette smokers. The NNAL-Gluc/NNAL ratio was 34% lower in European 
Americans (P <0.01) and 22% lower in African Americans (Muscat et al. 2009). In 
subsequent human liver microsome studies, menthol inhibited the rate of NNAL-O-
glucuronidation and NNAL-N-glucuronidation. These results suggest that menthol may 
modify the detoxification of the potent lung carcinogen NNAL (Muscat et al. 2009).  
A similar study has been performed and published by the tobacco industry (Heck 2009). 
They investigated 112 smokers (28 African Americans and 84 European Americans; 54 
menthol cigarette smokers and 58 non-menthol cigarette smokers). Smokers continued 
smoking ad libitum throughout the one week study interval. The participants were 
provided with a commercially available menthol cigarette brand and several non-
mentholated brands of similar smoke yield. Menthol content in smoke was determined as 
0.34 mg/cigarette. Content of 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) 
was determined as 63 ng/cigarette in the mentholated brand and with a range from 45 to 
80 ng NNK/cigarette in five non-mentholated brands (Heck 2009). Neither total urinary 
NNAL nor urinary nicotine equivalents exhibited statistically significant differences 
between the menthol and non-menthol cigarette smokers (Heck 2009). 
Recently, a study was published from the tobacco industry on 3341 cigarette smokers 
(Wang et al. 2010). The participants smoked either mentholated or non-mentholated 
cigarettes with different tar yields. European Americans in the menthol group smoked 
more cigarettes than European Americans in the non-menthol group. No differences were 
found between menthol and non-menthol groups with respect to nicotine equivalents per 
day, carboxyhaemoglobin (COHb) and serum cotinine. The authors concluded that 
menthol did not influence the metabolism of nicotine. However, the study was not 
designed to answer this specific question.  
The possible influence of menthol on the metabolism of nicotine was investigated in a 
cross-over study in 14 healthy smokers (Benowitz et al. 2004). Subjects were randomly 
assigned to smoke mentholated or non-mentholated cigarettes for one week, then to 
cross over to the other type of cigarettes for another week. The blood levels of 
deuterium-labelled nicotine and cotinine were measured after intravenous infusion of 
these compounds. It was demonstrated that, when smoking similar numbers of 
mentholated and non-mentholated cigarettes of similar machine-determined yield and 
nicotine content, the systemic intake of nicotine and carbon monoxide during non-
menthol cigarette smoking is on average not affected by mentholation. Furthermore, it 
was shown that mentholated cigarette smoking inhibits the metabolism of nicotine. 
Inhibition of nicotine metabolism by menthol most likely involves inhibition of both 
oxidative metabolism to cotinine, and glucuronide conjugation (Benowitz et al. 2004). In 
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vitro studies using human liver microsomes showed that menthol inhibits nicotine 
metabolism (MacDougall et al. 2003) However, mentholated cigarette smoking did not 
substantially affect cotinine metabolism. Finally, the systemic intake of menthol was 
determined as 12.5 mg menthol from 20 cigarettes. Thus, on average 20% of menthol 
contained in each cigarette is absorbed systemically by the smoker (Benowitz et al. 
2004).  
Studies on the influence of menthol on puff numbers and puff volume gave conflicting 
results. Puff numbers have been investigated in seven studies, three showing a reduced 
number of puffs in smokers of mentholated cigarettes (Jarvik et al. 1994, McCarthy et al. 
1995, Nil and Bättig 1989). Four other studies did not show any influence of 
mentholation on the number of puffs (Ahijevych et al. 1996, Caskey et al. 1993, Miller et 
al. 1994, Pickworth et al. 2002). Puff volume was investigated in six studies, three of 
them showing a decrease in puff volume when smoking mentholated cigarettes (Jarvik et 
al. 1994, McCarthy et al. 1995, Nil and Bättig 1989). Two studies did not find any effect 
of mentholation on puff volume (Ahijevych et al. 1996, Miller et al. 1994) and one study 
even showed an increase in puff volume (Ahijevych and Parsley 1999). 
The results of studies on the CO exhalation in smokers of mentholated and non-
mentholated cigarettes are contradictory. In a study with experimental cigarettes 
smokers inhaled defined volumes of cigarette smoke. The experimental cigarettes had 
been injected with 0 mg, 4 mg or 8 mg of menthol. The CO content in exhaled air 
increased from 5.6 ppm to 6.1 ppm and reached 8.1 ppm CO after use of 8 mg menthol 
cigarettes (Miller et al. 1994). Clark and colleagues did find a non-significant difference of 
40.3 ppm CO (mentholated cigarettes) against 35.8 ppm CO (non-mentholated 
cigarettes) (Clark et al. 1996). In a study in women, smokers of non-mentholated 
cigarettes showed a higher CO exhalation (10.6 ppm) than smokers of mentholated 
cigarettes (6.5 ppm) (Ahijevych et al. 1996). In a cross-over study, Benowitz and 
colleagues did not find any significant difference in the blood carboxyhaemoglobin 
content in smokers of mentholated and non-mentholated cigarettes (Benowitz et al. 
2004). Six other studies also did not show significant differences between CO uptake or 
CO exhalation in smokers of mentholated or non-mentholated cigarettes (Caskey et al. 
1993, Heck 2009, Jarvik et al. 1994, McCarthy et al. 1995, Nil and Bättig 1989, 
Pickworth et al. 2002). 
Menthol may increase the degree of dependence, or promote maintenance of smoking 
behaviour. Several findings suggest that menthol is involved in tobacco addiction. Some 
investigators have found that menthol cigarette use increases cotinine levels, and a 
significant correlation between cotinine and nicotine dependence has been reported, as 
well as a reduction in time to first cigarette of the day (Pomerleau et al. 1990). 
Greater smoking urgency among menthol compared to non-menthol adolescent 
cessation-treatment seekers has been reported (Collins and Moolchan 2006).  
Evaluating the tobacco industry documents, it was shown that cigarettes with low 
contents of menthol appeal to young smokers, new smokers, and smokers that do not 
like the harshness of the smoke. This can be due to the fact that lower contents of 
menthol in the smoke cover the harshness of the smoke, whereas a large dose of 
menthol causes harshness. On the other hand, cigarettes with a higher concentration of 
menthol appeal to smokers who are used to the harshness of the smoke (Kreslake et al. 
2008b). 
3.8.3.2. Ammonia and other additives affecting smoke pH 
Armitage et al. (2004) described a study in which 10 volunteers smoked either control 
cigarettes, cigarettes with diammonium hydrogen phosphate (DAP) or cigarettes with 
urea added. The venous blood levels of nicotine were independent of the amount of DAP 
or urea added to the tobacco. Preliminary data of a human study performed by a 
governmental research group at the RIVM (van Amsterdam et al., submitted for 
publication), comparing two commercial brands (one with low and one with high 
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ammonia content) with respect to nicotine absorption, showed no difference in venous 
blood nicotine levels (no difference in total absorption and peak plasma of nicotine) when 
smoking the two brands. These findings are in agreement with data of Labstat test 
laboratory (Rickert 1997) clearly showing that the amount of ammonia in tobacco does 
not lead to higher yields of nicotine and ammonia in mainstream smoke or a higher 
smoke pH of 10 commercial products. Furthermore, in a review of Seeman (2007), it is 
concluded that the fraction of free base nicotine trapped in aged smoke particulate 
matter has not been shown to be a useful predictor of the amount or total rate of 
nicotine absorption by smokers. 
The bioavailability of nicotine is dependent upon the pH as only uncharged nicotine is 
volatile and can be absorbed readily across cell membranes. The different ways of 
manipulating cigarettes so that more free nicotine is delivered have recently been 
reviewed (Wayne and Carpenter 2009). At lower pH the nicotine molecule will be 
positively charged and an equilibrium between the three forms of nicotine is created in 
relation to the pH (see figure 3). 
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Figure 3: Chemical form of nicotine (charged or free base) and their percentages as 
function of pH, ranging from 2 to 9.5 (adapted from Hoffmann and Hoffmann 
(1997)). 
 
Initially, cigarette smoke is lightly acidic and the nicotine is therefore poorly absorbed. 
However, the pH value is higher in the lungs (7.4) and some of the nicotine is found in 
uncharged form. Internal documents from the tobacco industry show that manufacturers 
started to use ammonia to increase smoke pH levels in the early 1970s (Willems et al. 
2006). Particular focus has been on ammonia and related compounds, but any compound 
that contributes to increasing the pH value will have a potential effect in increasing the 
impact of nicotine and the rate at which inhaled nicotine is absorbed into the 
bloodstream.  
While it has been shown that the absorption of nicotine in smokeless tobacco by the oral 
mucosa is dependent on the pH of the product (Fant et al. 1999), it is uncertain if the pH 
in cigarette smoke has a significant impact on the nicotine absorption in the lungs. This is 
due to the high local buffering capacity of the lung lining fluid which will cause free 
nicotine to be charged (protonated) again in the deeper airways (Willems et al. 2006). 
The high buffering capacity of mucus has been shown experimentally in human 
volunteers (Holma and Hegg 1989).  
It is widely accepted that smoke from different pyrolysed tobacco delivery devices (e.g. 
cigarettes, cigars, waterpipes, etc.) is inhaled differently. For example, cigarette and 
 Addictiveness and Attractiveness of Tobacco Additives  
 55
waterpipe smoke tends to be inhaled into the lungs, while cigar smoke is typically only 
inhaled into the mouth (except among former cigarette smokers who have switched to 
cigar smoking, in which case they often smoke cigars like cigarettes). It has been argued 
that this may be due to the characteristics of both the delivery device (for example, 
waterpipes cool the tobacco smoke, thereby allowing easier, deeper inhalation) and the 
tobacco itself. Waterpipe smoking is associated with greater smoke exposure (a larger 
volume of smoke is inhaled) than cigarette smoking (Maziak et al. 2009). 
This difference in inhalation may be due in part to the more acidic pH of cigarette smoke. 
The smoke of most cigars has an alkaline pH; as a result, nicotine contained in the 
smoke can be readily absorbed across the oral mucosa without inhalation into the lung. 
The more acidic pH cigarette smoke produces a protonated form of nicotine which is 
much less readily absorbed by the oral mucosa, and the larger absorptive surface of the 
lung is required for the smoker to receive the desired dose of nicotine. According to the 
National Cancer Institute (NCI), cigarette smokers must inhale to ingest substantial 
quantities of nicotine (the active agent in smoke), whereas cigar smokers can ingest 
substantial quantities of nicotine without inhaling (NCI 1998). The difference may, 
however, also be explained by the fact that cigar smoke is more concentrated and 
contains much more nicotine than cigarette smoke. 
While there has been considerable research into the effects of product characteristics on 
cigarette smoking behaviour (such as ventilation holes in “light” cigarettes resulting in 
compensatory smoking whereby smoke is inhaled more deeply to extract the required 
dose of nicotine), there is relatively little research into the effects of other delivery 
devices such as waterpipes. This is despite the rapid growth in the popularity of 
waterpipe smoking in European countries in recent years. 
3.8.3.3. Conclusions on most prominent additives 
Menthol is one of the most prominent additives in tobacco. If it is added in milligram 
amounts to cigarettes it dominates the taste of the smoke and the application is usually 
mentioned in the brand name. Menthol has a cooling effect on mucosal surfaces and a 
local anaesthetic activity. The use of menthol causes a subjective sensation of improved 
airflow without any change in nasal airway resistance, breathing pattern or ventilation. It 
has been proposed, that the cooling and local anaesthetic effects could lead to deeper 
inhalation of the smoke and higher exposure to other smoke constituents, but current 
data are inconclusive. However, menthol has been shown to inhibit the metabolism of 
nicotine. Furthermore, the taste of menthol could be an important reason for some 
smokers to consume mentholated cigarettes.  
It has been proposed that the addition of ammonia compounds increases the absorption 
of nicotine in the lungs by raising the pH in smoke, but this seems unlikely because of 
the high buffering capacity of the lung lining fluid. 
3.8.4. Additives in tobacco products other than cigarettes 
3.8.4.1. Cigars  
Very few additives are used in the classical manufacture of cigars; recently marketed 
cigarillos being an exception. In general, cigar brands contain only glue as an additive; 
several compounds are used as glue (e.g. ethyl-2-hydroxy ethyl cellulose, sodium 
carboxy methyl cellulose, gummi arabicum, methyl hydroxy ethyl cellulose). Several 
brands contain humectants such as propylene glycol or glycerol. Citric acid is added to 
influence the burning properties of the cigars. Some companies sum up their flavouring 
ingredients as “flavouring”, whilst others mention all compounds, including the amounts 
used.  
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As written earlier, in Germany, the information about ingredients of cigars can be found 
on the website of the Federal Ministry of Nutrition, Agriculture and Consumer Protection9. 
Consumers can search for brands and ingredients.  
Data from 2008, published on this website, showed that many of the flavourings were 
added in tiny amounts of 1 ppm. However, other flavourings such as 2-methylburic acid 
were added at a level of 60 ppm and ethyl vanillin was added at levels up to <0.5%. 
Some cigar manufacturers disclosed probably most, if not all of the additives, for 
example 211 additives are listed for the brand “7B Bonajuto” starting with 34 mg 
dextrose down to 8 µg clary sage oil.  
3.8.4.2. Pipe tobacco 
Pipe tobaccos contain humectants (e.g. glycerol and propylene glycol), preservatives 
(e.g. sodium benzoate, potassium sorbate), sweetening agents (e.g. dextrose, fructose, 
invert syrup, honey) and many flavours (e.g. cocoa, prune flavour, apple treacle 
concentrate, tamarind extract).  
The ingredients reported in 2009 in Germany can also be found at the website of the 
Federal Ministry of Nutrition, Agriculture and Consumer Protection9.  
3.8.4.3. Water pipes 
The use of waterpipes has increased in the eastern Mediterranean region since the 1990s 
with the introduction of maassel, a sweetened and flavoured tobacco (Maziak et al. 
2004a). During recent years, the smoking of waterpipes has become a habit among 
teenagers in Germany and other European countries, and in the USA (BZgA 2008, 
Jackson and Aveyard 2008a, Primack et al. 2008). The mild, sweet and flavoured tobacco 
appeals to many waterpipe smokers, especially young smokers. No information is 
available about the flavours used in waterpipe tobacco. The nicotine content in flavoured 
waterpipe tobacco ranged from 1.8 to 6.3 mg nicotine/g tobacco; the average was 
3.35 mg nicotine/g tobacco. In contrast, the traditional waterpipe tobacco without flavour 
contained 30 to 41 mg nicotine/g tobacco (Hadidi and Mohammed 2004).   
There are major differences in the consumption of waterpipes compared to other tobacco 
products. In contrast to cigarettes and cigars, the tobacco in waterpipes is not burned. 
The waterpipe tobacco is placed in the tobacco head, which is covered by a perforated 
aluminium foil on which the glowing charcoal is placed. In a study in Lebanon, Shihadeh 
measured the temperature during a waterpipe session. Within 15 minutes the foil 
reached a temperature of 400 to 450°C, whereas the waterpipe tobacco reached 
temperatures ranging from 60°C (after 10 minutes) to 120°C (after 50 minutes) 
(Shihadeh 2003). To prevent the tobacco from burning, high amounts of humectants are 
added to waterpipe tobacco. Besides glycerol and propylene glycol, the companies use 
honey and molasses. The resulting smoke is very mild and it is easy to inhale, even for 
inexperienced smokers. Since the smoke has almost no harshness the smoker can inhale 
huge volumes. Some waterpipe smokers refuse to smoke cigarettes. Waterpipe smokers 
inhale between 0.3 and 1.0 l per puff (Eissenberg and Shihadeh 2009, Monn et al. 2007, 
Shihadeh 2003, Shihadeh et al. 2004) compared to approximately 0.050 l per puff in 
cigarette smokers (Kozlowski and O'Connor 2002).  
In Germany, the addition of humectants to waterpipe tobacco is restricted to an upper 
limit of 5%. The Federal Institute for Risk Assessment (Bundesinstitut für 
Risikobewertung (BfR)) argued that it is possible that higher concentrations of glycerine 
in the waterpipe tobacco could lead to higher contents of acrolein in waterpipe smoke. 
Acrolein is present in waterpipe smoke as shown in a recent investigation from Lebanon. 
The authors not only found acrolein, but also high amounts of acetaldehyde. In one 
waterpipe session, 2520 µg acetaldehyde was measured in the smoke (Al Rashidi et al. 
2008). 
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In 2008, few companies reported added ingredients in waterpipe tobacco to the German 
authorities. However, the values reported were interesting: in some brands the total 
tobacco content was small, for example the label “Al-Waha” contained per kg: 200 g 
tobacco, 710 g fructose, 50 g glycerine and 40 g flavouring. Another label (“Sindbad”) 
contained per kg: 398 g invert syrup, 210 g water, 42 g propylene glycol, 28.6 g 
flavouring, 6 g ethyl alcohol and 1.92 g potassium sorbate, leaving 313 g of tobacco. The 
tobacco content of waterpipe tobacco is thus not very high (20 to 31%). 
Studies from Syria show that waterpipe use can be addictive. The frequency of waterpipe 
use was strongly correlated with the participants’ subjective judgement of how hooked 
they are on waterpipes (Maziak et al. 2004b).  
3.8.4.4. Smokeless tobacco 
There are many different types of smokeless tobacco in use around the world, some 
being more toxic than others. 
In Europe, smokeless tobacco is widely used in Sweden (24% of men, 3% of women), in 
particular in the form of moist snuff called “snus”. Snus is sold in loose weight in boxes 
or in small “tea-bag”-like sachets. The sale of snus is banned in all other EU countries. As 
described in the SCENIHR opinion on smokeless tobacco products (SCENIHR 2008), the 
frequency of smokers in Sweden is lower than in other European countries and the 
morbidity due to tobacco related diseases is also lower.  
On the other hand, according to a recent study in the US, the promotion of smokeless 
tobacco as a safer alternative to cigarettes is unlikely to result in a substantial health 
benefit at a population level (Mejia et al 2010). The dual use of smokeless tobacco and 
cigarettes may in part explain the findings. The tobacco industry has marketed and 
promoted snus as a way to cope with smokefree environments, at the same time 
advocating the endorsement of snus as a harm reduction product by public health 
authorities. This aspect is outside the scope of the current opinion, but as indicated in the 
SCENIHR report from 2008, all smokeless tobacco products (STP), including snus, 
contain carcinogenic compounds and cause addiction and dependence (SCENIHR 2008). 
Moreover, the studies comparing the efficiency of smokeless tobacco with established 
therapies for smoking cessation are inconclusive.  
Due to immigration, many different smokeless tobacco products have found their way 
into EU countries, and their use is typically clustered in local communities. A similar 
clustering of use may be seen with now increasingly rare traditional European products 
such as nasal snuff.  
The Swedish “snus” is, according to the manufacturers (Swedish Match13, Fiedler & 
Lundgreen14), a standardised product using mainly air cured tobacco. Sodium carbonate 
is added in order to raise the pH to around 8, thus facilitating the uptake of uncharged 
nicotine in the mouth (Fant et al. 1999). A number of artificial or natural flavours are 
added according to the brand; the flavours all comply with food regulations. Two sorts of 
humectants are used, glycerol and propylene glycol. Snus is pasteurised and the 
fermentation that takes part in other tobacco products is thus inhibited, leading to a 
lower content of tobacco specific nitrosamines. More than 250 additives are found in 
different snus brands, most of them are flavours which are used in small amounts. Table 
4 shows the 50 substances that are added in greatest amount. 
Gutkha is another smokeless tobacco product that is popular among Indian communities 
in the UK. This is a chewing tobacco that in addition to tobacco contains areca nut, 
catechu, lime, saffron, saccharine, mint and various flavourings. A table describing the 
                                          
13 www.swedishmatch.com/ 
14 www.flsnus.se 
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many different smokeless products that are rarer in Europe is found in the SCENIHR 
report from 2008 (SCENIHR 2008).   
 
Table 4 The 50 additives present in greatest amount in different snus brands15  
Ingredient 
Maximum percentage added to 
different snus brands 
Sodium chloride 6.7 
Ethanol 5.1 
Propylene glycol 4.2 
Coffee extract 3.7 
Plant fibre 3.7 
Glycerol 3.6 
Sodium carbonate 2.9 
Benzyl alcohol 2.1 
Anethole (trans-) 1.5 
Peppermint oil 1.5 
Maltodextrin 1.4 
Calcium carbonate 1.2 
Licorice and liquorice extract 1.1 
Gum Arabic 0.9 
Lemon oil 0.7 
Ammonium chloride 0.6 
Vanillin 0.6 
Lime oil 0.4 
Ginger extract 0.3 
Linalyl acetate 0.3 
Menthol 0.3 
Ethyl butyrate 0.2 
Eucalyptus oil 0.2 
Hydroxyphenyl-2-butanone (4-(para-)) 0.2 
Potassium sorbate 0.2 
Sugar, invert 0.2 
Acesulfame K 0.1 
Acetic acid 0.1 
Benzaldehyde 0.1 
Buchu leaf oil 0.1 
Butyric acid 0.1 
Citronellol 0.1 
Clary sage oil 0.1 
Damascenone 0.1 
                                          
15 Data extracted from www.swedishmatch.se 
 Addictiveness and Attractiveness of Tobacco Additives  
 59
Ingredient 
Maximum percentage added to 
different snus brands 
Damascone (beta-) 0.1 
Diacetyl 0.1 
Dimethyl-1,2-cyclopentadione (3,4-) 0.1 
Ethyl 2-methylbutyrate 0.1 
Ethyl acetate 0.1 
Geraniol 0.1 
Geranium rose oil 0.1 
Hexen-1-ol (cis-3-) 0.1 
Hexen-1-yl acetate (cis-3-) 0.1 
Hexenyl butyrate 0.1 
Hexenyl formate (cis-3-) 0.1 
Hexyl alcohol 0.1 
Hydroxy-2,5-dimethyl-3(2H)-furanone (4-) 0.1 
Ionone (alpha-) 0.1 
Ionone (beta-) 0.1 
Jasmone 0.1 
Lactic acid 0.1 
3.8.4.5. Conclusions on tobacco products other than cigarettes 
Compared with the widespread use of cigarettes, other tobacco products are consumed 
much less commonly. There is a great variety of additives which either have a specific 
function as humectants, glues, acidity regulators etc., or determine the specific flavour of 
the product or brand. Most flavours are added in small amounts. There is a lack of data 
to clarify that any of the additives are by themselves contributing to addictive potential, 
either directly or indirectly. The additives and the design characteristics of tobacco 
products are likely to attract specific groups of consumers and perhaps facilitate initiation 
of tobacco use. The aspects of target groups will be addressed in later sections (3.10.2). 
3.8.5. Overall conclusions concerning additives which can increase the 
addictiveness and/or attractiveness of tobacco products 
For most tobacco additives, information about possible effects on addictiveness and 
attractiveness does not exist. A number of studies have been conducted by the tobacco 
industry, and there are indications that some additives have effects in relation to 
addictiveness and attractiveness.  
The pyrolysis of sugar substances to acetaldehyde and more complex aldehydes may 
increase nicotine addictiveness, but the data are not yet conclusive, although an 
important role of inhibition of monoamine oxidases by tobacco smoke has been 
repeatedly demonstrated. Additives that increase the pH, and thereby the formation of 
free nicotine, may contribute to addictiveness, but the efficacy of these compounds has 
not been shown. In view of the buffer capacity of the body fluids involved (saliva, lung 
lining fluid), the presence of such an effect is doubtful.  
A large number of additives are used to increase attractiveness. Among these, various 
sugars constitute an important part. Menthol is widely used in certain brands in 
considerable amounts while most other additives are used in small amounts, and the 
mixture of additives is characteristic for each brand. This is an important aspect for 
maintaining consistency of the tobacco products and in targeting special groups. 
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3.9. Experimental animal models 
Several animal models are available to study particular responses that are related to 
nicotine addiction. Thus, predictive models are available in animals to evaluate the 
development of nicotine tolerance and physical dependence as well as the 
rewarding/reinforcing effects produced by nicotine. The animal methods currently used to 
evaluate nicotine addictiveness are mainly based on the evaluation of its 
rewarding/reinforcing properties. New complex behavioural models that resemble the 
main diagnosis for drug addiction in humans have been developed very recently. 
However, these new models can only be applied for some particular drugs and are not 
yet available for nicotine addiction. 
3.9.1. Experimental models to evaluate the development of nicotine 
tolerance and physical dependence 
Long-term consumption of nicotine produces adaptive changes in the central nervous 
system leading to the development of tolerance and physical dependence that can be 
easily evaluated in animal models. Thus, chronic nicotine administration produces 
tolerance to most of its pharmacological effects (Benowitz 2008). Tolerance to several 
nicotine responses such as hypolocomotion, convulsive effects, hypothermia or 
antinociception has been widely described in animal models, whereas an absence of 
tolerance to the effects on cognitive processes has been currently reported in these 
studies (Benowitz 2008, Collins et al. 1988, Damaj and Martin 1996, Marks et al. 1986, 
Miner and Collins 1988).  
In humans, cessation of tobacco intake precipitates both somatic and affective symptoms 
of withdrawal which may include severe craving for nicotine, irritability, anxiety, loss of 
concentration, restlessness, decreased heart rate, depressed mood, impatience, 
insomnia, increased appetite and weight gain (Hughes and Hatsukami 1986, Hughes 
2007). In rodents, nicotine withdrawal is also characterised by the manifestation of both 
somatic signs and affective changes similar to those observed in humans. The somatic 
signs include teeth chattering, palpebral ptosis, tremors, wet dog shakes, and changes in 
locomotor activity and other behavioural manifestations (Malin et al. 1992). Although the 
development of nicotine tolerance and physical dependence is concurrent to the 
development of addiction, they are not aetiologically related to nicotine addiction (Volkow 
and Li 2005). However, the affective manifestations of nicotine withdrawal seem to play 
an important role in the maintenance of the nicotine addictive process. These 
manifestations can be evaluated in rodents by measuring several emotional symptoms 
such as increased anxiety, aversive effects and reward deficits (Jackson et al. 2008b, 
Johnson et al. 2008). The aversive manifestations of withdrawal are mainly evaluated in 
rodents by using the place conditioning paradigm, whereas the associated reward deficits 
are currently evaluated using intracranial self-stimulation techniques. Both behavioural 
paradigms have also been extensively used to evaluate nicotine rewarding effects and 
will be described in the next section. 
3.9.2. Experimental models to evaluate nicotine rewarding effects 
Drug consumption is promoted and maintained by the rewarding properties of the drug. 
However, it is important to underline that drug consumption is a requirement for the 
development of addiction, although addiction is not a necessary consequence of drug 
intake. 
3.9.2.1. Self-administration paradigms 
Self-administration methods are widely used to directly evaluate the reinforcing 
properties of a drug. The procedures are considered by most researchers to be valid and 
reliable models of drug consumption in humans, and to have a high predictive value. It is 
assumed that the neurobiological mechanisms involved in drug self-administration in 
animals are similar to those underlying drug-intake in humans (Sanchis-Segura and 
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Spanagel 2006). Self-administration methods can be classified considering the route of 
administration and the behavioural paradigm. From a behavioural perspective, these 
methods can be classified as operant and non-operant procedures. Non-operant 
paradigms are centred on the amount of drug consumed whereas the operant procedures 
require a conditioned response in order to obtain the drug, and the analysis of this 
response provides valuable information about different behavioural aspects of drug 
consumption. Non-operant paradigms in animals are mainly restricted to oral self-
administration and they are very useful for alcohol research considering the similarities 
with the route of alcohol consumption by humans. The use of the appropriate route of 
self-administration for each drug of abuse provides an additional source of validity to 
these animal models, and these non-operant paradigms are therefore not useful in 
evaluating nicotine rewarding effects. 
The use of operant models is based on the learning contingency defined as “positive 
reinforcement”. In these models, the drug constitutes a positive reinforcer that is 
delivered contingently to the completion of the schedule requirements (Sanchis-Segura 
and Spanagel 2006). The operant chambers are equipped with one or more manipulandi, 
transmitting the operant response and devices to deliver the drug (reinforcer). Usually, 
there is an active manipulandum that is linked to the delivery of the drug and an inactive 
one, which results in the delivery of the drug vehicle or lacks any programmed 
consequence. The programmes of reinforcement commonly used are the fixed ratio and 
the progressive ratio schedule and the animal species currently used for nicotine self-
administration is the rat. It is suggested that fixed ratio schedules measure the 
pleasurable or hedonic effects of a drug (McGregor and Roberts 1995, Mendrek et al. 
1998), whereas progressive ratio schedules are more related to motivation and provide a 
better measure of incentive salience or craving (Arnold and Roberts 1997). Under a fixed 
ratio schedule, the drug is delivered every time that a pre-selected number of responses 
are completed. For nicotine self-administration, the number of responses required to 
obtain the drug is generally kept low, and the most used is the fixed ratio 1 (a nicotine 
delivery after each response in the active manipulandum), although fixed ratio 3 and 5 
schedules of reinforcement have also been used (for instance, Shram et al. 2008). 
Multiple studies have demonstrated that rats easily maintain an operant behaviour to 
self-administer nicotine under these fixed ratio experimental conditions (Maldonado and 
Berrendero 2009). In contrast with other drugs of abuse, when dose-response curves 
have been constructed for nicotine self-administration in rats, they have been relatively 
flat or inverted U-shaped, which may be because of the aversive effects and toxicity 
associated with high doses of nicotine (Corrigall and Coen 1989, Shoaib et al. 1997). In a 
large number of studies the dose of 0.03 mg/kg (free base) per infusion showed very 
robust self-administration behaviour in rats (Corrigall and Coen 1989, Donny et al. 1999, 
Shoaib et al. 1997).  
Under the progressive ratio schedule, the response requirement to deliver the drug 
escalates according to an arithmetic progression. The common index of performance 
evaluated in this schedule is the break point defined as the highest number of responses 
that the animal accomplished to obtain a single delivery of drug. In rats, several studies 
have also revealed that nicotine can maintain self-administration on a progressive ratio 
schedule of reinforcement. The break point achieved for nicotine self-administration has 
been compared by the authors with other drugs of abuse. They found that it was lower 
than the final ratio obtained for cocaine under an identical schedule of reinforcement, 
higher than that reported for heroin under similar progressive ratio schedule, and slightly 
lower than heroin when a slowly accelerating schedule was used (Donny et al. 1999). 
However, comparison across studies and drugs is difficult due to procedural differences in 
training parameters, sequence of progressive reinforcement or degree of drug 
dependence (Stafford et al. 1998). Increasing doses of nicotine usually resulted in a 
more linear increase in the performance in the progressive ratio schedule than in the 
fixed ratio schedule (Donny et al. 1999). The maximum break points usually reached by 
the adult rats when using the progressive ratio schedule are around 50 responses to 
obtain a single nicotine injection (Shram et al. 2008). Interestingly, higher break point 
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values were obtained in adolescent rats (around 95) than in adult rats (Shram et al. 
2008). 
Operant nicotine self-administration has been difficult to establish in mice. A recent study 
has reported the validation of a new reliable operant model of nicotine self-
administration, extinction and relapse in mice. This model was developed in C57BL/6 
mice which are particularly sensitive to the behavioural effects of nicotine (Martín-García 
et al. 2009). Mice were successfully trained to self-administer a dose of nicotine similar 
to that previously used in rats (0.03 mg/kg, free base) under a fixed ratio 1 schedule of 
reinforcement. An inverted U-shaped dose-response function was also obtained using 
mice to self-administer different doses of nicotine (Galeote et al. 2009). Similar to other 
drugs of abuse, the break point achieved for nicotine self-administration in mice was 
lower than in rats. Indeed, the maximum break point (27 responses to obtain a single 
nicotine injection) was reached by the mice when using the dose of nicotine of 0.042 
mg/kg (free base) (Galeote et al. 2009). 
3.9.2.2. Conditioned preference paradigms 
In the conditioned preference paradigms, the subjective effects of the drug are 
repeatedly paired to a previously neutral stimulus. Through this repeated conditioning 
process, this stimulus acquires the ability to act as a conditioned stimulus, and the 
animal will prefer or avoid this conditioned stimulus depending on the rewarding or 
aversive effects produced by the drug. The most commonly used paradigms apply a 
spatial environmental stimulus as conditioned stimulus and the animal will show a 
conditioned place preference or a conditioned place aversion for the environment 
associated with the effects of the drug or its withdrawal. Although a conditioned 
approach/avoidance towards specific stimuli can also occur in humans as a result of drug 
consumption (Bardo and Bevins 2000), the place conditioning paradigms are not 
primarily intended to model any particular feature of human behaviour. These paradigms 
mainly represent an indirect assessment of the rewarding or aversive effects of a drug or 
its withdrawal, by measuring the response of the animal towards the conditioned 
stimulus. Drugs of abuse display a differential ability to produce conditioned place 
preference. Opioids and psychostimulants easily produce robust place preference over a 
wide range of experimental conditions, whereas other drugs such as ethanol, 
cannabinoids or nicotine produce more inconsistent results (Sanchis-Segura and 
Spanagel 2006). Thus, nicotine has been shown to induce in rodents conditioned place 
preference across a wide range of doses in some experiments, although inverted U-
shaped dose-response curves have been often reported, and the magnitude of the effect 
is generally small and affected by environmental stimuli or previous handling history 
(Castañé et al. 2006, Forget et al. 2005, Grabus et al. 2006, Le Foll and Goldberg 2004). 
Nicotine also produced aversive effects when used at high doses in some, but not all, 
studies (Grabus et al. 2006, Le Foll and Goldberg 2004). These results suggest that the 
rewarding effects of nicotine may be weaker than other drugs of abuse in this particular 
experimental paradigm (LeFoll and Goldberg 2004). Interestingly, sex differences were 
clearly revealed in mice exposed to nicotine in the conditioned place preference 
paradigm. Thus, female mice responded more to the conditioned rewarding effects of 
nicotine compared with males (Isiegas et al. 2009). 
3.9.2.3. Intracranial self-stimulation paradigms 
Intracranial electric self-stimulation procedures were essential in the discovery of the 
brain reward circuits (Olds and Milner 1954) and are now widely used to study the effects 
of drugs of abuse in the activity of the reward circuits (Sanchis-Segura and Spanagel 
2006). In this paradigm, animals are trained to maintain an operant behaviour in order 
to obtain an electric pulse through an electrode that has been previously implanted in a 
reward-related brain site, most frequently the lateral hypothalamic area. The threshold of 
the minimal current needed to promote intracranial electric self-stimulation is estimated. 
A drug that stimulates the reward circuit will decrease this threshold, which would be 
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related to its rewarding properties, whereas a drug having aversive effects will enhance 
the minimal current required to maintain the self-stimulation (Markou and Koob 1993). 
Nicotine as well as other drugs of abuse such as psychostimulants, opioids or ethanol, 
reduces the threshold to promote intracranial electric self-stimulation in some reward 
brain areas (Huston-Lyons and Kornetsy 1992, Kornetsky and Bain 1992, Wise 1996). 
Therefore, this behavioural paradigm clearly demonstrates the capability of nicotine to 
activate the brain reward circuits. 
3.9.3. Experimental models to evaluate nicotine addiction 
The behavioural models available to evaluate drug rewarding effects have been very 
useful in clarifying the neurobiological basis of drug taking. However, addiction is not just 
the taking of drugs, but represents a relapsing disorder characterised by compulsive drug 
use maintained despite adverse consequences for the user (APA 1994). Behavioural 
models that resemble the main diagnosis criteria for addiction are difficult to validate in 
animals. Recently, two independent research groups have validated behavioural models 
of compulsive drug seeking in rodents that resemble addictive behaviour in humans 
(Belin et al. 2008, Deroche-Gamonet et al. 2004, Vanderschuren and Everitt 2004). In 
these models the authors have evaluated the difficulties in stopping drug use by 
measuring the persistence of drug seeking during a period of signalled non-availability. 
The extremely high motivation of the addicts to take the drug has been evaluated by 
using a progressive ratio schedule where the number of operant responses to obtain a 
single drug injection was increased progressively within the same session. The maximal 
amount of work that the animal performs before cessation of responding (referred to as 
the break point) is considered a reliable index of the motivation for the drug. These new 
animal models of addiction report a break point over 500 to obtain a single cocaine 
injection in “addict rats” (Deroche-Gamonet et al. 2004). In these new animal models of 
addiction, the continued use of the drug despite its harmful consequences has been 
resembled by the persistence of the animal’s responding for the drug when drug delivery 
was associated with a punishment. 
However, these models validated for cocaine consumption are still not available for other 
drugs, such as nicotine. Indeed, nicotine self-administration has not been reported to be 
maintained when drug delivery was associated with a punishment. In addition, only 
moderate break point values were obtained when a progressive schedule of 
reinforcement was used for nicotine self-administration. Thus, the maximum break points 
usually reached to obtain nicotine, i.e. around 50 responses in adult rats (see for 
instance, Shram et al. 2008) and around 95 in adolescent rats (Shram et al. 2008), are 
far away from the break point values (over 500) reached to obtain cocaine by the 
“addicted rats” (Deroche-Gamonet et al. 2004). 
In contrast, recent advances using animal models of relapse have shown that nicotine 
seeking after extinction of the operant behaviour can be triggered in rats and mice by 
nicotine-associated (conditioned) cues (Caggiula et al. 2002, Liu et al. 2007, Martín-
García et al. 2009), stressors (Bilkei-Gorzo et al. 2008, Buczek et al. 1999) (e.g. mild 
footshocks) and re-exposure to the previously experienced drug (Chiamulera et al. 1996, 
Dravolina et al. 2007, Shaham et al. 1997), which are the same events that trigger 
nicotine craving and relapse in humans. Nicotine-paired cues have a critical role in 
sustaining nicotine self-administration after prolonged periods of abstinence and in 
maintaining smoking behaviour in humans. Indeed, a critical role of the environmental 
stimuli previously associated with drug consumption has been attributed when explaining 
the high rate of nicotine relapse (Caggiula et al. 2001, Caggiula et al. 2002, Liu et al. 
2007). In agreement, the exposure to the associated cues was the most effective 
stimulus reinstating nicotine-seeking in mice, whereas stress exposure reinstated 
nicotine-seeking behaviour in half of the mice, and a priming injection of nicotine only 
reinstates seeking behaviour in a low percentage of mice (Martín-García et al. 2009). The 
neurobiological mechanisms involved in the processes underlying relapse to nicotine 
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seeking are poorly understood. Further studies will be required to clarify the mechanisms 
involved in nicotine relapse using these animal models now available. 
3.9.4. Conclusions on experimental animals 
Animal models to evaluate the rewarding and the reinforcing properties of nicotine, and 
the development of nicotine tolerance and dependence, are available. The models most 
currently used to evaluate nicotine addictiveness are based on its rewarding/reinforcing 
properties, are well established and have been widely used for other drugs of abuse to 
determine their addictive potential. Among these models, the operant self-administration 
paradigm is particularly useful considering its high predictive value for the abuse liability 
of a drug and therefore also possibly for its addictive potential in humans. A response 
easy to evaluate in the self-administration paradigm that has been related to the 
addictive potential is the break point (highest number of responses that the animal 
accomplishes to obtain a single delivery of a drug). A higher break point represents a 
direct measure of the motivation of the animal to obtain the drug and is often taken to 
imply an increase in the addictive potency of the drug. New complex behavioural models 
that resemble the main diagnosis for drug addiction in humans have been developed very 
recently, although these new models can only be applied for some particular drugs and 
experimental conditions at the present moment. 
3.10. Human studies of the role of additives in addictiveness and 
attractiveness of tobacco products 
Tobacco addiction is maintained by nicotine, and tobacco products that do not deliver 
nicotine do not sustain addiction. However, it is important to distinguish between the 
stages of tobacco use, from early experimentation and initiation (prior to the 
development of dependence), through to regular use (and possible dependence) and 
possibly eventual cessation. Therefore, nicotine and additives may play different roles, or 
may differ in their relative importance during experimentation and initiation compared 
with the progression to regular use. In addition, the role of additives will differ according 
to whether the tobacco is delivered as a smoked or smokeless product. 
Smoking and inhalation into the lungs, in particular, is a highly efficient form of nicotine 
administration, as the drug enters the circulation rapidly through the lungs and moves 
into the brain within seconds. This also allows precise dose titration, so a smoker may 
obtain the desired effects (Benowitz 2008). Therefore, additives and design 
characteristics which require the inhalation of tobacco smoke will be associated with 
increased dependence potential, and this will be particularly true when inhalation into the 
lungs (as opposed to the oral cavity only) is encouraged. In addition, various tobacco 
additives and flavourings can modulate the impact of nicotine, including via 
administration and inhalation behaviour. The impact of these additives on the 
attractiveness and palatability of tobacco products, in particular in naive users, may 
influence initiation of use and progression to regular use, before dependence is 
established. 
Tobacco dependence is operationalised in multiple ways, but all definitions share core 
features of tolerance and withdrawal symptoms in relation to tobacco use. Most studies 
use either the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for 
tobacco dependence, or a proxy measure such as the Fagerström Test for Nicotine 
Dependence (FTND), or the number of cigarettes smoked per day. However, the number 
of cigarettes smoked per day is often a poor measure of dependence, given the 
substantial inter-individual variability in the amount of nicotine extracted from a 
cigarette. The majority of the variance in scores on the FTND is accounted for by the first 
item (“How soon after you wake do you have your first cigarette?”), and it is likely that 
many dependent cigarette users can be identified by how soon after waking they smoke 
their first cigarette. This is most likely due to the short half-life of nicotine, which means 
that after a period of sleep most tobacco users have very low levels of circulating 
nicotine, resulting in withdrawal symptoms which are rectified by tobacco use. 
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Human behavioural studies require either subjective or objective measures of the effects 
of tobacco, and this allows a comparison of these effects between tobacco products which 
do and do not contain specific additives. Subjective measures include self-report 
measures of mood and craving, which may be as simple as single visual analogue scale 
measures of liking (e.g. “How much do you like the taste of this cigarette”), or include 
validated questionnaire measures (e.g. the Positive and Negative Affect Schedule). The 
latter refers to a range of laboratory assessments, including actual smoking behaviour 
through smoking topography measurement, which allows the detailed measurement of 
number of puffs taken per cigarette, depth of inhalation, inter-puff interval, and so on. 
This may also include self-administration or cigarette choice paradigms (e.g. presenting 
participants with two cigarettes, only one of which contains an additive of interest, to 
determine which is preferentially smoked), which are more closely comparable with 
paradigms used in animal studies. 
These measures are generally impossible or impractical to collect in survey studies, 
although the rates of use of different tobacco products, containing different additives, 
may allow their attractiveness to certain sub-groups (e.g. defined by age or ethnicity) to 
be inferred. A further complication is the possibility that what constitutes an attractive or 
palatable product may be culturally or ethnically specific. 
3.10.1. Experimental and observational studies 
Cigarette smoking topography describes the pattern of smoking behaviour for an 
individual cigarette smoker, and includes measures of puff volume, puff duration, puff 
flow, interpuff interval, and number of puffs per cigarette. This technology can be used to 
assess the effects of product design characteristics and additives on smoking behaviour. 
There is good evidence, for example, that cigarette smokers partially compensate for the 
low nicotine delivery by low tar cigarettes, possibly by inhaling more deeply, taking more 
puffs per cigarette, and so on (Frost et al. 1995), so that the addictive potential of low 
tar cigarettes may not be substantially different from that of high tar cigarettes (see also 
section 3.5.5). Similar effects have been observed when comparing nicotinised and 
denicotinised cigarettes (Strasser et al. 2007). 
Neurological techniques have also been used (e.g. by Philip Morris) to assess the effects 
of additives on smokers’ central nervous system functioning. Electroencephalography 
(EEG), pattern reversal evoked potential (PREP), and chemosensory event-related 
potential (CSERP) were used to measure physiological, sensory, and cognitive changes 
related to nicotine, flavourings and other additives (Gullotta 1994).   
Other chemicals (e.g. pyrazine, vanillin, and propylene glycol) appear to increase P1-N2 
amplitudes (the first positive and second negative peaks in the EEG waveform elicited by 
a novel stimulus, corresponding to early sensory processing) (Philip Morris 1995), and 
different tobacco flavourings affect CSERPs (EEG waveforms elicited by olfactory or 
gustatory stimuli) differently, even when smokers were unable to discriminate these 
subjectively (Gullotta 1994). This indicates that objective measures may be more 
sensitive to the modulation of smoking behaviour by specific additives than subjective 
measures (see also section 3.8.1 and 3.8.2). 
The sensory effects of tobacco smoke may themselves acquire reinforcing properties 
through their repeated association with the rewarding properties of tobacco. This has 
been shown in various studies where, for example, denicotinised cigarettes continue to 
be smoked in the absence of nicotine reward but are not smoked as frequently when the 
upper airway is anaesthetised to block the sensory effects of the tobacco smoke (Rose et 
al. 1985). This may explain in part the loyalty to specific brands shown by tobacco users, 
since the exact sensory properties of individual brands will differ. It is also possible that 
extended product characteristics (e.g. pack designs) may acquire reinforcing properties 
through similar processes, although this has not yet been investigated systematically. 
A variety of product design strategies (e.g. ventilation holes, see section 3.5) and 
application of additives (e.g. ammonia or ammonia-derivatives, see section 3.8.1.3 and 
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3.8.3.2) may play important roles either via smoking behaviour such as puffing 
characteristics (see section 3.5.5), or via more direct biological effects such as nicotine 
bioavailability. These may in turn influence addictive effects and appeal to the user 
(Baker et al. 2004c, Djordjevic and Doran 2009). As reported by the tobacco industry, 
approximately 600 substances are used as cigarette additives, but among the most 
commonly used products only one additive (menthol) is widely advertised by the industry 
(Ahijevych and Garrett 2004). 
3.10.2. Target groups (age, ethnicity, gender, socioeconomic position) 
Internal tobacco industry documents illustrate that additives and technical characteristics 
have been extensively evaluated in relation to their appeal to specific target groups and 
markets (Carpenter et al. 2007). Some of this evidence relates to the US experience, in 
particular with respect to ethnicity, and it is not clear whether these results will 
generalise, in full or in part, to the European situation. However, some findings, such as 
those relating to younger age groups and gender, are more likely to generalise.  
3.10.2.1. Age groups 
There is evidence from tobacco industry documents that flavourings have been used to 
target younger smokers: “[U]se the FLITE technology to inject various flavours into the 
blend. These flavours would be new and unconventional. Two flavours which were 
discussed as options were Root Beer and Brazilian Fruit Juice, both of which tend to 
appeal to the younger generation while being rejected by their parents” (BAT 1997). This 
may act as a gateway to subsequent tobacco use in adulthood. 
A survey in the US showed that 17 year old smokers are three times as likely to use 
flavoured cigarettes as are smokers over the age of 25 (Klein et al. 2008). Therefore, the 
addition of exotic flavours may be used to increase the appeal of tobacco products 
(including smokeless products), and in particular their appeal to naive users and younger 
age groups. Dutch survey data indicate that taste and smell are important determinants 
of brand preference among young smokers aged 10-18 years, with brands with light or 
mild taste regarded as less unhealthy (Talhout et al. 2009). 
3.10.2.2. Ethnicity 
In the USA, there is a striking difference in the use of mentholated cigarettes among 
African Americans and European Americans, with the prevalence of mentholated cigarette 
smoking much higher in the former group. Menthol is the most widely-studied additive, 
and therefore provides a case-study for some of the behavioural consequences of 
tobacco additives. This suggests that specific additives may be used to improve the 
attractiveness of tobacco products to specific populations or target groups. 
Internal tobacco industry documents, available under the Freedom of Information Act in 
the USA, describe the relationships between sensory perception and the attitudes, 
preferences, and patterns of cigarette use among menthol smokers. Two unique types of 
menthol smoker are described: those who cannot tolerate the harshness and irritation 
associated with smoking non-menthol cigarettes, and those who seek out the specific 
menthol flavour and associated physical sensation (Kreslake et al. 2008b). 
Additives also contribute to the effects of other tobacco products with either marginal or 
region-specific use. For example, clove cigarettes, used predominantly by East Asian 
populations, are composed of a mixture of tobacco (60–80%) and ground clove buds 
(20–40%), available with or without filters. Eugenol, an analgesic, is naturally occurring 
in cloves, and is present in milligram quantities in the clove cigarette filler. Like menthol, 
eugenol diminishes the harshness of the tobacco smoke (Djordjevic and Doran 2009). 
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3.10.2.3. Gender 
While the targeting of specific groups and populations (e.g. young people, women, ethnic 
groups) is primarily through advertising campaigns for tobacco products, this targeting 
can also include the development of specific tobacco products, and the use of specific 
additives in these products. For example, cigarettes with perfumed scents and labelled as 
“slim” or “light” brands have been marketed to women. This is reflected in evidence that 
more women than men smoke light and ultra-light cigarettes (ONS 2007). 
3.10.2.4. Socioeconomic position 
Tobacco use is heavily socially patterned in developed countries, with prevalence of use 
being higher in lower income groups compared to higher income groups (Eek et al. 2010, 
Main et al. 2008). While tobacco use in general, and cigarette use in particular, has 
declined dramatically in wealthier socioeconomic groups over the last few decades, the 
decline in less wealthy socioeconomic groups has been much less pronounced. In 
particular, in the most economically disadvantaged groups, tobacco use prevalence has 
remained almost unchanged over this period. As a result, tobacco use is one of the 
largest causes of health disparities between socioeconomic groups in European countries. 
However, there is a lack of data to show if changing patterns of use in Europe are 
influenced by tobacco industry's targeting of certain socioeconomic groups. 
3.10.3. Emotional/subjective effects 
Flavours impart a specific taste or aroma to a product, while other additives may be used 
for a specific technological purpose in the manufacture of tobacco products (Baker et al. 
2004b). Both flavours and other additives can confer emotional and subjective effects. 
The term “impact” is widely used in tobacco industry research and documents, and is a 
tobacco industry term for smokers’ subjective awareness of the drug effects of nicotine. 
Organic acids have been used since the 1950s to improve “smoothness” of cigarettes. For 
example, Philip Morris found that lactic acid decreased subjective ratings of harshness 
and bitterness, and produced a sweeter flavour. Citric additives have been used not only 
for reduced harshness and flavour modification, but also to modify smoke pH, to 
neutralize nicotine “impact” (an industry term denoting the organoleptic sensation caused 
by nicotine; smokers often describe this as “throat catch” or “throat hit”). Tartaric and 
lactic acids likewise modify the pH of smoke. All of these organic acids increased 
smoothness and are associated with a decrease in nicotine “impact” (Philip Morris 1989, 
see also section 3.8.2.2). However, it is unclear whether these effects are due directly to 
pH modification. 
Unregulated botanical and chemical additives might have “multiple-use” purposes, such 
as enhancing flavour and producing “smoother” cigarette smoke, as well as potentially 
preventing or masking symptoms associated with smoking-related illnesses (Rabinoff et 
al. 2007). 
3.10.4. Conclusions 
A wide range of subjective and behavioural effects of tobacco additives have been 
reported in humans, but there are relatively few studies published in the scientific 
literature, with much information having been obtained from tobacco industry documents 
under freedom of information legislation. In principle, similar methods to many of those 
used in experimental animal models may also be used in humans. However, there is 
greater variability in the specific methods employed, which include subjective reports of 
liking, behavioural measures of drug choice, neurobiological measures of drug effects 
(such as neuroimaging techniques), and direct measures of drug administration (such as 
cigarette smoking topography). The majority of additives used appear to be flavourings, 
and these may be used to target specific markets, such as young people, women, or 
ethnic groups. There is some evidence that these additives modify objective measures of 
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cigarette smoking behaviour (i.e. smoking topography), but this is somewhat 
inconsistent. 
3.11. Effects of additives on nicotine-addictive properties 
3.11.1. Modification of the pharmacology and reinforcement properties 
of nicotine  
3.11.1.1. Comparison of addictive properties of nicotine vs. 
whole tobacco and modification of reinforcing properties 
of nicotine 
Acetaldehyde is formed in high concentrations when cigarette constituents, including 
sugars, are burned. Animal research conducted by Philip Morris demonstrated a 
synergistic interaction between nicotine and acetaldehyde, using a lever-pressing model 
of self-administration in rodents (Charles et al. 1983, DeNoble et al. 1997). Rats pressed 
a bar more for the combination of nicotine and acetaldehyde than for either substance 
alone. If these results apply to humans, smokers would puff more with the combination 
of nicotine and acetaldehyde. As described below, an inhibitory effect of acetaldehyde on 
MAO-A and B is one of the possible mechanisms that reinforce the properties of nicotine. 
It should be noted that the contribution of acetaldehyde in smoke to the level in blood is 
minimal compared to, for example, the effect of ethanol consumption (Chen et al. 2007b, 
McLaughlin et al. 1990). There are indications that users of smokeless tobacco do not 
have a reduced MAO activity, suggesting that constituents of the smoke such as 
aldehydes are needed to inhibit MAO activity (Berggren et al. 2007). In section 3.8.1.4 
the action of acetaldehyde and other aldehydes is described in more detail.  
Tobacco is a potent reinforcing agent in humans, and nicotine is generally considered to 
be the major compound responsible for its addictive properties (Balfour et al. 2000, Dani 
et al. 1996, Di Chiara 2000). However, animal experiments indicate some discrepancies 
between the effects of nicotine and those of other drugs of abuse. For example, the 
capacity of repeated nicotine administration to elevate dopamine levels in the nucleus 
accumbens is controversial (Balfour et al. 1998, Di Chiara 2000, Vezina et al. 1992) and 
repeated nicotine treatments in rats induce a behavioural sensitisation which vanishes 
more quickly than that for other drugs of abuse (Ksir et al. 1985, Villégier et al. 2003). 
Furthermore, with the exception of ethanol which possesses potent sedative effects, most 
drugs of abuse, such as psychostimulants and opiates, induce a substantial locomotor 
hyperactivity both in rats and mice. Nicotine, however, is a weak locomotor stimulant in 
rats and generally fails to induce locomotor hyperactivity in mice at any dose (Marks et 
al. 1983, Sparks and Pauly 1999). Nevertheless, when animals are pretreated with an 
inhibitor of monoamine oxidases, nicotine is able to induce a potent locomotor 
hyperactivity, even in mice (Villégier et al. 2006a). These differences could suggest that 
the addictive effects of tobacco are not only due to nicotine and that monoamine oxidase 
inhibitors have a critical effect.  
In fact, tobacco and tobacco smoke are known to contain a number of compounds, 
among which monoamine oxidase (MAO) inhibitors, such as harman, norharman or 
acetaldehyde, have been the focus of special interest (Breyer-Pfaff et al. 1996, Gäddnäs 
et al. 2000, Rommelspacher et al. 2002). Monoamine oxidases exist under two forms; 
MAO-A and MAO-B. They are enzymes that degrade dopamine, serotonin and 
noradrenaline - three neurotransmitters involved in addiction. The inhibition of MAO 
increases levels of monoamines in the brain which decrease the sensitivity of their 
respective receptors. Human MAO-A and MAO-B genes isolated from X 
chromosome-specific libraries span at least 60 kilobases, consist of 15 exons, and exhibit 
identical exon-intron organisation (Grimsby et al. 1991). Inhibition of monoamine 
oxidases by tobacco smoke does not result from the actions of nicotine (Carr and 
Basham 1991), but from that of other compounds also present in other psychotropic 
plants (Uelbelack et al. 1998). It was shown that MAO inhibitor pre-treatment allows the 
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maintenance of behavioural sensitisation to nicotine in rats (Villégier et al. 2003), thus 
suggesting a role of MAO inhibitors in the addictive properties of tobacco. More recently, 
tranylcypromine, a cyclized amphetamine 5000 times as potent an MAO inhibitor as 
amphetamine (Zirkle and Kaiser 1964), was found to be able to trigger a locomotor 
response to nicotine in mice (Villégier et al. 2006a) and nicotine self-administration in 
rats (Guillem et al. 2005, Villégier et al. 2006a). Moreover, increases in extracellular 5-
HT levels induced by monoamine oxidase inhibitors appeared to be crucial for these 
effects (Villégier et al. 2006b). 
Nicotine is commonly considered as a monoamine releaser (Summers and Giacobini 
1995, Summers et al. 1996) that increases serotonergic neurons firing (Li et al. 1998, 
Marubio et al. 1999, Olausson et al. 2001a, Olausson et al. 2001b, Olausson et al. 2002). 
This increased release of 5-HT, in absence of MAO inhibitors, is however transient. 
Indeed, an immediate inhibitory retro-control blocking the firing of serotonergic raphe 
neurons through the stimulation of somato-dendritic 5-HT1A receptors has been 
described (Engberg et al. 2000, Li et al. 1998, Mihailescu et al. 1998). It has therefore 
been proposed that MAO inhibitors, because of their enhancing effects on extracellular 5-
HT levels, compensate the consequences of the indirect inhibition of serotonergic cells by 
nicotine, thus suggesting a mechanism by which MAO inhibitors contained in tobacco 
smoke could act in synergy with nicotine to induce addiction (Tassin 2008). Very recent 
experiments using 5-HT1A agonists and antagonists have indicated that MAO inhibitors 
contained in tobacco desensitize 5-HT1A autoreceptors to trigger the strong addictive 
properties of tobacco (Lanteri et al. 2009).  
In humans, nicotine replacement therapies are the most widely used form of 
pharmacological intervention, but have proven to be remarkably unsuccessful (Medioni et 
al. 2005, Silagy et al. 2004). Interestingly, most tobacco smokers (> 80%) relapse after 
a few weeks withdrawal, i.e. when inhibition of MAO activity by tobacco and tobacco 
smoke is likely to have disappeared. It has also been argued that the lack of efficacy of 
nicotine replacement therapies was due to the continuous delivery of nicotine by gums or 
patches. It was indeed believed that peaks of nicotine occur in the brain after each puff 
of tobacco smoke. Very recent experiments, performed with positron emission 
tomography (PET) and 11C-nicotine, indicate that these peaks exist only in the arterial 
blood of smokers and do not appear in the brain (Rose et al. 2010a). The half-life of 
nicotine in the human brain is 13 minutes, which is much longer than the ~45 seconds 
which separates two successive puffs. Indeed, brain nicotine levels increase regularly 
along with the cigarette consumption (Rose et al. 2010a).  
The role of tobacco smoke on MAO is even more important than originally thought. A 
substantial inhibition of MAO-A has been found by neuroimaging in chronic smokers 
(Leroy et al. 2009). Another study has shown that smokers have the methylation 
frequency of their MAO-B gene promoter markedly lower (P <0.0001) than non-smokers, 
thus inducing a higher quantity of MAO-B in smokers (Launay et al. 2009). Interestingly, 
this is also true for smokers who have quit for about 10 years. This was explained by 
showing that cigarette smoke induces an increase of nucleic acid demethylase activity 
and an epigenetic regulation of MAO-B. Altogether, these authors have shown that 
metabolism of 5-HT is modified in smokers but that it is also true for those who have 
stopped smoking for a long time (over 10 years) (Launay et al. 2009). 
It seems therefore that MAO inhibitors, or any compound able to modify 5-HT 
metabolism and desensitize 5-HT1A autoreceptors, may provide a more complete 
scheme of the addictive properties of tobacco in experimental models of reward. 
3.11.2. Conclusions on effects of additives on nicotine addictive 
properties 
There is evidence that nicotine cannot, by itself, explain the high addictive potential of 
tobacco and tobacco smoke. The increase of nicotine in the brain resulting from smoking 
a single cigarette is extremely rapid due to the absorption of smoke inhaled into the 
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lungs but the peak observed in arterial blood after a puff is not reflected in the brain 
where the half-life of nicotine is much higher than in blood. Converging data indicate that 
MAO (monoamine oxidase) inhibitors contained in tobacco and tobacco smoke act 
synergistically with nicotine to enhance addiction potential. Smokers have reduced levels 
of MAO in the brain. Among MAO inhibitors, compounds resulting from sugar combustion, 
such as acetaldehyde and more complex aldehydes, may play a crucial role in tobacco 
addiction. MAO inhibitors increase serotonin extracellular levels and desensitize 5-HT1A 
autoreceptors, thereby allowing nicotine to activate serotonergic neurons and become 
addictive. As yet, data about the role of acetaldehyde are the only ones available. They 
are inconclusive and further investigation about other aldehydes is needed before the 
role of sugars as indirectly addictive compounds can be confirmed. 
3.12. Methods to assess attractiveness 
3.12.1. Introduction 
According to the World Health Organisation (WHO), the terms “attractiveness” or 
“consumer appeal” refer to factors such as taste, smell and other sensory attributes, 
ease of use, flexibility of the dosing system, cost, reputation or image, assumed risks 
and benefits, and other characteristics of a product designed to stimulate use (WHO 
2007b). 
Overall, attractiveness is likely to be influenced by a subtle array and interaction of any 
number of these factors, although at certain times individual factors may take 
precedence (e.g. price, particularly during a recession). In addition, certain factors might 
be essential for enduring attractiveness (e.g. the presence and ease of delivery of 
nicotine).  
The factors influencing attractiveness can be broadly divided into: extrinsic factors (e.g. 
marketing, packaging, pricing); and intrinsic factors (e.g. taste, smell, sensory attributes, 
and pharmacological factors). Additives play a role mainly in the intrinsic factor category, 
but marketing and packaging can also reflect the presence of additives in a way to attract 
and maintain customers (e.g. by signalling that the tobacco product contains menthol). 
Given the subtle interactions between different factors however, identifying and 
measuring the influence of individual addictives on attractiveness of products is difficult. 
Separating the role of additives in enhancing addictiveness, from their role in enhancing 
other attractive attributes of a tobacco product is also complex.  
3.12.2. Measuring attractiveness 
There are two main ways of examining the influence of additives on the attractiveness of 
a product. Firstly, one can assess individual tobacco products, and compare their 
attractiveness on a number of scales/dimensions, against other tobacco products. By 
then examining what is known about the additive content of these products, indirect 
inferences can be made as to the role of individual additives in the overall attractiveness 
of the product, although there are important limitations to studies of this kind. Secondly, 
one can examine the influence of individual additives on attractiveness of a tobacco 
product, along a number of scales, by experimentally adjusting tobacco products to 
include or exclude individual additives and testing responses to them. In addition, the 
quantity of the additive can be varied to assess dose response and whether there is a 
threshold below which any impact is not observed. However, in practice this may be 
difficult to achieve by research groups outside of the tobacco industry, who are likely to 
lack the resources to manipulate additive content in this way. 
Tobacco industry documents show that the tobacco companies frequently tested human 
smokers on their reaction to different cigarettes using focus groups, market testing, 
human smoking behaviour studies or consumer panels. For example, one study carried 
out by British American Tobacco in 1980 exposed a panel of smokers, trained to be 
objective in their evaluation of cigarettes, to different conditions wherein brand 
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identification was either masked or visible, in order to understand how brand 
identification and imagery affected subjective evaluation of cigarettes (Ferris 1980).  
The difficulties with this type of research are that ethical restrictions will usually preclude 
human testing of different tobacco products, particularly among non-users or children. In 
addition, there are technical constraints on the ability to manipulate the presence or 
absence of specific additives in tobacco products. While the tobacco industry may be able 
to achieve this, such manipulations may be beyond the resources of independent 
academic research groups. 
Both the main methods have advantages and disadvantages and should be seen as 
complementary. Ideally, a variety of methods and tests would be utilised and assessors 
would be looking for overall consistency in the findings, in order to conclude that an 
additive affected attractiveness.  
3.12.2.1. Measuring attractiveness of different brands 
Actual brand choices 
Assessing actual brand use gives an overall indicator of attractiveness of products which 
reflects all the factors listed at the outset of this section covering both extrinsic and 
intrinsic variables, of which additive content is only one factor. A major difficulty of this 
approach will therefore be separating the influence of these factors. The largest influence 
is likely to be the marketing budget. For example, the popularity of Marlboro worldwide is 
likely due to the substantial funding spent on its advertising and promotion. A further 
complication with interpretation of brand preference data over time is that the tobacco 
industry has been expanding the number of variants of existing brands; since 1998 brand 
families have increased by more than 50%. For example, Benson & Hedges increased the 
number of brands from four in 1998 to 12 by 2008 (ASH 2010). 
Brand choices can be examined cross-sectionally in populations (nationally and globally) 
but longitudinal data enable trends in brand preferences to be examined over time and in 
relation to changing product make up (content and design) as well as tobacco control 
policies and other factors. Brand preferences should be examined in subpopulations such 
as by gender, age, and sociodemographic factors, which might reflect targeting by 
tobacco companies. Brand preferences in younger age groups (e.g. 11-16 year olds) are 
especially important to identify as these can enable an assessment of attractiveness and 
appeal to children. In particular, it is important to assess which brands are used initially 
by children, followed by those that they progress onto over time. Products that attract 
children to smoking have been referred to in the literature as “starter products”. This 
refers to two main types of products: confectionary products which are made and 
packaged to look like cigarettes, thereby enabling children to imitate smoking (e.g. candy 
cigarettes, not discussed further here), and tobacco products which are made to look like 
confectionary (e.g. candy-flavoured cigarettes), thought particularly to appeal to children 
and ethnic minorities (Connolly 2004).  
Comprehensive sources of data on brand preferences at country level broken down by 
socio-demographics are not readily accessible. As an example, we have selected data 
from the UK which suggest that brand preferences of children and adults can be quite 
similar. The top five brands in 2009 were identified as: Lambert & Butler King Size, 
Mayfair King Size, Marlboro King Size Gold, Benson & Hedges King Size Gold and 
Richmond King Size (Hegarty 2010). Comparable data are not available for youth from 
2009 but in 2006, the most popular brands with 11-16 year olds were: Mayfair (58%), 
Lambert & Butler (56%), Richmond (45%), Benson & Hedges (28%) and Sovereign 
(23%) (Amos and Hastings 2009). Four of the brands were common to both adults and 
youth, and for each age group there was a dominance of economy brands. Trends over 
time indicate increasing popularity of economy over premium brands suggesting price 
may be playing a key role in current brand choices. As indicated in section 3.13.2, there 
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may be a trend in the UK for preferring brands marketed as containing no additives, but 
this observation needs confirmation.   
Careful monitoring of brand preferences over time will be important for future research, 
as will disclosure by the tobacco industry of detailed product content information for all 
brands on the market.  
Perceived brand preferences 
By showing different brands to consumers, assessments can be made about how 
attractive the products are perceived to be. For non-tobacco users, responses will largely 
reflect extrinsic factors such as the packaging, but will also reflect their knowledge of 
experiences of others with the products. For users, such assessments also reflect 
knowledge and experience of using the products in addition. The role of additives 
therefore will need to be assessed and inferred alongside these other factors, assuming 
that differences in additives between the different brands are known. As stated above, 
this research involves examining the look of a pack, and its design and packaging. 
Packages can be digitally altered experimentally to test the responses of the presence or 
absence of attributes (e.g. whether listing an additive such as menthol alters how people 
respond to the product). However, studies have shown that colours of packs quickly 
become associated with certain attributes; for example, one study in New Zealand found 
that green colouring indicated the presence of menthol (Peace et al. 2007). In these 
types of studies, different population groups should be compared to test if some products 
are more appealing than others. For example, one experimental study indicated that 
some adolescents had more favourable impressions of tobacco brands that featured 
cherry flavouring in the packaging (Manning et al. 2009).  
This type of research has now been carried out in a variety of settings (e.g. internet, 
supermarket, and mall intercept studies) and using a variety of qualitative and 
quantitative research techniques (Hammond et al. 2009a, Hammond and Parkinson 
2009b, Manning et al. 2009). The products have been assessed along several attributes 
including their perceived attractiveness, harmfulness, ease of initiation or cessation. 
Standardised designs, methodologies and questions therefore exist which can be utilised 
to facilitate comparative analysis. 
Sensory attributes to users and others 
Consumer perceptions of sensory attributes such as taste or palatability, smoke irritation 
and odour, can also be useful for indicating differences in brands. Although there is likely 
to be some impact of packaging and design on expectations of sensory effects, this area 
of testing will be more focused on attributes of the content and emissions of the product 
itself. This research can be done in two main ways: 
a) Through surveys of smokers in which questions cover reasons for selecting the 
brands they smoke and the role of sensory attributes.  
b) Experimentally, using panels of test subjects trying products and expressing 
preferences using, for example, visual analogue scales (see section 3.10). However, 
whilst perceived responses to these attributes are important, it is also useful to see 
how sensory differences translate into topography measurements and the presence of 
biomarkers, such as cotinine (see below). 
These factors could be attractive to a smoker as they make it less troublesome for others 
in their presence, who are then less likely to complain about their smoking. The sensory 
attributes to be measured here would include smoke irritation, smoke odour, and 
visibility of sidestream and mainstream smoke. These assessments can be made as 
described above, but of non-smokers who live, work or are in the presence of smokers.  
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3.12.3. Conclusions on methods to assess attractiveness  
Attractiveness depends on multiple factors that combine to stimulate use. These include 
extrinsic factors such as marketing, packaging and price, and intrinsic factors such as 
taste and smell. It is very difficult to identify the role of individual additives in enhancing 
addictiveness or enhancing other attractive attributes of tobacco products. The 
attractiveness of a product may be assessed by the direct comparison of different 
products by surveys, experimental measures or human testing.  
Another way to examine the attractiveness of individual additives is to test a certain 
tobacco product by introducing the additive in different doses. When additives are 
thought to act in synergy, they may be tested together. In practice, however, overall 
attractiveness is assessed by comparison of brand choice in subpopulations according to 
gender, age and sociodemographic factors. By showing different brands to consumers, 
assessments can be made about their perceived attractiveness.  
Sensory attributes such as taste, irritation etc. may be tested by surveys of users or 
experimentally on panels of test subjects. In general, methods similar to those described 
in section 3.10 may be used.  
The main disadvantage of using any of the data described above is the lack of detailed 
information available on additive content of different brands and the extent to which 
additives contribute to any differences observed, over and above other factors intrinsic to 
the brand, and the price and marketing of the brands.  
3.13. Tobacco use in the European Union 
Manufactured cigarettes are by far the most preferred tobacco products in the 27 
Member States of the European Union. Cigarettes constitute well over 90% of the 
tobacco sold whereas tobacco used in pipes and for RYO cigarettes (roll your own) 
amounts to about 5%. In most Western EU countries, smoking prevalence among men 
and women has in general stabilised or is decreasing. The number of smokers has also 
started to decrease in some countries in the eastern part of EU, although generally it is 
only stabilizing among men, with no clear overall trends, and in some cases a slight rise 
in prevalence among women is being recorded. In the EU as a whole the situation has 
been stable over the last decade (WHO 2007a). 
The use of smokeless tobacco (snus) is common among males in Sweden. The sale of 
snus is banned in all other countries in the EU but other oral tobacco products may be 
sold. In the United Kingdom, both male and female migrants from the Indian 
subcontinent use a wide variety of smokeless tobacco products. Elsewhere, smokeless 
tobacco use is rare but a wide variety of tobacco products do find their way to Europe 
through immigration (SCENIHR 2008). Similarly, waterpipe smoking is spreading through 
cultural influence, mainly by migrants from the Middle East. However, during recent 
years, waterpipe use has become increasingly popular among teenagers in the general 
population.  
The latest comprehensive data from the 27 Member States were collected for 2006, 
(WHO 2009). Where data are missing or misleading (Cyprus and Poland) other sources 
have been used.  
3.13.1. EU adult smoking rates 2006  
The overall adult daily estimated smoking prevalence (population-weighted) has 
stabilised at around 27.5% in the EU. The estimated average smoking prevalence among 
males is 33.2%: in 11 (mostly Eastern European) countries the rate of male smoking is 
higher, while in 11 (mostly Western European) countries the male smoking prevalence is 
below 30% (see figure 4). The estimated average female smoking prevalence in the EU is 
21.8%. In 10 (mostly Western European) countries the prevalence rate is higher, while in 
only three countries it is 15% or less (see figure 5). 
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3.13.1.1. Gender differences 
In all but one country (Sweden), smoking prevalence is higher among men than among 
women. Data from Latvia show the widest gender gap of 29%. A small difference 
between male and female smoking prevalence of less than 10% can be found in 11 
(mostly Western European) countries. 
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Figure 4: 2006 Rates of daily smokers among males in EU countries (WHO 2009) 
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Figure 5: 2006 Rates of daily smokers among females in EU countries (WHO 2009) 
3.13.1.2. Changes in smoking prevalence 
Estimates for male and female smoking prevalence for 2002 and 2005 are available for 
24 of the 27 EU countries. Only relative differences of more than +/-10% have been 
taken into account as noteworthy changes when comparing data for these two years. 
Since the 2002 European report on tobacco control policy, smoking prevalence among 
the male population has in general stabilised across the EU. A notable decrease has been 
reported for Sweden (16.5% to 14.1%), but in most countries in the EU male smoking 
prevalence did not show a significant change between 2002 and 2005. There was no 
significant change in female smoking prevalence although slight increases were observed 
in many countries. 
In May 2010, near completion of the present report, the Special Eurobarometer 332/72.3 
was published (EC 2010). This Eurobarometer, performed upon request of Directorate 
General Health and Consumers (SANCO) of the European Commission, reports on the 
results of an EU-wide telephone survey on tobacco conducted in late 2009. The survey 
method is standardised but the results are not directly comparable to the WHO reports 
quoted above. Furthermore, they are not comparable to an earlier Eurobarometer 
published in 2006 (EC 2006) due to changes of design (EC 2006, EC 2007a). Still, some 
additional information can be extracted. The Eurobarometer (EC 2010) reports the 
proportion of smokers as 29% (males 35%, females 25%) but does not distinguish 
between daily and non-daily smokers. It is not possible to ascertain whether this 
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represents a further drop in adult daily smoking rates compared to the WHO report from 
2009 (figures 4 and 5) showing data collected in 2006.  
However, Eurobarometer (EC 2010) provides other data of interest. The average number 
of cigarettes consumed is 14.4/day, ranging from 22 in Cyprus to 10 in Sweden. Men 
smoke, on average, three cigarettes/day more than women. When asked to single out 
the most important reason for choice of brand, taste is most important for 22% of 
smokers in the EU 27 while price is most important for 6%. The package scored 0%. One 
out of 10 smokers in the EU believes that a less harmful cigarette can be identified by 
taste (ranging from 27% in Hungary to 3% in Denmark). Unique for the Eurobarometer 
(EC 2010) is the data on waterpipe smoking. On average, 11% of EU adults have tested 
or use a waterpipe occasionally, whereas 1% smoke it daily. Differences of use vary 
between countries but being a young adult appears to increase the probability of use.    
3.13.1.3. Conclusions on tobacco use in different EU countries 
Manufactured cigarettes are by far the most preferred tobacco products in the 27 
countries of the European Union and constitute well over 90% of smoked tobacco. The 
overall adult daily estimated smoking prevalence (population-weighted) has stabilised at 
around 27.5% in 2006 (males 33.2%, females 21.8%) but higher rates are found mainly 
in Eastern European countries. Smoking rates have not changed significantly between 
2002 and 2006. Smokeless tobacco is used by over 10% of the population in Sweden but 
its use is rare in other EU countries. 
3.13.2. Brand preference, use of additives and consumption patterns  
The cigarette market in the UK (and Ireland and Malta) is quite divergent from the 
continental European countries. This is mainly because in the UK some typical “English” 
brands are popular and have a large market share. Some quite surprising observations 
can be made when looking at the top-10 brands marketed in the UK (Hegarty 2010): 
1. Of the top-10 brands (according to market share), three brands (Lambert & Butler 
King Size, Richmond King Size and Richmond Superkings) contain no additives 
(water is not considered as an additive).   
2. Five brands contain up to 10 additives.  
3. Two brands (Marlboro King Size Gold of PMI and Royals King Size Red of JTI) both 
contain over a dozen additives.  
4. Lambert & Butler King Size is by far the most sold cigarette brand. Brands without 
additives have a market share of 42%, whereas those with 1 to 10 additives have a 
market share of 48%. Brands containing over a dozen additives have a market 
share of only 10%.  
The “taste” of a tobacco product is not only defined by additives but also by blend-
selection. English brands i.e. the typical UK brands are made predominantly from flue-
cured Virginia tobacco, which contains relatively high amounts of sugars. Marlboro for 
instance uses the “American blend” (a mixture of Virginia, Burley and Oriental tobaccos) 
as a base to which many compounds are added during the manufacture. 
By blending, it is possible to manufacture cigarettes with a characteristic taste, without 
using additives. Imperial Tobacco has thus succeeded in producing a typical brand 
(Lambert & Butler King Size) via the blending approach. In addition, cigarettes marketed 
as “additive free”, may appeal to smokers that prefer “natural products”.  
In Canada, the cigarette market consists almost exclusively of Virginia tobacco which is 
considered to contain relatively few additives. It should be noted, however, that 
domestically manufactured “Virginia flue-cured cigarettes” from Canada are by no means 
“additive-free” (Hammond and O’Connor 2008). 
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Tobacco products in Central and Eastern European countries before and after 
1990 
Before 1990, the tobacco used for making cigarettes was usually domestic black shag, 
and most cigarettes were made with low amounts of additives. Cigarettes were sold 
without filters and tar levels of 20 to 30 mg per cigarette have been reported. The 
average nicotine content in Poland in the 1980s was 2 mg per cigarette implying that 
levels were 1.5 to 2 times the level in Western Europe. After 1990, the large international 
tobacco companies quickly took over and cigarettes were manufactured in Central and 
Eastern Europe according to international standards. Most cigarettes are manufactured 
from light tobacco and the proportion of filter cigarettes rose to 90%. The properties of 
cigarettes, additives and taste enhancers are now similar to those used in Western 
Europe and follow the European Union requirements (Zatonski 2008). Availability, 
marketing, trends, taste, and attractiveness are all factors that may have contributed to 
the rapid market change.  
3.13.3. Smoking prevalence among young people/Target Groups 
The analysis of smoking prevalence among young people is from the European Tobacco 
Control Report 2007 based on the WHO Health Behaviour in School-aged Children 
(HBSC) study, a cross-national research study conducted every four years: 1993/1994, 
1997/1998 and 2001/2002 (WHO 2007a). The 2005/2006 survey was launched in 41 
countries and regions and no comparable data are yet available. Information based on a 
second survey instrument, the Global Youth Tobacco Survey (GYTS) was also used (GYTS 
Collaborative Group 2002). The GYTS was developed by the United States Centers for 
Disease Prevention and Control (CDC) and WHO and has been carried out in a large 
number of countries in the European Region (see table 5). With more and more countries 
carrying out and repeating the GYTS, comparisons should be possible in the coming 
years.  
3.13.3.1. Current status 
According to the HBSC study, weekly smoking prevalence rates were on average 2% 
among 11-year-olds, 8% among 13-year-olds, and 24% among 15-year-olds. In general, 
smoking prevalence rates increased more steeply between the ages of 11 and 13 years 
than between 13 and 15 years. The results of the HBSC and GYTS studies show that 
weekly smoking prevalence rates in 15-year-old boys were especially high (>30%) in 
some Eastern European countries (Estonia, Latvia and Slovakia). The highest smoking 
prevalence rates (>30%) among 15-year-old girls were found mostly in Western 
European countries such as Austria, the Czech Republic, Finland and Spain. The lowest 
smoking prevalence rates among 15-year-old boys (<15%) were in Greece and Sweden. 
Smoking prevalence rates among girls were below 10% only in Greece. An overview of 
smoking prevalence rates among young people in the EU obtained by the HBSC and 
GYTS studies is provided in table 5. 
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Table 5 Weekly smoking rates among boys and girls in EU countries (WHO 2007a) 
HBSC 
1997-1998 2001-2002 
GYTS 
2001/2004 
 
Country 
Boys Girls Boys Girls Year Boys  Girls 
Austria 30 36 26.1 37.1    
Belgium 28 28 21.3 23.5    
Bulgaria     2002 28.7 26.4 
Czech Rep. 22 18 28.7 30.6 2002 29.9 32.8 
Denmark 20 28 16.7 21    
Estonia 24 12 30.4 18.2 2002-3 31.8 23.0 
Finland 25 29 28.3 32.2    
France 28 31 26.0 26.7    
Greece 18 19  13.5 14.1 2003 16.3 9.5 
Hungary 36 28 28.2 25.8 2003 24.1 27.4 
Ireland 25 25 19.5 20.5    
Italy   21.8 24.9    
Latvia 37 19 28.9 21.1 2002 30.2 22.1 
Lithuania 24 10 34.9 17.9 2001 29.0 20.5 
Malta   16.9 17.4    
Netherlands   22.5 24.3    
Poland 27 20 26.3 17.0 2003 20.8 14.3 
Portugal 19 14 17.6 26.2    
Romania     2004 16.8 12.8 
Slovakia 28 18   2003 31.3 28.8 
Slovenia   29.5 29.7 2003 24.2 28.8 
Spain   23.6 32.3    
Sweden 18 24 11.1 19.0    
United Kingdom 25 33 21.1 27.9    
 
3.13.3.2. Gender differences 
The prevalence of weekly smoking among 15-year-old girls was higher than that of 15-
year-old boys in 16 mainly Western European countries of those that implemented the 
HBSC study in 2001/2002 (Austria, Belgium, the Czech Republic, Denmark, Finland, 
France, Greece, Ireland, Italy, Malta, the Netherlands, Portugal, Slovenia, Spain, Sweden 
and the United Kingdom). In Austria, Belgium, Sweden and the United Kingdom, this 
difference was even greater than in the late 1990s. In the remaining (mainly Eastern 
European) countries (Estonia, Hungary, Latvia, Lithuania, Poland), smoking prevalence in 
girls was lower, but in many of these 10 countries, it was catching up and, in two 
countries (Czech Republic and Hungary), even overtaking smoking prevalence in boys. 
The GYTS data in general confirmed the pattern of higher rates of smoking prevalence 
among boys than girls in Eastern Europe.  
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3.13.3.3. Changes in smoking prevalence 
Sixteen countries implemented the HBSC survey both in 1997/1998 and 2001/2002. 
A comparison of the results from these two surveys shows that weekly smoking 
prevalence rates in 15-year-old boys decreased in 11 (mostly Western European) 
countries of the 16 countries, increased in four countries and remained stable in one. The 
picture among 15-year-old girls is quite similar: weekly smoking prevalence rates 
decreased in nine out of the 16 countries, and increased in seven. 
A calculation of the averages from these two HBSC surveys shows that the average 
weekly smoking prevalence among 15-year-old boys and girls did not change 
significantly between the two periods, although a slight downward trend in boys and a 
slight upward trend in girls can be observed. 
3.13.3.4. Conclusions on smoking according to different groups 
of young people 
Weekly smoking rates among children and adolescents living in the European Union 
increase four-fold from about 2% at age 11 to 8% at age 13, and another 3-fold increase 
to 24% at age 15. The highest rates among boys are found in some Eastern EU countries 
whereas the highest rates among girls are seen in some Western EU countries. From the 
year 2000, non-significant trends towards decreased smoking among boys and increased 
smoking among girls have been observed. Smokeless tobacco use is common among 
adolescent boys in the Nordic countries but rare elsewhere.  
Referring to section 3.12 it is clear that the tobacco industry not only has aimed to target 
different groups of users through advertising and promotion. They have also manipulated 
the cigarettes themselves. We have very limited data on market share by brand. Top ten 
lists have only been found from the UK (2009) and Germany (2007). Detailed 
information on annual cigarette sales in individual EU countries can be purchased from 
commercial sources, but the price is quite high. 
However, even in those publications no data on brand preferences according to gender, 
age, ethnicity or culture/region are presented. Again, referring to section 3.12 it is 
conceivable that such information is collected by the manufacturers but treated as trade 
secrets.  
Information about top selling individual brands in EU countries is available from 
commercial sources. In the public domain, only limited data are available. Data on brand 
preferences according to gender, age, ethnicity or culture/region are almost non-existent 
with a couple of limited reports from the UK being the exception. Referring to section 
3.12 it is conceivable that such information is collected by the tobacco companies but 
treated as trade secrets. 
3.13.4. Conclusions on EU 
European Union tobacco smokers prefer manufactured cigarettes. The overall adult daily 
estimated smoking prevalence (population-weighted) had stabilised at around 27.5% in 
2006 (males 33.2%, females 21.8%) but higher rates were found mainly in Eastern 
European countries. Smoking rates had not changed significantly between 2002 and 
2005. The prevalence of weekly smoking among 15-year-old girls was higher than that of 
15-year-old boys in 16 mainly Western European countries whereas the opposite was 
found in most Eastern European countries. In some countries (e.g. the UK) a large 
proportion of smokers preferred cigarettes marketed as “additive free”. Significant use of 
smokeless tobacco was seen only in Sweden and the UK.  
3.14. Gaps of knowledge 
In a number of areas, it was noted that insufficient information was available concerning 
tobacco additives and their roles for addiction and attractiveness. These areas include:  
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• Smoke composition of tobacco products other than cigarettes (cigars, cigarillos, and 
waterpipes). 
• The neurophysiological basis of nicotine addiction. 
• Importance of the level of different sugars for the addictive potency of tobacco 
products. 
• Objective measures for attractiveness of tobacco products and additives. 
• Information about which brands are preferred by new smokers and the reasons for 
brand choice 
These areas are elaborated upon in the following section. 
3.15. Research Recommendations 
Although proposals for research recommendations were not part of the mandate of 
SCENIHR, we have found it useful to indicate some of the topics that were identified 
during the work on the opinion. It is evident that advanced studies on the action of 
nicotine and tobacco additives need considerable financial resources that are generally 
not available in public laboratories. Technological advances have been made in recent 
years that permit new information to be obtained, for instance on smoke composition and 
neural networks (functional neuroimaging). We propose either calls for European 
collaborative projects addressing questions about tobacco and additives or the creation of 
a European Institute for research on drugs of abuse. An improved knowledge in these 
areas would allow evidence-based regulation of the manufacture and marketing of 
tobacco products to be established. Among the proposed research areas are the 
following: 
Smoke composition of tobacco products other than cigarettes 
Very little is presently known regarding the composition of smoke emanating from cigars, 
cigarillos and waterpipes. Thus, knowledge necessary for assessing the potential of 
smoke constituents to facilitate inhalation of tobacco smoke and also the possibility for 
smoke to increase addiction is sparse. 
The neurophysiological basis of tobacco addiction 
It is suggested to determine, by neuroimaging studies, whether nicotine alone (e.g. given 
as pills) induces signals in the brain of dependent smokers that are different from non-
smokers.  
Furthermore, to perform experimental studies in vivo and in vitro (e.g. by neuroimaging, 
microelectrode arrays, neurochemical, and behavioural approaches) that investigate the 
influence of different tobacco additives on the addictive potential of nicotine. These 
studies are crucial to define the exact role of the multiple tobacco additives in the final 
high addictive potential of tobacco (in humans). 
Importance of the level of different sugars for the addictive potency of tobacco 
products 
Sugars are present in significant amounts in Virginia tobacco or are added in high 
quantities to Burley based tobacco products. It has been established that a high sugar 
content increases the attractiveness of tobacco products, but it has not yet been clearly 
demonstrated that sugars increase the addictive potency of tobacco products. It is, 
however, known that sugars generate numerous aldehydes upon heating, and scientific 
data indicate that these aldehydes increase the addictive potency of tobacco. 
Studies both in animals and humans are therefore required to establish whether the 
sugar content is related to the addictive potency of tobacco products. 
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Topics to be studied: (1) Relative efficacy of various sugars to generate aldehydes; (2) 
Mode of action; and (3) The capacity of different tobaccos (i.e. plain Burley tobacco, 
Burley tobacco enriched with sugars vs. Virginia tobacco) to form aldehydes and inhibit 
MAO in situ. Other compounds besides aldehydes and possible mechanisms other than 
MAO inhibition should also be considered to explain the high addictive potential of 
tobacco products. 
Objective measures for attractiveness of tobacco products and additive 
It is necessary to perform innovative techniques such as neuroimaging to assess the 
attractiveness of tobacco additives objectively. The methods should be sufficiently 
sensitive to detect the contribution of a single additive added to a tobacco product.  
Information on brands preferred by new smokers and the reasons for brand 
choice, focussed on tobacco additives 
Certain typical UK brands are popular although no additives have been used in their 
manufacture, whereas popular continental brands contain many additives. The 
differences between these two types with respect to addictive potency should be 
investigated in comparable user groups. Comparison of use patterns across countries are 
not likely to give relevant information about the role of additives.  
Topics of research: (1) Comparison of the sugar content in different brands; (2) 
Comparison of the potency to generate aldehydes; and (3) Comparison of the addictive 
potency (measure the consumption pattern at individual level). 
The outcome provides the scientific rationale for the option to control sugars as tobacco 
additives and to limit their content in tobacco products. 
It is also deemed necessary to determine what makes a specific brand attractive for new 
smokers. Is it the image, popularity, peer influence, taste, or other factors? In this 
context, epidemiological/sociological studies on trends (studies designed to evaluate the 
effect of additives on smoking behaviour and their role for initiation) can provide 
information on what can determine attractiveness. 
3.16. Conclusions 
In the present report, the available scientific evidence for the role of additives in the 
addictiveness and attractiveness of tobacco products has been evaluated. The main 
addictive substance in tobacco leaves is nicotine. However, the abuse liability of pure 
nicotine in animal studies is low, and great variations are found between individual 
animals. In contrast, the addictive potential of tobacco products in humans is high; 
therefore other substances in the final tobacco must play a role in addiction. The vast 
majority of tobacco products are consumed as cigarettes, and they typically contain 
around 10% additives by weight; mainly sugars, humectants and various flavours. It has 
not been possible to define specific additives that influence the addictiveness of tobacco 
products, but the possible importance of aldehydes formed by combustion of sugar and 
polysaccharides has been underlined. Sugars and flavours are important for the 
attractiveness of tobacco products, but it is difficult to distinguish the effects of these 
additives from indirect effects such as the marketing towards specific groups. Various 
gaps of knowledge have been indicated and some recommendations for research are 
made. In the following chapter (section 4), the scientific evidence detailed in the previous 
sections is summarised in order to answer the questions concerning the contribution of 
additives to addictiveness and attractiveness of tobacco products. 
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4. OPINION 
In the light of the most recent scientific information, the Scientific Committee is 
requested to answer the following questions: 
1. Which are the criteria which will define whether an additive or a 
combination of additives increases the addictive potency of the final tobacco 
product?  
In human studies there are clinical criteria for dependence (e.g. diagnostic and statistical 
manual of mental disorders (DSM), difficulty in quitting), laboratory measures of self-
administration (e.g. neurobiological measures) and smoking frequency and depth of 
inhalation, as well as preference studies. These criteria indicate that tobacco in humans 
has a high addictive potential, but they have limitations when assessing the 
addictiveness of individual additives in the final tobacco product. There is no widely-
agreed universal standard for human studies and as a result various possible endpoints 
exist. An addicted individual can be considered as someone who is suffering from a 
specific set of chronic conditions related to a modification of the regulation of their neural 
networks. It is the potential to induce these modifications which should be the criteria 
used to define the addictive potency of a product.  
In animal studies the reinforcing potency of a drug is used as a criterion for addictive 
potential. Self-administration studies indicate that the abuse liability of pure nicotine is 
weaker than the addictive potential of tobacco products in humans. At present it is not 
possible to evaluate whether additives increase the addictive potency of the final tobacco 
product. Drugs of abuse such as nicotine induce different types of behavioural and 
neurochemical dysregulations in animal studies but no consensus about which of those 
are directly related to the addiction process in humans has yet been attained among 
scientists.  
In conclusion, the criteria for defining dependence indicate that tobacco is highly 
addictive in humans. Animal studies that use intravenous administration indicate that the 
abuse liability of pure nicotine is weaker than the addictive potential of tobacco products 
in humans. In contrast to additives, the combustion-product acetaldehyde has been 
widely investigated in animals.  
2. What are the methods currently used for assessing the addictive potency of 
a substance and are they considered adequate? 
Many different methods are used in humans, but there is a lack of consistency between 
these methods. Human studies have many limitations in design (e.g. the use of 
conditioned cues and the need to work with smokers). Furthermore, ethical issues may 
arise when testing substances in humans.  
There is currently no animal model to assess the addictive potency of the final tobacco 
product; however, pure nicotine has been studied extensively. 
The methods currently used in animals to evaluate the addictiveness of any drug of 
abuse, including nicotine, are mainly based on the evaluation of the re-inforcing 
properties of the drug. These experimental animal models are mainly based on self-
administration protocols in rodents, usually rats. The model with the highest predictive 
validity is the operant self-administration paradigm. A response which is easy to evaluate 
is the break point. This is defined as the highest number of responses that the animal 
completes in order to obtain a single delivery of a drug. A higher break point represents a 
direct measure of the motivation of the animal to obtain the drug and is often taken to 
imply an increase in the addictive potency of the drug.  
Other models have also been used, such as the intracranial self-stimulation and the 
conditioned place preference paradigms. New complex behavioural models that resemble 
the main diagnosis for drug addiction in humans have been developed very recently, 
although these new models can only be applied for some particular drugs and 
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experimental conditions at the present moment. The methods have additional limitations 
as in animal studies pure nicotine is injected intravenously and shows only a weak 
addictive potential whereas in humans tobacco is used differently (e.g. inhalation, oral 
consumption). The operant self-administration paradigm has been widely accepted as a 
reliable animal model with high predictive value for the abuse liability of a drug and 
therefore, possibly also for its addictive potential in humans. However, a consensus 
between scientists has not yet been attained on whether this method, which is 
appropriate to define the abuse liability, would also be the most suitable method to 
define the addictive potential of a drug.  
In conclusion, there are many methods for assessing the addictive potency of a 
substance in humans, but they have limitations in design and ethical issues may arise. 
Animal studies using self-administration protocols evaluate the reinforcing properties 
after intravenous injection of the drugs but there is no consensus concerning the most 
suitable method for defining the addictive potential. The current methods can thus not be 
considered adequate.  
3. Is the development of nicotine addictiveness dose-dependent?  
In humans, there are little data available on pure nicotine use. However, when consumed 
in tobacco, frequency of use (number of cigarettes smoked per day) is positively 
correlated with dependence. This suggests that individuals who maintain higher nicotine 
levels in blood are more dependent than individuals who maintain low levels.  
Based on the criteria described in Question 1, dose-dependency appears to have been 
shown in animal studies. In general, an inverted U-shaped dose-response has been 
revealed in animals, suggesting that the addictiveness of nicotine is not directly linear 
with the dose. In addition, pure nicotine is only weakly addictive in some animal studies.  
There is substantial variation in response to nicotine and addictive potential in both 
animals and humans, and genetic factors probably play an important role.  
4. Which additives are addictive by themselves in tobacco products?  
No tobacco additives which are addictive by themselves have so far been identified. 
However, sugars, polysaccharides and cellulose fibres, which are naturally present in 
tobacco, or sugars added in high quantities to most tobacco products, give rise by 
pyrolysis to aldehydes, such as acetaldehyde, which is self-administered by animals and 
may thus be considered as potentially addictive.  
However, experiments using denicotinised cigarettes show that besides nicotine, a 
mixture of factors in cigarette smoke probably plays an important role in craving and 
reinforcement. Although these factors do not have pharmacological effects similar to 
nicotine, they play a role in smoking behaviour.  
5. Which additives enhance the addictiveness of nicotine and how?  
A large percentage of the additives found in tobacco are sugars, or their derivatives, that 
by pyrolysis produce numerous toxic substances, including different combinations of 
aldehydes, one of which is acetaldehyde. Acetaldehyde injected into experimental 
animals enhances the addictiveness of nicotine, probably by inhibiting monoamine 
oxidases (MAO) in the brain. Smokers have indeed decreased levels of MAO in the brain. 
However, there is no proof that acetaldehyde in the smoke contributes significantly to 
blood levels of acetaldehyde, and it is likely those aldehydes other than acetaldehyde 
intervene directly or through the generation of new compounds in the smoke in the 
inhibition of MAO.  
Additives that facilitate deeper inhalation (e.g. menthol) may enhance the addictiveness 
of nicotine indirectly. Other substances may enhance the addictiveness of nicotine by 
inhibiting its metabolism. Substances such as ammonia that increase the pH of the 
tobacco (and the smoke) result in higher amounts of uncharged nicotine, that is more 
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easily absorbed by the cells. However, due to the high buffer capacity of the lining fluid in 
the lungs it is uncertain if more nicotine is absorbed with higher smoke pH. It is unlikely 
that additives in smoked tobacco would increase nicotine blood levels sufficiently to 
enhance the addictive potential of the tobacco product. For smokeless tobacco it has 
been shown that more nicotine is absorbed in the mouth when the pH of the product is 
increased.  
In conclusion, apart from the possible action of combustion products of sugars 
(acetaldehyde and similar compounds that enhance the action of nicotine by inhibition of 
MAO), there is no evidence as yet that additives enhance the addictiveness of nicotine 
and therefore of tobacco. 
6. Which are the methods used to quantify the potency of additives in 
enhancing the addictiveness of nicotine and are they considered adequate?  
The methods used to quantify the potency of additives to enhance the addictiveness of 
nicotine or tobacco, are described in the answer to question 2. The limitations of these 
methods arise from technical challenges in experimentally manipulating the presence or 
absence of an additive in the tobacco products used in these experiments. Such 
experiments have probably been carried out by the tobacco industry for some additives, 
especially sugars and their derivatives, but they require technical and financial resources 
that are not generally available except to the tobacco industry. In addition, there are 
ethical issues if testing in humans is considered.  
In conclusion, the methods used to quantify the potency of additives in humans or 
animals have limitations, and the available methodologies are thus not considered 
adequate for a reliable quantification. 
7. Which technical characteristics enhance the addictive potential of tobacco 
products?  
A number of technical characteristics of cigarettes influence the content of different 
substances in the smoke and the size of smoke particles. The so-called TNCO values (tar, 
nicotine and carbon monoxide) are determined by, amongst other things, ventilation 
(paper, filter), the packing of the tobacco and the geometry of the cigarettes. Smokers 
usually compensate for a lower dose of nicotine by increasing puff volume and frequency, 
and by deeper inhalation. In order to achieve the desired level of nicotine impact many 
smokers apparently take more puffs and inhale deeper when smoking low nicotine 
cigarettes.  
A change of the technical characteristics of cigarettes may affect the mean particle size 
and, therefore, the distribution of the smoke aerosol. However, based on the limited 
publicly available information, it seems that exposure to nicotine cannot be substantially 
increased by altering the particle size of the smoke aerosol.  
In conclusion, technical characteristics can modulate smoking behaviour and thereby 
exposure to nicotine. However, there is no clear evidence that technical characteristics 
per se modulate the addictive potential of tobacco products. 
8. Which are the criteria based on which an additive or a combination of 
additives can be considered (classified) attractive?  
The criterion of attractiveness is the stimulation to use the product.  
Attractiveness of additives refers to factors such as taste, smell and other sensory 
attributes. In addition, a number of external factors (e.g. ease of use, flexibility of the 
dosing system, cost etc.) contribute to the attractiveness of the product.   
The attractiveness of tobacco products may be increased by a number of additives. Many 
different additives are used to create a specific taste/flavour in order to attract certain 
target groups. An attractive effect may be obtained by changing the appearance of the 
product and the smoke, decreasing the harshness of the smoke, and inducing a pleasant 
 Addictiveness and Attractiveness of Tobacco Additives  
 85
experience of smoking. The sweetness of the smoke is an important characteristic for 
certain users. Finally, in order to make smoking more acceptable to other people nearby, 
some additives have the function of reducing lingering odour or side-stream smoke 
visibility. 
In conclusion, many different factors influence the attractiveness of tobacco products, not 
only the additives used but also a number of external factors. 
9. What are the methods currently used for assessing attractiveness and are 
they considered adequate?  
Animal models do not currently exist to allow the assessment of attractiveness.  
There are two main ways of examining the influence of additives on the attractiveness of 
a product which have largely been conducted by tobacco industry. 
The first is to assess individual tobacco products and compare their attractiveness 
against other tobacco products on a number of scales/dimensions. By then examining 
what is known about the additive content of these products, judgements can be made as 
to the role of individual additives in the overall attractiveness of the product. This can be 
done using a variety of research methods, such as panel studies and surveys, 
experimental measures and human testing.  
The second is to examine the influence of individual additives or combination of additives 
on attractiveness of a tobacco product, along a number of scales, by experimentally 
adjusting tobacco products to include or exclude individual additives and testing 
responses to them. In addition, the quantity of the additive can be varied to assess dose 
response and whether there is a threshold below which any impact is not observed.  
The difficulties with this type of research include ethical considerations that will usually 
preclude human testing of different tobacco products, particularly among non-users or 
children.  
In conclusion, it is only possible to assess attractiveness in humans, and this may be 
done by comparison of different products used or by adjusting tobacco products 
experimentally. However, such studies in human subjects are difficult to carry out due to 
ethical considerations and the current methods are thus not considered adequate for a 
reliable quantification of attractiveness in humans.   
10. Which additives increase attractiveness of tobacco products?  
Numerous additives are used in order to increase the attractiveness of tobacco products.  
Various sugars constitute a large proportion of additives, and the sweetness of the smoke 
is an important characteristic of the product.  
Some additives are used to attract certain target groups, because they give the product a 
specific taste/flavour particularly appreciated by the target group. The best known 
example is menthol (African Americans) and the use of fruit and candy flavours in high 
amounts to favour smoking initiation by young people.  
A number of additives decrease the harshness and increase the smoothness of the 
smoke. As a result the smoke inhaled is less aversive, cooler and milder, which improves 
the experience of smoking and promotes smoking initiation. The harshness depends 
partly on the tar/nicotine ratio, but may also be decreased by additives such as 
propylene glycol and glycyrrhizin, a substance in liquorice. Menthol, due to its local 
anaesthetic effect may enable a deeper inhalation of the smoke. It also acts on sensory 
nerve endings, resulting in a cooling effect appreciated by smokers.  
For cigarettes, certain additives yield a full and white smoke (for example, magnesium 
oxide, magnesium carbonate, sodium acetate, sodium citrate, calcium carbonate). Other 
additives reduce the lingering odour of the smoke in order to favour the acceptability of 
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smoking to people around (for example, acetylpyrazine, anethole, limonene, vanillin, 
benzaldehyde). 
In conclusion, many different additives have been used to increase the attractiveness of 
tobacco products but it is very difficult to identify the role of individual additives in 
enhancing attractiveness. In several countries there is a growing trend of using “natural” 
tobacco products advertised as containing no additives. 
11. What is the association between additives and tobacco consumption 
(independent of any addictive potential they might have)? Which additives 
are used to target specific groups?  
Additives considered attractive may in principle lead to brand preference or a higher 
consumption of tobacco products, although it is difficult to disentangle the direct effects 
of additives from indirect effects such as the marketing of specific products at specific 
groups. For example, the consumption of menthol cigarettes is much higher among 
African Americans in the USA than among other populations, while flavourings (e.g. fruit 
and candy) appear to be targeted at young people. 
It is notable that waterpipe smoking is becoming increasingly popular in some EU 
countries (and elsewhere), potentially due to the flavoured tobaccos used and the mild 
smoke, which facilitate the inhalation of large volumes into the lungs. Smokeless tobacco 
products have gained increased interest from the tobacco industry because they may be 
used in places where smoking is prohibited.  
Additives and design characteristics may modify consumption patterns, theoretically in a 
way which may impact on uptake of tobacco use and/or the development of dependence. 
However, in spite of the many additives commonly used, tobacco products openly 
marketed as containing specific additives (e.g. menthol cigarettes) command a relatively 
small market share in EU countries and in some markets so-called natural tobacco 
products are becoming popular.  
In conclusion, additives have been used largely by the tobacco industry to target specific 
groups. However, the effect of marketing is probably very important and there is 
currently a trend in several countries to use products labelled “without additives”.  
 
 
Research Recommendations 
A number of knowledge gaps of importance for determining the effects of tobacco 
additives on addiction and attractiveness have been identified. Some of these gaps have 
been translated into specific research recommendations that are summarised here.  
In addition, it has been noted that due to financial constraints, it is not possible to 
perform many of the suggested research recommendations at ordinary public research 
laboratories. Instead, there is a need for European collaborative projects addressing 
questions about tobacco and additives or even the creation of a European Institute for 
research on drugs of abuse, in which questions pertaining to tobacco use should also be 
investigated. An improved knowledge of the roles for tobacco additives in addiction and 
attractiveness would allow evidence-based regulation of the manufacture and marketing 
of tobacco products to be established. 
 
Specific areas where research is strongly needed include: 
Smoke composition of tobacco products other than cigarettes 
The knowledge necessary for assessing the potential of smoke constituents to facilitate 
inhalation of tobacco smoke and also the possibility for smoke to increase addiction is 
sparse. 
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The neurophysiological basis of nicotine addiction  
This includes studies of effects on the brain due to nicotine ingestion in both smokers and 
non-smokers, as well as experimental studies on the influence of additives on the 
addictive potential of nicotine.  
Importance of the level of different sugars for the addictive potency of tobacco products 
Although it has been established that a high sugar content increases the attractiveness of 
tobacco products, it has not yet been clearly demonstrated that sugars increase the 
addictive potency of tobacco products. Studies, both in animals and humans, are 
therefore required to establish whether the sugar content is related to the addictive 
potency of tobacco products. 
Objective measures for attractiveness of tobacco products and additives 
It is necessary to perform experimental studies to assess the attractiveness of tobacco 
additives objectively. The methods should be sufficiently sensitive to detect the 
contribution of a single additive added to a tobacco product. 
Information about which brands are preferred by new smokers and the reasons for brand 
choice 
It is deemed necessary to determine what makes a specific brand attractive for new 
smokers. In this context, epidemiological/sociological studies on trends (studies designed 
to evaluate the effect of additives on smoking behaviour and their role for initiation) can 
provide information on what can determine attractiveness. 
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5. COMMENTS RECEIVED DURING THE PUBLIC CONSULTATION  
Information about the public consultation has been broadly communicated to national 
authorities, international organisations, and other stakeholders. The website opened for 
comments the 9th of July 2010 and the deadline for submission was the 5th of September 
2010. The number of responses submitted by the website was 31; 22 contributions were 
from organisations, and nine were from individuals. Of the organisations, three were 
non-governmental, nine business, four public authorities, two academic institutions and 
four other institutes. In evaluating the responses from the consultation, submitted 
material has only been considered for revision of the opinion if:  
1. It directly refers to the content of the report and relates to the issues that the report 
addresses; 
2. It contains specific comments and suggestions on the scientific basis of the opinion;  
3. It refers to peer-reviewed literature published in English, the working language of the 
SCENIHR and the working group. In some cases, however, other documents have also 
been considered, especially technical reports from the tobacco industry (further 
explained in the methodology section 3.2);  
4. It has the potential to add to the preliminary opinion of SCENIHR. 
Each submission which meets these criteria has been carefully considered by the Working 
Group. Overall, many of the comments were relevant and of good quality and the opinion 
has been partly revised based on these comments. Several of the submissions repeated 
arguments included in the response to the call for information in November 2009. The 
literature has been updated with relevant publications up to September 2010.  
In the following section the comments and revisions to each of the 11 questions to the 
committee are considered. For all of the questions the majority of the submissions 
agreed or mostly agreed with the response given by the committee 
1. Criteria which will define whether an additive or a combination of additives 
increases the addictive potency of the final tobacco product 
One comment addressed the clinical criteria. As mentioned already in the text, the 
clinical criteria follow the ICD-10 classification and are also in accordance with definitions 
made by WHO expert groups. The expression “weak” addictive potential of nicotine has 
been criticised by some stakeholders and the meaning has been clarified in several places 
by using a statement such as the following: “self-administration studies in animals 
indicate that the abuse liability of pure nicotine is weaker than the addictive potential of 
tobacco products in humans”. In order to document that tobacco is highly addictive in 
humans, a new table (table 1) summarising epidemiological and other studies has been 
inserted in section 3.1. 
2. Methods currently used for assessing the addictive potency of a substance 
Some stakeholders criticised the use of animal models. However, for all the questions we 
have evaluated data available from animal models in parallel with data from human 
studies. In vitro methods do not presently allow responding to questions that involve 
complex interactions in the body. Self-administration methods are commonly used in 
animals to test the reinforcing properties of different products. It has been found that the 
reinforcing effect of a compound presents a high predictive value for the abuse liability in 
humans. Therefore, although these methods are not directly measuring the addictive 
effects of a compound, there is a consensus of the scientific community about the 
interest of such animal models in the study of addiction. 
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3. Dose-dependency of development of nicotine addictiveness 
Some comments question the dose-dependency of nicotine. The dose dependency is 
certainly not linear, but we maintain that the pharmacological effects of nicotine, 
including its reinforcing effects, are dose-dependent. Similarly to other drugs of abuse, 
an inverted U-shape dose-response curve has been reported for the reinforcing effects of 
nicotine. This dose-response curve reveals: 
a) The reinforcing effects of nicotine are directly dependent on the dose until a 
maximum level is reached.  
b) After reaching this level, the reinforcing effects also decrease in a dose-dependent 
manner, probably due to the appearance of other pharmacological responses that 
include aversive effects. This decrease of the reinforcing effects has been also 
reported when using high doses of all the other drugs of abuse (i.e. cocaine, 
amphetamine, heroin, morphine, alcohol, cannabinoids and others). 
Some stakeholders emphasize the lack of accumulation of nicotine in dependent 
smokers. However, the lack of accumulation has no relationship with the dose-
dependence of pharmacological effects. Concerning the well-reported desensitization of 
the nicotinic binding sites after repeated nicotine administration, this is not related to the 
presence or absence of dose-dependence in the pharmacological effects of nicotine. 
Indeed, other drugs of abuse that induce dose-dependent pharmacological effects also 
produce receptor desensitization (opioids, psychostimulants, alcohol, cannabinoids and 
others), which has been mostly related to the development of tolerance to their 
pharmacological responses.  
Concerning the genetics of nicotinic acetylcholine receptors, several recent articles 
mentioned in the opinion reveal an association between genetic variations of such 
receptors and nicotine dependence.  
One stakeholder mentions that smokers and non-smokers have a similar absorption and 
metabolism of nicotine and this would suggest a possible absence of pharmacokinetic 
tolerance. However, it would not be related to the dose-dependence of the 
pharmacological effects of nicotine. On the other hand, the development of physical 
dependence (presence of withdrawal symptoms) has been well reported in animal and 
human studies to be directly dependent on the dose of nicotine.  
4. Additives in tobacco products which are addictive by themselves 
Some comments addressed the sugar content of tobacco. It should be underlined that 
some tobaccos (e.g. Burley tobacco) initially have a low content of sugars due to curing 
methods. However, sugars are added during the processing so that the final product has 
a sugar content comparable to that of other tobaccos. This proves the importance of 
added sugars/inherent sugars for the flavour of the product. This final composition also 
explains why there is no significant difference between sugar-related pyrolytic end-
products (mainly aldehydes) in the smoke from American blend and Virginia cigarettes. 
We agree that the sentence indicating that “sugars, added in high quantities in most 
tobacco products”, is not correct because some tobaccos such as Virginia tobacco have a 
high natural content of sugars. The text has thus been changed in several places.  
As mentioned in the opinion, acetaldehyde which is formed by combustion of sugars and 
polysaccharides, is self-administered in animals and may thus be addictive in itself. There 
is no proof that acetaldehyde from tobacco smoke enters the brain, but many other 
aldehydes are formed that may have the same effect, see also the comments below on 
the increased addictiveness of nicotine caused by aldehydes.  
Apart from sugar, no other additives have been found to be addictive by themselves in 
the doses used in tobacco products. 
5. Additives that enhance the addictiveness of nicotine 
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As indicated above, aldehydes are formed by burning of sugars (and polysaccharides), 
not only formaldehyde and acetaldehyde but also more complex aldehydes which are 
probably not degraded by aldehyde dehydrogenase. Many comments indicate that there 
is little scientific evidence that acetaldehyde present in tobacco or tobacco smoke and 
produced by sugar pyrolysis is responsible for an increased addictiveness of nicotine 
through an inhibition of monoamine oxidases. In animal studies, infusion of acetaldehyde 
potently increases the rate of nicotine self-administration and inhibits monoamine 
oxidases. Although acetaldehyde is formed in tobacco smoke from sugar combustion, we 
agree that it is not demonstrated that acetaldehyde in tobacco smoke enters the brain 
through the smoke inhaled. It is however clear that tobacco smoke contains compounds 
which inhibit monoamine oxidases. Aldehydes are intermediary products formed by 
monoamine oxidases which transform monoamines to organic acids and are therefore 
potent inhibitors of monoamine oxidases. Aldehydes are also “alcohol dehydrogenated” 
compounds and can be formed through the combustion of poly-alcohols such as sugars. 
It is thus very likely that acetaldehyde is not the only aldehyde obtained following sugar 
combustion and these more complex aldehydes may also inhibit monoamine oxidases. 
Moreover, their complexity would protect them from the action of the aldehyde 
dehydrogenase which oxidizes acetaldehyde. In addition, some of the added flavours are 
complex aldehydes. The possible role of complex aldehydes arising from sugar 
combustion is now emphasised in the report.  
Two comments indicate that Berlin and Anthenelli acknowledge, in their 2001 paper, that 
it is a “hypothesis” that chronic habitual smoking can be understood in terms of reduced 
MAO activity. Berlin and Anthenelli also acknowledge that their conclusion regarding MAO 
inhibition by compounds found in tobacco smoke or tobacco can potentiate nicotine’s 
effect is “speculation”. Although we agree with this quotation we would like to note that 
Berlin and Anthenelli wrote this comment in 2001 and since this date many studies have 
indicated the fundamental role of inhibitors of monoamine oxidases in the effects of 
tobacco. All the references are quoted in the opinion. Briefly, it has been shown that 
irreversible mixed A and B monoamine oxidases increase the serotonin cerebral 
extracellular levels and induce a desensitization of 5-HT1A receptors. This desensitization 
of raphe nucleus 5-HT1A receptors allows nicotine: (i) to induce locomotor activity in 
mice; (ii) to be readily self-administered by rats; and (iii) to uncouple noradrenergic and 
serotonergic neurons in mice. This latter finding indicates that a synergy between 
nicotine and inhibitors of monoamine oxidases can occur even if the pharmacokinetics of 
each compound is entirely different. 
As mentioned in the opinion, there is no proof that ammonia in tobacco enhances the 
nicotine uptake due to increased pH in cigarette smoke. Note that although ammonia is 
not on the common list of ingredients submitted to the European Commission, 
ammonium salts and other buffering salts are used as additives.  
Concerning mentholated cigarettes, the contradictory results from studies on puffing 
intensity and human smoking behaviour has been presented already in the opinion. The 
same is true for the biomarker studies: the results for COHb, NNAL, nicotine equivalents 
have been described. The CYP2A6 polymorphism has been addressed elsewhere 
(3.6.1.5). One comment confirmed the statement about the function of TRPM8 and the 
interaction of menthol with this receptor. Further statements about the lack of interaction 
with other receptors seem not to be relevant for the opinion. One comment made 
reference to the recent NCI bibliography on menthol and tobacco with 340 references. In 
the opinion only the most relevant references have been used. The inhibition of nicotine 
metabolism by menthol was illustrated with results of the Benowitz et al. (2004) study. 
This study had been performed in a clinical setting with i.v. application of deuterated 
nicotine and deuterated cotinine. Therefore the possibility of inhibiting influences could 
be determined more precisely than in field studies comparing nicotine metabolite 
excretion from smokers of mentholated and non-mentholated cigarettes (e.g. Wang et al. 
2010). 
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Some comments addressed smokeless tobacco and pointed out that the additives used 
were not all found in the same product. This is correct and we have clarified the 
appropriate text sections accordingly. 
6. Methods to quantify the potency of additives in enhancing the addictiveness 
of nicotine 
Some comments criticised the use of animal models. As indicated in question 2, we have 
evaluated data available from animal models in parallel with data from human studies. 
Self-administration methods are commonly used in animals to test the reinforcing 
properties of different products. The reinforcing effect of a compound in animal studies 
presents a high predictive value for the abuse liability in humans. Therefore, although 
these methods are not directly measuring the addictive effects of a compound, there is a 
consensus of the scientific community about the interest of such animal models in the 
study of addiction. 
7. Technical characteristics that enhance the addictive potential of tobacco 
products 
Few comments addressed this point specifically. Changes in technical characteristics may 
influence smoking behaviour, but it is not certain whether this leads to a higher risk for 
addiction. 
8. Criteria for considering an additive or a combination of additives as 
attractive 
In the definition of attractiveness, we have used the criteria employed in the WHO report 
(WHO 2007b). The broadness of the term “attractiveness” is acknowledged in the report. 
Industry terms such as “acceptability” and “preference” have more specific meaning, but 
capture only part of what constitutes the attractiveness of a product. The role of sensory 
and environmental cues is already acknowledged. It is acknowledged in the opinion that 
there is a lack of evidence regarding the specific impact of menthol on smoking 
behaviour. Although some smokers are not particularly attracted by the sweetness, it is 
generally admitted that the sweetness is an important characteristic of tobacco. The 
tobaccos that do not naturally have a high sugar content are treated with casing to 
increase the sugar content and add various flavours (see section 3.4). 
9. Methods currently used for assessing attractiveness 
We agree with the comments that there is a lack of standardised methods for assessing 
attractiveness in the context of tobacco products. This is already acknowledged in the 
report, although the basic principles of how to assess subjective ratings are well 
established in behavioural science. Greater consistency across studies which investigate 
these factors would be welcome. Survey and market data may provide useful 
information, but any relationships between, for example, market share and the presence 
or absence of additives will be minimally informative due to the potential for multiple 
confounding influences, and cross-country differences in “national taste” etc. Some 
comments addressed the question of ethics of panel testing of tobacco products. While 
studies of the presence or absence of additives on smoking behaviour in established 
smokers may be ethically acceptable, these will be minimally informative with respect to 
effects on initiation. It would generally be regarded to be unacceptable to present 
tobacco (with or without additives), a harmful product with high addiction liability, to 
tobacco naive participants. 
10. Additives that increase attractiveness of tobacco products 
It is acknowledged in the report and has been acknowledged for a long time by the 
tobacco industry that a large number of additives seeking to increase the attractiveness 
of their products are used. However, bearing in mind the broad meaning of 
“attractiveness”, the report does not provide clear evidence that a specific additive 
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affects the attractiveness of tobacco products intended for smoking. For smokeless 
tobacco there were some comments on possible harm reduction and use of smokeless 
tobacco as cessation aid. These questions have been treated in detail in the SCENIHR 
report from 2008 and we have now inserted some remarks in the text. In brief, there is 
no evidence that promotion of smokeless tobacco will result in substantial public health 
benefits due to dual use of cigarettes and smokeless tobacco. There is also no evidence 
that smokeless tobacco is more efficient as a smoking cessation aid than established 
therapies.  
11. Association between additives and tobacco consumption – target groups 
A number of comments addressed this point. The potential for menthol and ammonia to 
influence smoking initiation and behaviour is discussed in the report but the data are 
inconclusive.  
Gaps of knowledge and Research recommendations 
A number of comments proposed to have more precise indications about knowledge gaps 
and research recommendations. Although this was not part of the mandate, this section 
has now been rewritten in order to explain better the considerations of the working group 
and the Scientific Committee. 
 
6. MINORITY OPINION 
None 
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7. LIST OF ABBREVIATIONS 
  
ACh Acetylcholine 
AM251 N-(piperidin-1-yl)-5-(4-iodophonyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APA American Psychiatric Association 
ASH Action on Smoking and Health 
BAT British American Tobacco 
BfR Bundesinstitut für Risikobewertung (Federal Institute for Risk Assessment) 
BN Bates Number 
BZgA Bundeszentrale für gesundheitliche Aufklärung (Federal Centre for Health 
Education) 
CAS Chemical Abstracts Service 
CB1 Cannabinoid receptor 1 
CDC Centers for Disease Prevention and Control 
CLD Cased Leaf Dryer 
CMD Count median diameter 
CNRS Centre national de la recherche scientifique (French National Center for 
Scientific Research) 
CNS Central nervous system 
CO Carbon monoxide 
COHb Carboxyhaemoglobin 
CSERP Chemosensory event-related potential 
CYP Cytochrome P450 monooxygenase 
DA Dopamine 
DAP Diammonium hydrogen phosphate 
DKFZ Deutsches Krebsfoschungszentrum (German Cancer Research Center) 
DNA Deoxyribonucleic acid 
DSM (-IV) Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) 
EC European Commission 
ECDC European Centre for Disease prevention and Control 
ECHA European Chemicals Agency 
EEG Electroencephalography/Electroencephalogram 
EFSA European Food Safety Authority 
EMA European Medicines Agency 
EU European Union 
FDA (United States) Food and Drug Administration 
FTND Fagerström Test for Nicotine Dependence 
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GABA Gamma (γ)-Aminobutyric acid 
Glu Glutamate 
GM Genetically modified 
GYTS Global Youth Tobacco Survey 
HBSC Health Behaviour in School-aged Children 
5-HT 5-Hydroxytryptamine 
IARC International Agency for Research on Cancer 
IC50 The half-maximal inhibitory concentration 
ICD International Classification of Diseases 
ICRP International Commission on Radiological Protection 
i.v. Intravenous 
JTI Japan Tobacco Inc. 
LD50 Median lethal dose 
MAO Monoamine oxidase 
mGlu5 Metabotropic glutamate 5 
mGlu2/3 Metabotropic glutamate 2/3 
MMD Mass median diameter 
mRNA Messenger ribonucleic acid 
NAc Nucleus accumbens 
nAChR Nicotine acetylcholine receptor 
NCI National Cancer Institute 
NMDA N-Methyl-D-aspartate 
NNAL 4-N-(Nitrosomethylamino)-1-(3-pyridyl)-1-butanol 
NNAL-Gluc NNAL-Glucuronide 
NNK 4-N-(Nitrosomethylamino)-1-(3-pyridyl)-1-butanone 
NRT Nicotine replacement therapy 
ONS Office for National Statistics 
PET Positron emission tomography 
pH Measure of acidity or basicity of a solution 
pKa Dissociation constant – measure of the strength of an acid or a base 
PMI Philip Morris International 
ppm parts per million 
PPTg Pedunculopontine tegmental nucleus 
PREP Pattern reversal evoked potential 
QNE Quantity not exceeded 
RECON Reconstituted tobacco 
RIVM Rijksinstituut voor Volksgezondheid en Milieu (The Netherlands National 
Institute for Public Health and the Environment) 
RYO Roll your own  
SCCS Scientific Committee on Consumer Safety 
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SCENIHR Scientific Committee on Emerging and Newly Identified Health Risks 
SCHER Scientific Committee on Health and Environmental Risks 
STP Smokeless tobacco products 
STRATUS Studies with Rimonabant and Tobacco Use 
T1/2 Half-life 
TNCO Tar, nicotine and carbon monoxide 
TRPM8 Transient receptor potential channel 
UK United Kingdom 
US(A) United States (of America) 
UV Ultraviolet 
VTA Ventral tegmental area 
WHO World Health Organization 
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9. GLOSSARY 
Abuse liability Abuse liability of a drug is the likelihood that its use will result 
in addiction (dependence) and it can be assessed in 
laboratories by methods referred to as abuse liability testing.  
Additives The present report uses the term additives for added 
ingredients or substances. Additives are defined as any 
substance that is added, except water, during the course of 
manufacture of a tobacco product, including preservatives, 
humectants, flavours, and processing aids. 
Addiction Addiction is the commonly used term referring to what is 
technically known as “dependence” and is widely employed to 
connote severe substance dependence. 
Addictiveness Addictiveness refers to the pharmacological potential of a 
substance to cause addiction. 
Agonist A ligand for a receptor which induces a response, identical or 
partial, to the response obtained with the endogenous ligand. 
Attractiveness The terms “attractiveness” or “consumer appeal” refer to 
factors such as taste, smell and other sensory attributes, ease 
of use, flexibility of the dosing system, cost, reputation or 
image, assumed risks and benefits, and other characteristics 
of a product designed to stimulate use. 
Break point Highest number of responses that the animal accomplishes to 
obtain a single delivery of a drug. 
Bronchodilatator A substance that dilates the bronchi and bronchioles.  
Casing Casing refers to the sauce composed of a variety of 
ingredients such as humectants, sugars, cocoa, liquorice and 
fruit extracts which is applied to tobacco during the 
manufacturing process. 
Conditioned cue Neutral stimulus that associates with a reward. Used in abuse 
liability testing.   
Curing Curing is the process for drying freshly harvested tobacco with 
partially or fully controlled temperature and moisture 
schedules. 
CYP2A6 It is an abbreviation of Cytochrome P-450 2A6 (family 2, 
subfamily A, polypeptide 6), a constituent of the endoplasmic 
reticulum P-450 mixed function oxidase system. CYP2A6 is the 
main enzyme system involved in the oxidative metabolism of 
nicotine and cotinine, as well as many other xenobiotics and 
pharmaceuticals. A significant interindividual variability in 
CYP2A6 and mRNA levels has been observed in humans and 
other mammals. 
Denicotinised The removal or reduction in the nicotine content of tobacco, 
for example by means of blending genetically-modified tobacco 
which has been engineered to lack nicotine. 
DSM Diagnostic and Statistical Manual of Mental Disorders. 
Published by the American Psychiatric Association (USA) which 
provides standard criteria for the classification of mental 
disorders. It is used in the United States and in varying 
degrees around the world. It is not exempt from scientific 
criticism in many countries. 
EEG Electroencephalogram. 
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GABA receptor An oligomeric class of neuron membrane receptors to which 
the γ–aminobutyric acid (GABA), the major inhibitory 
neurotransmitter in the brain, binds. 
Harman A beta-carboline that is formed in smoke by interaction 
between acetaldehyde and tryptophan. It inhibits the enzyme 
monoamine oxidase (MAO). 
Harshness A chemically induced physical effect associated with a 
roughness, rawness experience generally localised in the 
mouth, and to a lesser degree, in the upper reaches of the 
throat and the trachea due to inhalation of tobacco smoke. It 
can cause a drying, rasping, coarse, astringent sensation. 
Hyperlocomotive effect Increase in locomotor activity usually recorded in rodents.  
IC50 Inhibitory concentration 50. The concentration of a compound 
that inhibits 50% a given maximal response (biological, 
biochemical, etc.). 
Ingredients see Additives. The present report uses the term additives for 
added ingredients or substances. 
LD50 Lethal dose 50. Dose of a compound that kills 50% of a group 
of administered animals (it represents a probabilistic concept).  
Manipulandum Device used in experimental settings in order to transmit an 
active response. In the present report the device is used to 
measure self-administration of drugs in experimental animals. 
MAO Monoamine oxidases exist in two forms, A and B. They 
metabolize monoamines such as noradrenaline, dopamine and 
serotonin. 
Metabolism The chemical processes occurring within a living cell or 
organism that are necessary for the maintenance of life. In 
metabolism some substances are broken down to yield energy 
while other substances are synthesized.  
Narghile or shisha Expressions for the Oriental waterpipe. 
Norharman Condensation product in smoke that inhibits the enzyme 
monoamine oxidase (MAO). See also harman. 
pH Measure of the acidity or alkalinity of a solution, numerically 
equal to 7 for neutral solutions, increasing with increasing 
alkalinity and decreasing with increasing acidity. The pH scale 
commonly in use ranges from 0 to 14.  
P450 enzyme system The cytochromes P450 are hemproteins and important 
constituents of the so-called monooxygenase system. 
Pyrolysis Chemical decomposition of condensed substances that occurs 
spontaneously at high enough temperatures. 
Receptor Protein or protein complexes present in the cell membranes 
(plasmatic, endoplasmic or nuclear) or the cytoplasm to which  
physiological signaling molecules, e.g. neurotransmitters, 
hormones, etc., drugs and xenobiotics specifically, bind. 
Reinforcement Ability of a stimulus to promote behavioural responses in order 
to obtain (positive reinforcement) or to avoid (negative 
reinforcement) such a stimulus. 
Rewarding Stimuli that have appetitive (desirable) consequences and/or 
produce a hypothetical pleasurable internal state (hedonia). 
Self-administration Experimental procedure that allows the animals/humans to 
administer a drug to themselves. Self-administration methods 
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are widely used to directly evaluate the reinforcing properties 
of a drug. 
Smoothness Reduction in the harsh irritation of nicotine-containing tobacco 
smoke. 
Uncharged Used e.g. for nicotine to describe the free base, that under 
acidic conditions (lower pH) may be charged (protonated) with 
one or two protons.  
 
